true
--06-30
2024
Q3
0001527728
0001527728
2023-07-01
2024-03-31
0001527728
2024-05-10
0001527728
2024-03-31
0001527728
2023-06-30
0001527728
2024-01-01
2024-03-31
0001527728
2023-01-01
2023-03-31
0001527728
2022-07-01
2023-03-31
0001527728
RENB:SeriesAPreferredStocksMember
2023-06-30
0001527728
us-gaap:CommonStockMember
2023-06-30
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001527728
us-gaap:RetainedEarningsMember
2023-06-30
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-06-30
0001527728
RENB:SeriesAPreferredStocksMember
2023-09-30
0001527728
us-gaap:CommonStockMember
2023-09-30
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001527728
us-gaap:RetainedEarningsMember
2023-09-30
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-09-30
0001527728
2023-09-30
0001527728
RENB:SeriesAPreferredStocksMember
2023-12-31
0001527728
us-gaap:CommonStockMember
2023-12-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001527728
us-gaap:RetainedEarningsMember
2023-12-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31
0001527728
2023-12-31
0001527728
RENB:SeriesAPreferredStocksMember
2022-06-30
0001527728
us-gaap:CommonStockMember
2022-06-30
0001527728
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001527728
us-gaap:RetainedEarningsMember
2022-06-30
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-06-30
0001527728
2022-06-30
0001527728
RENB:SeriesAPreferredStocksMember
2022-09-30
0001527728
us-gaap:CommonStockMember
2022-09-30
0001527728
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001527728
us-gaap:RetainedEarningsMember
2022-09-30
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-09-30
0001527728
2022-09-30
0001527728
RENB:SeriesAPreferredStocksMember
2022-12-31
0001527728
us-gaap:CommonStockMember
2022-12-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001527728
us-gaap:RetainedEarningsMember
2022-12-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-12-31
0001527728
2022-12-31
0001527728
RENB:SeriesAPreferredStocksMember
2023-07-01
2023-09-30
0001527728
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001527728
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-07-01
2023-09-30
0001527728
2023-07-01
2023-09-30
0001527728
RENB:SeriesAPreferredStocksMember
2023-10-01
2023-12-31
0001527728
us-gaap:CommonStockMember
2023-10-01
2023-12-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-10-01
2023-12-31
0001527728
us-gaap:RetainedEarningsMember
2023-10-01
2023-12-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-10-01
2023-12-31
0001527728
2023-10-01
2023-12-31
0001527728
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001527728
RENB:SeriesAPreferredStocksMember
2024-01-01
2024-03-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-03-31
0001527728
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01
2024-03-31
0001527728
RENB:SeriesAPreferredStocksMember
2022-07-01
2022-09-30
0001527728
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001527728
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001527728
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-07-01
2022-09-30
0001527728
2022-07-01
2022-09-30
0001527728
RENB:SeriesAPreferredStocksMember
2022-10-01
2022-12-31
0001527728
us-gaap:CommonStockMember
2022-10-01
2022-12-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2022-10-01
2022-12-31
0001527728
us-gaap:RetainedEarningsMember
2022-10-01
2022-12-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-10-01
2022-12-31
0001527728
2022-10-01
2022-12-31
0001527728
RENB:SeriesAPreferredStocksMember
2023-01-01
2023-03-31
0001527728
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001527728
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-01-01
2023-03-31
0001527728
RENB:SeriesAPreferredStocksMember
2024-03-31
0001527728
us-gaap:CommonStockMember
2024-03-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001527728
us-gaap:RetainedEarningsMember
2024-03-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-03-31
0001527728
RENB:SeriesAPreferredStocksMember
2023-03-31
0001527728
us-gaap:CommonStockMember
2023-03-31
0001527728
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001527728
us-gaap:RetainedEarningsMember
2023-03-31
0001527728
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31
0001527728
2023-03-31
0001527728
srt:ScenarioPreviouslyReportedMember
2024-03-31
0001527728
srt:RestatementAdjustmentMember
2024-03-31
0001527728
RENB:RestatedMember
2024-03-31
0001527728
srt:ScenarioPreviouslyReportedMember
2023-07-01
2024-03-31
0001527728
srt:RestatementAdjustmentMember
2023-07-01
2024-03-31
0001527728
RENB:RestatedMember
2023-07-01
2024-03-31
0001527728
srt:ScenarioPreviouslyReportedMember
2024-01-01
2024-03-31
0001527728
srt:RestatementAdjustmentMember
2024-01-01
2024-03-31
0001527728
RENB:RestatedMember
2024-01-01
2024-03-31
0001527728
RENB:BlackScholesOptionPricingModelMember
2024-03-31
0001527728
srt:MinimumMember
RENB:BlackScholesOptionPricingModelMember
2024-03-31
0001527728
srt:MaximumMember
RENB:BlackScholesOptionPricingModelMember
2024-03-31
0001527728
srt:MinimumMember
RENB:BlackScholesOptionPricingModelMember
2023-07-01
2024-03-31
0001527728
srt:MaximumMember
RENB:BlackScholesOptionPricingModelMember
2023-07-01
2024-03-31
0001527728
RENB:BlackScholesOptionPricingModelMember
2023-07-01
2024-03-31
0001527728
RENB:InitialRecognitionMember
2024-03-31
0001527728
srt:MinimumMember
RENB:InitialRecognitionMember
2024-03-31
0001527728
srt:MaximumMember
RENB:InitialRecognitionMember
2024-03-31
0001527728
srt:MinimumMember
RENB:InitialRecognitionMember
2023-07-01
2024-03-31
0001527728
srt:MaximumMember
RENB:InitialRecognitionMember
2023-07-01
2024-03-31
0001527728
RENB:InitialRecognitionMember
2023-07-01
2024-03-31
0001527728
us-gaap:FairValueInputsLevel1Member
2023-06-30
0001527728
us-gaap:FairValueInputsLevel2Member
2023-06-30
0001527728
us-gaap:FairValueInputsLevel3Member
2023-06-30
0001527728
us-gaap:FairValueInputsLevel1Member
2023-07-01
2024-03-31
0001527728
us-gaap:FairValueInputsLevel2Member
2023-07-01
2024-03-31
0001527728
us-gaap:FairValueInputsLevel3Member
2023-07-01
2024-03-31
0001527728
us-gaap:FairValueInputsLevel1Member
2024-03-31
0001527728
us-gaap:FairValueInputsLevel2Member
2024-03-31
0001527728
us-gaap:FairValueInputsLevel3Member
2024-03-31
0001527728
srt:MinimumMember
RENB:LabEquipmentAndInstrumentsMember
2024-03-31
0001527728
srt:MaximumMember
RENB:LabEquipmentAndInstrumentsMember
2024-03-31
0001527728
RENB:LabEquipmentAndInstrumentsMember
2024-03-31
0001527728
RENB:LabEquipmentAndInstrumentsMember
2023-06-30
0001527728
us-gaap:LeaseholdImprovementsMember
2024-03-31
0001527728
us-gaap:LeaseholdImprovementsMember
2023-06-30
0001527728
srt:MinimumMember
us-gaap:FurnitureAndFixturesMember
2024-03-31
0001527728
srt:MaximumMember
us-gaap:FurnitureAndFixturesMember
2024-03-31
0001527728
us-gaap:FurnitureAndFixturesMember
2024-03-31
0001527728
us-gaap:FurnitureAndFixturesMember
2023-06-30
0001527728
us-gaap:PatentsMember
2024-03-31
0001527728
us-gaap:PatentsMember
2023-06-30
0001527728
us-gaap:PatentsMember
2023-07-01
2024-03-31
0001527728
RENB:AccumulatedAmortizationMember
2023-06-30
0001527728
RENB:AccumulatedAmortizationMember
2023-07-01
2024-03-31
0001527728
RENB:AccumulatedAmortizationMember
2024-03-31
0001527728
us-gaap:GoodwillMember
2023-06-30
0001527728
us-gaap:GoodwillMember
2023-07-01
2024-03-31
0001527728
us-gaap:GoodwillMember
2024-03-31
0001527728
RENB:IPRAndDMember
2023-06-30
0001527728
RENB:IPRAndDMember
2023-07-01
2024-03-31
0001527728
RENB:IPRAndDMember
2024-03-31
0001527728
2017-11-12
2017-11-13
0001527728
2018-06-18
2018-06-19
0001527728
2022-06-19
2022-06-20
0001527728
2023-04-17
2023-04-18
0001527728
2023-04-18
0001527728
us-gaap:GeneralAndAdministrativeExpenseMember
2024-01-01
2024-03-31
0001527728
us-gaap:GeneralAndAdministrativeExpenseMember
2023-07-01
2024-03-31
0001527728
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-03-31
0001527728
us-gaap:GeneralAndAdministrativeExpenseMember
2022-07-01
2023-03-31
0001527728
RENB:MarchNote2024Member
2024-03-14
0001527728
RENB:MarchNote2024Member
2024-03-13
2024-03-14
0001527728
RENB:JanuaryNote2024Member
2024-01-11
0001527728
RENB:JanuaryNote2024Member
2024-01-10
2024-01-11
0001527728
RENB:JanuaryNote2024Member
2024-01-12
0001527728
RENB:JanuaryNote2024Member
2024-03-31
0001527728
RENB:JanuaryNote2024Member
2023-07-01
2024-03-31
0001527728
RENB:DecemberNote2023Member
2024-03-31
0001527728
us-gaap:PrivatePlacementMember
RENB:DecemberNote2023Member
2023-07-01
2024-03-31
0001527728
us-gaap:PrivatePlacementMember
2024-01-30
2024-01-31
0001527728
RENB:Note2024Member
2023-07-01
2024-03-31
0001527728
RENB:DecemberNote2023Member
2023-07-01
2024-03-31
0001527728
RENB:Note2024Member
2024-03-31
0001527728
RENB:Note2023Member
2023-10-05
0001527728
RENB:Note2023Member
2023-09-05
2023-10-05
0001527728
RENB:Note2023Member
2024-01-11
0001527728
RENB:Note2023Member
2024-01-01
2024-03-31
0001527728
RENB:Note2023Member
2023-07-01
2024-03-31
0001527728
RENB:Note2023Member
2024-03-31
0001527728
RENB:ConvertibleNotesPayablesMember
2020-02-06
0001527728
RENB:ConvertibleNotesPayablesMember
2020-02-05
2020-02-06
0001527728
RENB:SecuredNotesMember
2022-12-29
2022-12-30
0001527728
RENB:SecuredNotesMember
2022-12-30
0001527728
RENB:SecuredNotesMember
2023-07-01
2024-03-31
0001527728
us-gaap:WarrantMember
RENB:SecuredNotesMember
2023-07-01
2024-03-31
0001527728
RENB:RSBioApSMember
2024-02-05
0001527728
RENB:RSBioApSMember
2024-02-04
2024-02-05
0001527728
us-gaap:InterestExpenseMember
us-gaap:BridgeLoanMember
RENB:RSBioApSMember
2023-07-01
2024-03-31
0001527728
RENB:AccruedExpensesMember
RENB:RSBioApSMember
2023-07-01
2024-03-31
0001527728
us-gaap:BridgeLoanMember
RENB:RSBioApSMember
2024-03-31
0001527728
RENB:January2024NoteMember
2024-01-02
0001527728
RENB:January2024NoteMember
2024-01-01
2024-01-02
0001527728
us-gaap:InterestExpenseMember
us-gaap:BridgeLoanMember
RENB:January2024NoteMember
2024-01-01
2024-03-31
0001527728
us-gaap:InterestExpenseMember
us-gaap:BridgeLoanMember
RENB:January2024NoteMember
2023-07-01
2024-03-31
0001527728
RENB:AccruedExpensesMember
RENB:January2024NoteMember
2023-07-01
2024-03-31
0001527728
us-gaap:BridgeLoanMember
RENB:January2024NoteMember
2024-03-31
0001527728
RENB:LoanAgreementMember
us-gaap:BridgeLoanMember
2023-11-22
2023-11-23
0001527728
RENB:AccruedExpensesMember
RENB:LoanAgreementMember
2023-07-01
2024-03-31
0001527728
us-gaap:BridgeLoanMember
RENB:LoanAgreementMember
2024-03-31
0001527728
RENB:November2023NoteMember
2023-11-03
0001527728
RENB:November2023NoteMember
2023-11-02
2023-11-03
0001527728
RENB:November2023NoteMember
2024-01-02
0001527728
RENB:November2023NoteMember
2024-01-01
2024-01-02
0001527728
us-gaap:InterestExpenseMember
RENB:November2023NoteMember
2024-01-01
2024-03-31
0001527728
us-gaap:InterestExpenseMember
RENB:November2023NoteMember
2023-07-01
2024-03-31
0001527728
RENB:AccruedExpensesMember
RENB:November2023NoteMember
2023-07-01
2024-03-31
0001527728
RENB:November2023NoteMember
2024-03-31
0001527728
RENB:PromissoryNoteMember
2020-03-30
0001527728
RENB:PromissoryNoteMember
2020-03-29
2020-03-30
0001527728
RENB:PromissoryNoteMember
2021-02-11
0001527728
RENB:PromissoryNoteMember
2022-05-16
2022-05-17
0001527728
srt:MinimumMember
RENB:PromissoryNoteMember
2022-05-17
0001527728
srt:MaximumMember
RENB:PromissoryNoteMember
2022-05-17
0001527728
RENB:PromissoryNoteMember
2022-05-17
0001527728
us-gaap:PrivatePlacementMember
2023-06-26
0001527728
us-gaap:PrivatePlacementMember
2023-06-25
2023-06-26
0001527728
us-gaap:InterestExpenseMember
RENB:PromissoryNoteMember
2024-01-01
2024-03-31
0001527728
us-gaap:InterestExpenseMember
RENB:PromissoryNoteMember
2023-07-01
2024-03-31
0001527728
us-gaap:InterestExpenseMember
RENB:PromissoryNoteMember
2023-01-01
2023-03-31
0001527728
us-gaap:InterestExpenseMember
RENB:PromissoryNoteMember
2022-07-01
2023-03-31
0001527728
RENB:PromissoryNoteMember
2024-03-31
0001527728
us-gaap:OtherCurrentLiabilitiesMember
RENB:FinanceAgreementMember
2023-11-30
0001527728
RENB:FinanceAgreementMember
2023-11-29
2023-11-30
0001527728
RENB:FinanceAgreementMember
2024-01-01
2024-03-31
0001527728
RENB:FinanceAgreementMember
2023-01-01
2023-03-31
0001527728
RENB:FinanceAgreementMember
2022-07-01
2023-03-31
0001527728
RENB:FinanceAgreementMember
2023-07-01
2024-03-31
0001527728
RENB:SeriesAConvertiblePreferredStockMember
2024-03-31
0001527728
RENB:SeriesAConvertiblePreferredStockMember
2023-06-30
0001527728
2022-06-20
0001527728
RENB:PurchaseAgreementMember
2023-06-20
0001527728
RENB:PreferredStockIssuancesMember
2023-07-29
2023-08-01
0001527728
RENB:PreferredStockIssuancesMember
2023-08-01
0001527728
RENB:PreferredStockIssuancesMember
2023-07-01
2024-03-31
0001527728
RENB:PreferredStockIssuancesMember
2024-03-31
0001527728
RENB:RenovaroCubeMember
2024-02-13
0001527728
RENB:RenovaroCubeMember
2024-02-12
2024-02-13
0001527728
RENB:CommonStockIssuancesMember
2023-07-28
2023-09-28
0001527728
RENB:AdvisoryServicesMember
2023-10-22
2023-10-23
0001527728
2023-12-03
2023-12-04
0001527728
RENB:StockPurchaseAgreementOfRenovaroCubeMember
2024-02-12
2024-02-13
0001527728
2024-02-14
2024-02-15
0001527728
us-gaap:WarrantMember
2024-02-20
0001527728
srt:MinimumMember
us-gaap:WarrantMember
2024-02-20
0001527728
srt:MaximumMember
us-gaap:WarrantMember
2024-02-20
0001527728
us-gaap:WarrantMember
2024-02-19
2024-02-20
0001527728
us-gaap:WarrantMember
RENB:SingleRangeMember
2024-02-20
0001527728
us-gaap:WarrantMember
RENB:SingleRangeMember
2024-02-19
2024-02-20
0001527728
RENB:DanDritDenmarkMember
2024-03-31
0001527728
us-gaap:StockOptionMember
2024-01-01
2024-03-31
0001527728
us-gaap:StockOptionMember
2023-07-01
2024-03-31
0001527728
us-gaap:StockOptionMember
2023-01-01
2023-03-31
0001527728
us-gaap:StockOptionMember
2022-07-01
2023-03-31
0001527728
RENB:EquityIncentivePlan2014Member
2014-02-06
0001527728
RENB:EmployeesMember
2024-01-01
2024-03-31
0001527728
RENB:EmployeesMember
2023-07-01
2024-03-31
0001527728
RENB:EmployeesMember
2023-01-01
2023-03-31
0001527728
RENB:EmployeesMember
2022-07-01
2023-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2024-01-01
2024-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2023-07-01
2024-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2023-01-01
2023-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2022-07-01
2023-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2024-01-01
2024-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2023-07-01
2024-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2023-01-01
2023-03-31
0001527728
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2022-07-01
2023-03-31
0001527728
RENB:BoardOfDirectorsAndScientificAdvisoryBoardMember
2024-01-01
2024-03-31
0001527728
RENB:BoardOfDirectorsAndScientificAdvisoryBoardMember
2023-07-01
2024-03-31
0001527728
RENB:BoardOfDirectorsAndScientificAdvisoryBoardMember
2023-01-01
2023-03-31
0001527728
RENB:BoardOfDirectorsAndScientificAdvisoryBoardMember
2022-07-01
2023-03-31
0001527728
RENB:PlanOptionsMember
2023-07-01
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
2024-03-31
0001527728
us-gaap:RestrictedStockMember
2024-01-01
2024-03-31
0001527728
us-gaap:RestrictedStockMember
2023-07-01
2024-03-31
0001527728
srt:MinimumMember
RENB:RenovaroMember
2023-07-01
2024-03-31
0001527728
srt:MaximumMember
RENB:RenovaroMember
2023-07-01
2024-03-31
0001527728
RENB:RenovaroMember
2023-07-01
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
RENB:ExercisePriceRange1Member
2023-07-01
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
RENB:ExercisePriceRange1Member
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
RENB:ExercisePriceRange2Member
2023-07-01
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
RENB:ExercisePriceRange2Member
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
RENB:ExercisePriceRange3Member
2023-07-01
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
RENB:ExercisePriceRange3Member
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
2024-03-31
0001527728
us-gaap:EmployeeStockOptionMember
2023-07-01
2024-03-31
0001527728
RENB:EmployeeStockOptionsMember
2023-06-30
0001527728
RENB:EmployeeStockOptionsMember
2022-07-01
2023-06-30
0001527728
RENB:EmployeeStockOptionsMember
2023-07-01
2024-03-31
0001527728
RENB:EmployeeStockOptionsMember
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
RENB:ExercisePriceRange1Member
2023-07-01
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
RENB:ExercisePriceRange1Member
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
RENB:ExercisePriceRange2Member
2023-07-01
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
RENB:ExercisePriceRange2Member
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
RENB:ExercisePriceRange3Member
2023-07-01
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
RENB:ExercisePriceRange3Member
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantsMember
2023-07-01
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantMember
2023-06-30
0001527728
RENB:CommonStockPurchaseWarrantMember
2023-07-01
2024-03-31
0001527728
RENB:CommonStockPurchaseWarrantMember
2022-07-01
2023-06-30
0001527728
RENB:CommonStockPurchaseWarrantMember
2024-03-31
0001527728
RENB:GTechMember
RENB:ConsultingAgreementMember
2018-07-08
2018-07-09
0001527728
RENB:GTechMember
RENB:LicenseAgreementMember
2020-01-30
2020-01-31
0001527728
RENB:GTechMember
RENB:LicenseAgreementMember
2020-02-05
2020-02-06
0001527728
2019-11-14
2019-11-15
0001527728
2021-08-24
2021-08-25
0001527728
2021-09-09
2021-09-10
0001527728
RENB:MarkDybulMember
2023-07-01
2024-03-31
0001527728
RENB:PromissoryNoteMember
RENB:PasecoApsMember
2024-03-26
0001527728
RENB:PromissoryNoteMember
RENB:PasecoApsMember
2024-03-25
2024-03-26
0001527728
RENB:PromissoryNoteMember
RENB:PasecoApsMember
us-gaap:SubsequentEventMember
2024-05-01
2024-05-02
0001527728
RENB:AccruedExpensesMember
RENB:PromissoryNoteMember
RENB:PasecoApsMember
2023-07-01
2024-03-31
0001527728
RENB:PromissoryNoteMember
RENB:PasecoApsMember
2024-03-31
0001527728
RENB:RsBioMember
2024-02-16
0001527728
RENB:RsBioMember
2024-02-14
2024-02-16
0001527728
RENB:PasecoApsMember
2024-02-16
0001527728
srt:MinimumMember
RENB:PasecoApsMember
2024-02-16
0001527728
srt:MaximumMember
RENB:PasecoApsMember
2024-02-16
0001527728
RENB:PasecoApsMember
2024-02-14
2024-02-16
0001527728
RENB:RsBioMember
2024-02-05
0001527728
RENB:RsBioMember
2024-02-04
2024-02-05
0001527728
RENB:RsBioMember
2023-07-01
2023-09-30
0001527728
RENB:RsBioMember
2023-07-01
2024-03-31
0001527728
RENB:RsBioMember
2024-03-31
0001527728
RENB:RsBioMember
RENB:JanuaryNote2024Member
2024-01-02
0001527728
RENB:RsBioMember
RENB:JanuaryNote2024Member
2024-01-01
2024-01-02
0001527728
RENB:RsBioMember
RENB:JanuaryNote2024Member
2023-07-01
2024-03-31
0001527728
RENB:RsBioMember
RENB:JanuaryNote2024Member
2024-01-01
2024-03-31
0001527728
RENB:RsBioMember
RENB:JanuaryNote2024Member
2024-03-31
0001527728
RENB:RsBioMember
RENB:November2023NoteMember
2023-11-03
0001527728
RENB:RsBioMember
RENB:November2023NoteMember
2023-11-02
2023-11-03
0001527728
RENB:RsBioMember
2023-11-02
2023-11-03
0001527728
RENB:GEDiCubeMember
2024-02-12
2024-02-13
0001527728
RENB:GEDiCubeMember
2023-07-01
2024-03-31
0001527728
RENB:GEDiCubeMember
2024-02-13
0001527728
RENB:ConsultingServicesMember
2024-04-04
2024-04-05
0001527728
us-gaap:SubsequentEventMember
RENB:PasecoApsMember
2024-04-09
0001527728
us-gaap:SubsequentEventMember
RENB:PasecoApsMember
2024-05-07
0001527728
us-gaap:SubsequentEventMember
RENB:PasecoApsMember
2024-04-15
2024-05-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q/A
(Amendment
No. 1)
☒ QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission file number 001-38758
Renovaro Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
45-2559340 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
incorporation or organization) |
|
Identification Number) |
|
|
|
2080 Century Park East, Suite 906
Los Angeles, CA |
|
90067 |
(Address of principal executive offices) |
|
(Zip Code) |
+1(305) 918-1980
(Registrant’s telephone number, including area
code)
N/A
(Former name, former address and former fiscal year,
if changed since last report)
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
Common Stock, par value $0.0001 per share |
|
RENB |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒
No ☐
Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
As of May 10, 2024, the number of shares of the registrant’s
Common Stock outstanding was 147,504,944.
EXPLANATORY NOTE
Renovaro Inc. (the “Company”,
“we”, “our”, or “us”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q/A (this
“Amendment”) to amend its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and
Exchange Commission (the “SEC”) on May 15, 2024, (the “Q3 2024 Form 10-Q”) to (i) restate its financial statements
as of and for the periods ended March 31, 2024, which should no longer be relied on and are being restated herein; and (ii) describe the
restatement and its impact on previously reported amounts.
We are filing this Amendment
to amend and restate the Q3 2024 Form 10-Q with modifications as necessary to reflect these restatements.
Background of Restatement
On August 14, 2024, the Audit
Committee (the “Audit Committee”) of the Board of Directors of the Company, based on the recommendation of the Company’s
management, and after consultation with the Company’s independent registered public accounting firm, concluded that the Company’s
previously issued unaudited interim condensed consolidated financial statements for the quarter ended March 31, 2024 contained a material
misstatement related to the value of its indefinite life intangible assets and, accordingly, should no longer be relied upon. Similarly,
related reports filed with the Securities Exchange Commission (the “SEC”), earnings releases, press releases, shareholder
communications, investor presentations or other communications describing relevant portions of the March 31, 2024, financial statements
should no longer be relied upon. The Company is restating the March 31, 2024, financial statements within this Amendment.
During the preparation of the
Company’s response to an SEC comment letter dated July 12, 2024, the Company’s management identified an error in the March
31, 2024, financial statements resulting from an error in the method used to measure the impairment charge associated with the termination
of the Weird Science License Agreement described in Note 6 of the March 31, 2024 financial statements. The error resulted in, among other
things, an overstatement of the Company’s assets and an understatement of the Company’s net loss and net loss per share for
the three and nine months ended March 31, 2024.
Refer to “Note 2 - Restatement
of Previously Issued Financial Statements” of “Part I - Item 1. Financial Statements” (“Note 2”) for
additional information.
Internal Control Considerations
Due to discovery of the error,
the Company’s management re-evaluated the effectiveness of the Company’s internal control over financial reporting (“ICFR”)
as of March 31, 2024 and believes the error relates to and is the result of a previously identified and reported material weakness which
has been disclosed in our Form 10-K filed on October 2, 2023. The material weakness remained in place as of March 31, 2024. For a discussion
of management’s consideration of disclosure controls and procedures, internal controls over financial reporting and the material
weaknesses identified, see “Part I - Item 4. Controls and Procedures” of this Amendment.
Items Amended in this Amendment
This Amendment amends and restates
the following items included in the original filing as appropriate to reflect the restatement of the relevant periods:
| ● | Part
I - Item 1. Financial Statements (Unaudited); |
| ● | Part
I - Item 2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations; and |
| ● | Part
II, Item 6. Exhibits. |
This Amendment includes new certifications
by our principal executive officer and principal financial officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of
2002 dated as of this filing in connection with this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2 hereto.
Except as described in Note 2,
no other information included in the Q3 2024 Form 10-Q is being amended or updated by this Amendment and, other than as described herein,
this Amendment does not purport to reflect any information or events subsequent to the Q3 2024 Form 10-Q. This Amendment continues to
describe the conditions as of the date of the Q3 2024 Form 10-Q and, except as expressly contained herein, we have not updated, modified
or supplemented the disclosures contained in the Q3 2024 Form 10-Q. Accordingly, this Amendment should be read in conjunction with the
Q3 2024 Form 10-Q and with our filings with the SEC subsequent to the Q3 2024 Form 10-Q.
RENOVARO INC. AND SUBSIDIARIES
- INDEX -
|
|
Page |
PART I – FINANCIAL INFORMATION: |
1 |
|
|
|
Item 1. |
Restated Financial Statements (Unaudited): |
1 |
|
|
|
|
Restated Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited)
and June 30, 2023 |
2 |
|
|
|
|
Restated Condensed Consolidated Statements of Operations for the Three and
Nine Months Ended March 31, 2024, and 2023 (Unaudited) |
3 |
|
|
|
|
Restated Condensed Consolidated Statements of Comprehensive Loss for the Three
and Nine Months Ended March 31, 2024, and 2023 (Unaudited) |
4 |
|
|
|
|
Condensed Consolidated Statements of Stockholders’ Equity for the Nine Months Ended March 31, 2024, and 2023 (Unaudited) |
5 |
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2024, and 2023 (Unaudited) |
7 |
|
|
|
|
Notes to the Condensed Consolidated Financial Statements (Unaudited) |
8 |
|
|
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
36 |
|
|
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
45 |
|
|
|
Item 4. |
Controls and Procedures |
45 |
|
|
|
PART II – OTHER INFORMATION: |
46 |
|
|
|
Item 1. |
Legal Proceedings |
46 |
|
|
|
Item 1A. |
Risk Factors |
48 |
|
|
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
63 |
|
|
|
Item 3. |
Defaults Upon Senior Securities |
64 |
|
|
|
Item 4. |
Mine Safety Disclosures |
64 |
|
|
|
Item 5. |
Other Information |
64 |
|
|
|
Item 6. |
Exhibits |
65 |
|
|
|
Signatures |
66 |
PART I – FINANCIAL INFORMATION
Item 1. Restated Financial
Statements.
During the
preparation of the Company’s response to an SEC comment letter dated July 12, 2024, the Company’s management identified an
error in the March 31, 2024 financial statements resulting from an error in the method used to measure the impairment charge associated
with the termination of a license agreement with Weird Science, LLC. The error resulted in, among other things, an overstatement of the
Company's assets and an understatement of the Company's net loss and net loss per share for the three and nine months ended March 31,
2024. Refer to “Note 2 - Restatement of Previously Issued Financial Statements” for additional information.
The accompanying restated financial
statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance
with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements.
In the opinion of management,
the restated financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present
fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.
The results for the period ended
March 31, 2024, are not necessarily indicative of the results of operations for the full year. These restated financial statements and
related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Form
10-K for the fiscal year ended June 30, 2023, filed with the Securities and Exchange Commission on October 2, 2023.
RENOVARO INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
March 31, |
|
June 30, |
|
|
2024 |
|
2023 |
|
|
(Unaudited) |
|
|
ASSETS |
|
|
(As restated) |
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
|
Cash |
|
$ |
312,697 |
|
|
$ |
1,874,480 |
|
Prepaids and other assets |
|
|
907,218 |
|
|
|
690,925 |
|
Total Current Assets |
|
|
1,219,915 |
|
|
|
2,565,405 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
488,915 |
|
|
|
508,989 |
|
|
|
|
|
|
|
|
|
|
OTHER ASSETS: |
|
|
|
|
|
|
|
|
Definite life intangible assets, net |
|
|
31,042 |
|
|
|
39,676 |
|
Indefinite life intangible assets |
|
|
10,755,255 |
|
|
|
42,611,000 |
|
Goodwill |
|
|
164,186,852 |
|
|
|
11,640,000 |
|
Deposits and other assets |
|
|
21,742 |
|
|
|
21,741 |
|
Operating lease right-of-use assets |
|
|
1,385,619 |
|
|
|
913,985 |
|
Total Other Assets |
|
|
176,380,510 |
|
|
|
55,226,402 |
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS |
|
$ |
178,089,340 |
|
|
$ |
58,300,796 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
Accounts payable – trade |
|
$ |
7,990,631 |
|
|
$ |
5,296,823 |
|
Accrued expenses |
|
|
3,754,976 |
|
|
|
723,173 |
|
Other current liabilities |
|
|
519,427 |
|
|
|
184,733 |
|
Contingent consideration liability, current (Note 4) |
|
|
1,006,438 |
|
|
|
— |
|
Current portion of operating lease liabilities |
|
|
483,226 |
|
|
|
193,422 |
|
Notes payable, net |
|
|
3,418,621 |
|
|
|
4,624,947 |
|
Convertible notes payable |
|
|
3,700,694 |
|
|
|
— |
|
Total Current Liabilities |
|
|
20,874,013 |
|
|
|
11,023,098 |
|
|
|
|
|
|
|
|
|
|
NON-CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating lease liabilities, net of current portion |
|
|
970,353 |
|
|
|
775,587 |
|
Contingent consideration liability, noncurrent (Note 4) |
|
|
19,064,562 |
|
|
|
— |
|
Deferred tax liability |
|
|
2,774,856 |
|
|
|
— |
|
Total Non-Current Liabilities |
|
|
22,809,771 |
|
|
|
775,587 |
|
Total Liabilities |
|
|
43,683,784 |
|
|
|
11,798,685 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (Note 10) |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY: |
|
|
|
|
|
|
|
|
Preferred stock, $0.0001
par value; 10,000,000 shares authorized;
zero 0 shares issued and outstanding
at March 31, 2024 and June 30, 2023 |
|
|
— |
|
|
|
— |
|
Common Stock, par value $0.0001, 350,000,000 shares authorized, 147,488,598 shares issued and outstanding at March 31, 2024, and 63,698,144 shares issued and outstanding at June 30, 2023 |
|
|
14,750 |
|
|
|
6,371 |
|
Additional paid-in capital |
|
|
442,304,652 |
|
|
|
290,554,875 |
|
Accumulated deficit |
|
|
(308,947,816 |
) |
|
|
(244,029,253 |
) |
Accumulated other comprehensive income (loss) |
|
|
1,033,970 |
|
|
|
(29,882 |
) |
Total Stockholders’ Equity |
|
|
134,405,556 |
|
|
|
46,502,111 |
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
178,089,340 |
|
|
$ |
58,300,796 |
|
See accompanying notes to the unaudited condensed consolidated
financial statements.
RENOVARO INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
For the Nine Months Ended |
|
|
March 31, |
|
March 31, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
|
(As restated) |
|
|
|
(As restated) |
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
$ |
7,652,379 |
|
|
$ |
3,796,057 |
|
|
$ |
19,558,981 |
|
|
$ |
12,365,960 |
|
Research and development |
|
|
1,087,156 |
|
|
|
239,137 |
|
|
|
2,274,321 |
|
|
|
3,170,471 |
|
Intangible asset impairment (Note 6) |
|
|
42,611,000 |
|
|
|
— |
|
|
|
42,611,000 |
|
|
|
— |
|
Depreciation and amortization |
|
|
30,305 |
|
|
|
28,242 |
|
|
|
90,727 |
|
|
|
85,487 |
|
Total Operating Expenses |
|
|
51,380,840 |
|
|
|
4,063,436 |
|
|
|
64,535,029 |
|
|
|
15,621,918 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS |
|
|
(51,380,840 |
) |
|
|
(4,063,436 |
) |
|
|
(64,535,029 |
) |
|
|
(15,621,918 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of contingent consideration (Note 4) |
|
|
486,500 |
|
|
|
— |
|
|
|
486,500 |
|
|
|
— |
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(120,018 |
) |
|
|
— |
|
Loss on extinguishment of contingent consideration liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(419,182 |
) |
Interest expense |
|
|
(303,802 |
) |
|
|
(122,289 |
) |
|
|
(758,057 |
) |
|
|
(310,766 |
) |
Interest and other income (expense) |
|
|
(16,272 |
) |
|
|
(142,571 |
) |
|
|
8,041 |
|
|
|
(133,938 |
) |
Total Other Income (Expense) |
|
|
166,426 |
|
|
|
(264,860 |
) |
|
|
(383,534 |
) |
|
|
(863,886 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS |
|
$ |
(51,214,414 |
) |
|
$ |
(4,328,296 |
) |
|
$ |
(64,918,563 |
) |
|
$ |
(16,485,804 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC AND DILUTED NET LOSS PER SHARE |
|
$ |
(0.48 |
) |
|
$ |
(0.08 |
) |
|
$ |
(0.82 |
) |
|
$ |
(0.30 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED |
|
|
107,480,475 |
|
|
|
55,974,605 |
|
|
|
79,168,663 |
|
|
|
55,524,511 |
|
See accompanying notes to the unaudited condensed consolidated
financial statements.
RENOVARO INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
LOSS
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
For the Nine Months Ended |
|
|
March 31, |
|
March 31, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
|
(As restated) |
|
|
|
(As restated) |
|
|
Net Loss |
|
$ |
(51,214,414 |
) |
|
$ |
(4,328,296 |
) |
|
$ |
(64,918,563 |
) |
|
$ |
(16,485,804 |
) |
Other Comprehensive Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation, net of taxes |
|
|
1,061,201 |
|
|
|
(2,110 |
) |
|
|
1,063,852 |
|
|
|
(1,949 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive Loss |
|
$ |
(50,153,213 |
) |
|
$ |
(4,330,406 |
) |
|
$ |
(63,854,711 |
) |
|
$ |
(16,487,753 |
) |
See accompanying notes to the unaudited condensed consolidated
financial statements.
RENOVARO INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’
EQUITY
(UNAUDITED)
| |
| |
| |
| |
| |
| |
| |
| |
|
| |
# of Series A Preferred Shares | |
Series A Preferred Shares Amount | |
# of common Shares | |
Common Shares | |
Additional Paid-In Capital | |
Accumulated Deficit | |
Accumulated Other Comprehensive Income | |
Total |
June 30, 2023 | |
| — | | |
| — | | |
| 63,698,144 | | |
$ | 6,371 | | |
$ | 290,554,875 | | |
$ | (244,029,253 | ) | |
$ | (29,882 | ) | |
$ | 46,502,111 | |
Issuance of preferred stock and warrants in private placement | |
| 280,505 | | |
| 28 | | |
| — | | |
| — | | |
| 1,999,972 | | |
| — | | |
| — | | |
| 2,000,000 | |
Issuance of preferred stock and warrants for conversion of Note Payable | |
| 280,505 | | |
| 28 | | |
| — | | |
| — | | |
| 1,999,973 | | |
| — | | |
| — | | |
| 2,000,001 | |
Restricted shares issued for services rendered | |
| — | | |
| — | | |
| 2,000,000 | | |
| 200 | | |
| 4,469,800 | | |
| — | | |
| — | | |
| 4,470,000 | |
Stock-based compensation | |
| — | | |
| — | | |
| — | | |
| — | | |
| 983,829 | | |
| — | | |
| — | | |
| 983,829 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (9,175,028 | ) | |
| — | | |
| (9,175,028 | ) |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (34,601 | ) | |
| (34,601 | ) |
September 30, 2023 | |
| 561,010 | | |
| 56 | | |
| 65,698,144 | | |
| 6,571 | | |
| 300,008,449 | | |
| (253,204,281 | ) | |
| (64,483 | ) | |
| 46,746,312 | |
Stock issued pursuant to warrants exercised | |
| — | | |
| — | | |
| 525,945 | | |
| 53 | | |
| 341,812 | | |
| — | | |
| — | | |
| 341,865 | |
Restricted shares issued for advisory services | |
| — | | |
| — | | |
| 1,000,000 | | |
| 100 | | |
| (100 | ) | |
| — | | |
| — | | |
| — | |
Stock-based compensation | |
| — | | |
| — | | |
| — | | |
| — | | |
| 999,228 | | |
| — | | |
| — | | |
| 999,228 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (4,529,121 | ) | |
| — | | |
| (4,529,121 | ) |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 37,252 | | |
| 37,252 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
December 31, 2023 | |
| 561,010 | | |
| 56 | | |
| 67,224,089 | | |
| 6,724 | | |
| 301,349,389 | | |
| (257,733,402 | ) | |
| (27,231 | ) | |
| 43,595,536 | |
Non-cash exercise of warrants | |
| — | | |
| — | | |
| 3,425,399 | | |
| 343 | | |
| 1,999,657 | | |
| — | | |
| — | | |
| 2,000,000 | |
Restricted shares issued for services rendered | |
| — | | |
| — | | |
| 50,000 | | |
| 5 | | |
| 99,995 | | |
| — | | |
| — | | |
| 100,000 | |
Issuance of common stock under private placement offering | |
| — | | |
| — | | |
| 344,827 | | |
| 34 | | |
| 999,966 | | |
| — | | |
| — | | |
| 1,000,000 | |
Issuance of common stock pursuant to acquisition of GEDi Cube (Note 12) | |
| — | | |
| — | | |
| 70,834,183 | | |
| 7,083 | | |
| 135,994,548 | | |
| — | | |
| — | | |
| 136,001,631 | |
Preferred stock converted to common stock pursuant to acquisition of GEDi Cube (Note 12) | |
| (561,010 | ) | |
| (56 | ) | |
| 5,610,100 | | |
| 561 | | |
| (505 | ) | |
| — | | |
| — | | |
| — | |
Stock-based compensation | |
| — | | |
| — | | |
| — | | |
| — | | |
| 1,861,601 | | |
| — | | |
| — | | |
| 1,861,601 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (51,214,414 | ) | |
| — | | |
| (51,214,414 | ) |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 1,061,201 | | |
| 1,061,201 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
March 31, 2024 (As restated) | |
| — | | |
$ | — | | |
| 147,488,598 | | |
$ | 14,750 | | |
$ | 442,304,652 | | |
$ | (308,947,816 | ) | |
$ | 1,033,970 | | |
$ | 134,405,556 | |
| |
#
of Series A Preferred Shares | |
Series
A Preferred Shares Amount | |
# of Shares | |
Common
Shares | |
Additional
Paid-In Capital | |
Accumulated
Deficit | |
Accumulated
Other Comprehensive Income | |
Total |
July 1, 2022 | |
| — | | |
| — | | |
| 53,007,082 | | |
$ | 5,302 | | |
$ | 276,989,179 | | |
$ | (204,345,197 | ) | |
$ | (30,436 | ) | |
$ | 72,618,848 | |
Stock issued pursuant to warrants
exercised | |
| — | | |
| — | | |
| 1,250,000 | | |
| 125 | | |
| 1,624,875 | | |
| | | |
| | | |
| 1,625,000 | |
Contingent shares issued pursuant
to acquisition agreement | |
| — | | |
| — | | |
| 1,250,000 | | |
| 125 | | |
| 2,762,375 | | |
| — | | |
| — | | |
| 2,762,500 | |
Stock-based compensation | |
| — | | |
| — | | |
| — | | |
| — | | |
| 1,026,008 | | |
| — | | |
| — | | |
| 1,026,008 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (7,699,760 | ) | |
| — | | |
| (7,699,760 | ) |
Foreign currency
translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (7,754 | ) | |
| (7,754 | ) |
September 30, 2022 | |
| — | | |
| — | | |
| 55,507,082 | | |
| 5,552 | | |
| 282,402,437 | | |
| (212,044,957 | ) | |
| (38,190 | ) | |
| 70,324,842 | |
Shares issued in lieu of interest
on $1.2 million notes payable extension | |
| — | | |
| — | | |
| 198,439 | | |
| 20 | | |
| 204,372 | | |
| — | | |
| — | | |
| 204,392 | |
Stock-based compensation | |
| — | | |
| — | | |
| — | | |
| — | | |
| 819,955 | | |
| — | | |
| — | | |
| 819,955 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (4,457,748 | ) | |
| — | | |
| (4,457,748 | ) |
Foreign currency
translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 7,915 | | |
| 7,915 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
December 31, 2022 | |
| — | | |
| — | | |
| 55,705,521 | | |
| 5,572 | | |
| 283,426,764 | | |
| (216,502,705 | ) | |
| (30,275 | ) | |
| 66,899,356 | |
Shares and warrants issued pursuant
to private placement offering | |
| — | | |
| — | | |
| 2,178,070 | | |
| 218 | | |
| 2,482,782 | | |
| — | | |
| — | | |
| 2,483,000 | |
Restricted shares issued for services
rendered | |
| — | | |
| — | | |
| 100,000 | | |
| 10 | | |
| 107,990 | | |
| — | | |
| — | | |
| 108,000 | |
Stock-based compensation | |
| — | | |
| — | | |
| — | | |
| — | | |
| 968,203 | | |
| — | | |
| — | | |
| 968,203 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (4,328,296 | ) | |
| — | | |
| (4,328,296 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Foreign currency
translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (2,110 | ) | |
| (2,110 | ) |
March 31,
2023 | |
| — | | |
$ | — | | |
| 57,983,591 | | |
$ | 5,800 | | |
$ | 286,985,739 | | |
$ | (220,831,001 | ) | |
$ | (32,385 | ) | |
$ | 66,128,153 | |
See accompanying notes to the unaudited condensed consolidated
financial statements.
RENOVARO INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended |
|
|
March 31, |
|
|
2024 |
|
2023 |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
(As restated) |
|
|
|
|
|
Net loss |
|
$ |
(64,918,563 |
) |
|
$ |
(16,485,804 |
) |
|
|
|
|
|
|
|
|
|
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
90,727 |
|
|
|
85,487 |
|
Change in fair value of contingent consideration |
|
|
(486,500 |
) |
|
|
— |
|
Loss on extinguishment of debt |
|
|
120,018 |
|
|
|
— |
|
Loss on extinguishment of contingent consideration liability |
|
|
— |
|
|
|
419,182 |
|
Stock based compensation expense |
|
|
3,844,658 |
|
|
|
2,922,166 |
|
Intangible asset impairment |
|
|
42,611,000 |
|
|
|
— |
|
Restricted shares for services rendered |
|
|
4,570,000 |
|
|
|
— |
|
Amortization of discount on notes payable |
|
|
494,809 |
|
|
|
223,863 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Other receivables |
|
|
— |
|
|
|
46 |
|
Prepaid expenses/deposits |
|
|
798,741 |
|
|
|
689,273 |
|
Accounts payable |
|
|
2,110,232 |
|
|
|
3,069,487 |
|
Accrued expenses |
|
|
2,194,293 |
|
|
|
(407,433 |
) |
Other current liabilities |
|
|
— |
|
|
|
(18,520 |
) |
Operating leases, net |
|
|
12,936 |
|
|
|
(10,684 |
) |
NET CASH USED IN OPERATING ACTIVITIES |
|
|
(8,557,649 |
) |
|
|
(9,512,937 |
) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
Notes receivable prior to acquisition |
|
|
(1,225,779 |
) |
|
|
— |
|
Cash received from acquisition |
|
|
65,851 |
|
|
|
— |
|
Purchase of property and equipment |
|
|
(46,878 |
) |
|
|
(23,633 |
) |
NET CASH USED IN INVESTING ACTIVITIES |
|
|
(1,206,806 |
) |
|
|
(23,633 |
) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Proceeds from issuance of promissory notes |
|
|
3,645,000 |
|
|
|
— |
|
Repayment of finance agreement |
|
|
(646,128 |
) |
|
|
(840,992 |
) |
Proceeds from private placement |
|
|
3,000,000 |
|
|
|
2,483,000 |
|
Proceeds from notes payable |
|
|
1,710,000 |
|
|
|
— |
|
Proceeds from exercise of warrants |
|
|
341,865 |
|
|
|
1,625,000 |
|
NET CASH PROVIDED BY FINANCING ACTIVITIES |
|
|
8,050,737 |
|
|
|
3,267,008 |
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash |
|
|
151,935 |
|
|
|
45,462 |
|
|
|
|
|
|
|
|
|
|
NET CHANGE IN CASH |
|
|
(1,561,783 |
) |
|
|
(6,224,100 |
) |
|
|
|
|
|
|
|
|
|
CASH, BEGINNING OF PERIOD |
|
|
1,874,480 |
|
|
|
9,172,142 |
|
|
|
|
|
|
|
|
|
|
CASH, END OF PERIOD |
|
$ |
312,697 |
|
|
$ |
2,948,042 |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|
|
|
|
|
|
|
|
Cash paid during the period for: |
|
|
|
|
|
|
|
|
Interest |
|
$ |
12,692 |
|
|
$ |
43,627 |
|
Income taxes |
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Finance agreement entered into in exchange for prepaid assets |
|
$ |
906,834 |
|
|
$ |
1,139,875 |
|
Shares in lieu of interest on $1.2 million notes payable extension |
|
$ |
— |
|
|
$ |
204,392 |
|
Common shares issued for contingent earn out liability |
|
$ |
— |
|
|
$ |
2,762,500 |
|
Conversion of note payable for issuance of preferred stock |
|
$ |
2,000,001 |
|
|
$ |
— |
|
Common shares issued upon acquisition |
|
$ |
136,001,631 |
|
|
$ |
— |
|
Contingent consideration issued upon acquisition |
|
$ |
20,557,500 |
|
|
$ |
— |
|
Note payable settled through non-cash exercise of warrants |
|
$ |
2,000,000 |
|
|
$ |
— |
|
Debt discount related to notes payable |
|
$ |
301,841 |
|
|
$ |
— |
|
See accompanying notes to the unaudited condensed consolidated
financial statements.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED
RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Business
– On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(“Renovaro”, and together with its subsidiaries, the “Company”, “we” or “us”). In
August 2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company engages
in the research and development of pharmaceutical and biological products for the treatment of cancer, HIV, and HBV with the intent
to manufacture said products. On February 13, 2024, Renovaro Inc. acquired Renovaro Cube Intl Ltd and its subsidiaries (“Renovaro Cube”), as a wholly
owned subsidiary pursuant to a stock purchase agreement.
Basis of Presentation
– The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange
Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash
flows at March 31, 2024, and 2023 and for the periods then ended have been made. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying
unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto
included in the Company’s June 30, 2023, audited financial statements. The results of operations for the period ended March
31, 2024 are not necessarily indicative of the operating results for the full year.
Consolidation – For
the three and nine months ended March 31, 2024, and 2023, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.
Accounting Estimates –
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses
during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value of assets
acquired in a business acquisition, contingent consideration, and equity instruments issued for goods or services.
Functional
Currency & Foreign Currency Translation – The functional currency of Renovaro Denmark is the Danish Kroner
(“DKK”) and the functional currency of Renovaro Cube is the Euro (“EUR”). The Company’s reporting
currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated
into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average
exchange rates prevailing during the periods ended March 31, 2024, and 2023. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the
statement of operations as incurred.
Cash and Cash Equivalents –
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.
Concentration of Credit Risk
– Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits
are held. As of March 31, 2024 and June 30, 2023, the Company has not experienced losses on these accounts and management believes the
Company is not exposed to significant risks on such accounts.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)
Property and Equipment –
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5.)
Intangible Assets – The
Company has both definite and indefinite life intangible assets.
Definite life intangible assets
include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Definite life intangible
assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent
will not be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized
on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.
Indefinite life intangible assets
include in-process research and development (“IPR&D”) and goodwill. The Company accounts for indefinite life intangible
assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. IPR&D represents the fair value of the technology
on the date acquired and is tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying
value may not be recoverable.
Goodwill – Goodwill
is not amortized but is evaluated for impairment annually as of June 30th of each fiscal year or whenever events or changes
in circumstances indicate the carrying value may not be recoverable.
Impairment of Goodwill and Indefinite
Life Intangible Assets – We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. The Company has elected to perform its annual analysis on June 30th.
The annual fair value analysis performed on goodwill supported that goodwill was not impaired as of June 30, 2023. There have been no
events which have caused the Company to conduct an interim evaluation of its goodwill through March 31, 2024 (see Note 6.)
For indefinite life intangible assets, such as IPR&D, on an annual basis
on June 30th we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the
asset over its fair value. For the year ended June 30, 2023, the carrying value of the IPR&D exceeded its fair value. Therefore, the
Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023. During the quarter ended March 31, 2024, the Company
recorded an impairment loss of $42,611,000 related to the termination of the license agreement with Weird Science LLC (see Note 6.).
Impairment of Long-Lived Assets
– Long-lived assets, such as property and equipment, definite and indefinite life intangible assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which
could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes
in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast
of continuing losses associated with the use of the asset; and current expectations that the asset will more likely than not be sold or
disposed of significantly before the end of its estimated useful life.
Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be
generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)
Leases – In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.
Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations.
For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on
a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited
condensed consolidated statements of operations.
The Company has elected the practical
expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance,
insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred
(see Note 7.)
Research and Development Expenses
– The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Oncology, HIV and HBV therapies and technologies for use in the prevention,
treatment, amelioration of and/or therapy for Oncology, HIV and HBV. Research and development expenses for the three and nine months ended
March 31, 2024, amounted to $1,087,156, and $2,274,321, respectively. Research and development expenses for the three and nine months
ended March 31, 2023, amounted to $239,137, and $3,170,471, respectively.
Income Taxes – The
Company accounts for income taxes in accordance with FASB ASC Topic 740, “Accounting for Income Taxes”, which requires an
asset and liability approach for accounting for income taxes.
Loss Per Share – The
Company calculates earnings/ (loss) per share in accordance with FASB ASC Topic 260, “Earnings Per Share”. Basic earnings
per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings
per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential
shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted
but have not been exercised and shares issuable upon conversion of convertible preferred stock and convertible notes. Because of the net
loss for the three and nine months ended March 31, 2024, and 2023, the dilutive shares for all periods were excluded from the Diluted
EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 9,522,967 and 5,410,460 potential
shares of Common Stock excluded from the Diluted EPS calculation as of March 31, 2024, and March 31, 2023, respectively.
Fair Value of Financial Instruments
– The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, “Fair Value Measurements”. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of March 31, 2024 and
2023, respectively. Level 3 liabilities held as of March 31, 2024, consisted of a contingent consideration
liability related to the February 13, 2024, acquisition of Renovaro Cube (see Note 4.)
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)
Stock Options and Restricted
Share Units – The Company has granted stock options, restricted share units (“RSUs”) and warrants. The Company accounts
for stock-based awards in accordance with the provisions of FASB ASC Topic 718, “Compensation - Stock Compensation”.
Stock-Based Compensation
– The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation - Stock Compensation”.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for
based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably
measurable. Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized
based on the fair value of the equity instruments issued and are recognized over the required service period, which is generally
the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the three and nine months ended March
31, 2024 were $1,861,601 and $3,844,658, respectively. Stock based compensation costs for the vesting of options and RSUs granted for
the three and nine months ended March 31, 2023 were $1,076,203 and $2,922,166, respectively (See Note 9.)
Recently Adopted Accounting
Pronouncements – Recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material
impact on the Company’s present or future financial statements.
NOTE 2 — RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
On July 12, 2024, the Company
received an SEC Comment Letter questioning its accounting for its indefinite life intangible assets impairment related to the
license agreement with Weird Science, LLC which was terminated on March 31, 2024, as described in Note 6.
After further analysis by
management and review of the applicable accounting requirements, the Company determined that its original impairment recognized in
its March 31, 2024 financial statements was not correct and those financial statements should be restated to reflect further
impairment of certain of its indefinite life intangible assets related to the license agreement with Weird Science, LLC.
The impact of the restatement on
these financial statements by line item is as follows:
Schedule
of restatement of previously issued financial statements | |
| |
| |
|
| |
As Reported | |
Change | |
As Rested |
Indefinite
life intangible assets | |
$ | 44,945,255 | | |
$ | (34,190,000 | ) | |
$ | 10,755,255 | |
| |
| | | |
| | | |
| | |
Total
other assets | |
$ | 210,570,510 | | |
$ | (34,190,000 | ) | |
$ | 176,380,510 | |
Total
assets | |
$ | 212,279,340 | | |
$ | (34,190,000 | ) | |
$ | 178,089,340 | |
Accumulated
deficit | |
$ | (274,757,816 | ) | |
$ | (34,190,000 | ) | |
$ | (308,947,816 | ) |
Total
stockholders’ equity | |
$ | 168,595,556 | | |
$ | (34,190,000 | ) | |
$ | 134,405,556 | |
Total
liabilities and stockholders’ equity | |
$ | 212,279,340 | | |
$ | (34,190,000 | ) | |
$ | 178,089,340 | |
Intangible
asset impairment | |
$ | 8,421,000 | | |
$ | 34,190,000 | | |
$ | 42,611,000 | |
Total
operating expenses for the three months ended March 31, 2024 | |
$ | 17,190,840 | | |
$ | 34,190,000 | | |
$ | 51,380,840 | |
Total
operating expenses for the nine months ended March 31, 2024 | |
$ | 30,345,029 | | |
$ | 34,190,000 | | |
$ | 64,535,029 | |
Loss
from operations three months ended March 31, 2024 | |
$ | (17,190,840 | ) | |
$ | (34,190,000 | ) | |
$ | (51,380,840 | ) |
Loss
from operations nine months ended March 31, 2024 | |
$ | (30,345,029 | ) | |
$ | (34,190,000 | ) | |
$ | (64,535,029 | ) |
Net
loss for the three months ended March 31, 2024 | |
$ | (17,024,414 | ) | |
$ | (34,190,000 | ) | |
$ | (51,214,414 | ) |
Net
loss for the nine months ended March 31, 2024 | |
$ | (30,728,563 | ) | |
$ | (34,190,000 | ) | |
$ | (64,918,563 | ) |
Comprehensive
loss for the three months ended March 31, 2024 | |
$ | (15,963,213 | ) | |
$ | (34,190,000 | ) | |
$ | (50,153,213 | ) |
Comprehensive
loss for the nine months ended March 31, 2024 | |
$ | (29,664,711 | ) | |
$ | (34,190,000 | ) | |
$ | (63,854,711 | ) |
Basic
and diluted net loss per share for the three months ended March 31, 2024 | |
$ | (0.16 | ) | |
$ | (0.32 | ) | |
$ | (0.48 | ) |
Basic
and diluted net loss per share for the nine months ended March 31, 2024 | |
$ | (0.39 | ) | |
$ | (0.43 | ) | |
$ | (0.82 | ) |
NOTE 3 — GOING CONCERN
The Company’s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional
financing to fund operations. The Company incurred a net loss of $51,214,414 and $64,918,563 for the three and nine months ended March
31, 2024, respectively. As of March 31, 2024, the Company had cash and cash equivalents of $312,697 and an accumulated deficit of $308,947,816
and a working capital deficit of $19,654,098. These conditions raise substantial doubt about the Company’s ability to continue as
a going concern for one year after the date the financial statements are issued. The condensed consolidated financial statements do not
include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3 — GOING
CONCERN (Continued)
Management has reduced overhead and administrative costs by streamlining the organization
to focus around two of its therapies (oncology and a HIV therapeutic vaccine) and investment in the development and validation of its
AI driven cancer diagnostics platform. The Company has tailored its workforce to focus on these therapies. In addition, the Company intends
to attempt to secure additional required funding through equity or debt financing. However, there can be no assurance that the Company
will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on reasonable terms,
and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders. If we do not obtain
required additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend
operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with
whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations,
we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their
investment in us.
Funding that we may receive during
the fiscal year 2024 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.
NOTE 4 — FAIR VALUE MEASUREMENTS
The Company accounts for fair
value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the
guidance establishes a three-tier fair value hierarchy, which
prioritizes the inputs used in measuring fair value as follows:
|
● |
Level 1. Observable inputs
such as quoted prices in active markets for identical assets or liabilities; |
|
● |
Level 2. Inputs, other
than quoted prices in active markets, that are observable either directly or indirectly; and |
|
● |
Level 3. Unobservable inputs
in which there is little or no market data, which require the reporting entity to develop its own assumptions. |
There
were no Level 1, 2 or 3 assets, nor any Level 1 or 2 liabilities as of March 31, 2024.
Level 3 liabilities held as of
March 31, 2024, consisted of a contingent consideration liability related to the February 13, 2014, acquisition of Renovaro
Cube, (the “Acquisition”). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) 70,834,183
shares of Common Stock, and (ii) the right to receive contingent shares pro rata
upon the exercise of convertible notes, options, and warrants, which were outstanding at closing. The contingent consideration liability
was recorded at fair value of $20,557,500
at the time of acquisition and is subsequently remeasured to fair value at the end
of each reporting period. At March 31, 2024, there were 8,474,146
contingent shares issuable in connection with the Acquisition of Renovaro Cube.
The fair value of the
contingent consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model.
The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the
volatility of the Company’s underlying stock. The key inputs to valuing the contingent consideration liability as of March 31,
2024, were:
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 — FAIR VALUE MEASUREMENTS (Continued)
Schedule of fair value contingent consideration | |
| | |
Stock Price | |
$ | 2.65 | |
Exercise Price | |
| $0.46 - $4.50 | |
Volatility | |
| 109% - 140% | |
Risk Free Rate | |
| 4.11% - 5.26% | |
Expected Dividends | |
| 0 | % |
Discount Rate (Monte-Carlo model only) | |
| 12 | % |
Expected Term (years) | |
| 0.43 – 9.75 | |
At initial recognition of the contingent consideration,
the inputs were:
Stock Price | |
$ | 1.92 | |
Exercise Price | |
| $0.46 - $4.50 | |
Volatility | |
| 107% - 133% | |
Risk Free Rate | |
| 4.22% - 5.14% | |
Expected Dividends | |
| 0 | % |
Discount Rate (Monte-Carlo model only) | |
| 12 | % |
Expected Term (years) | |
| 0.56 – 9.88 | |
Unless otherwise disclosed,
the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable,
accrued expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.
The following table sets forth
the Level 3 liability at March 31, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required,
this liability is classified based on the lowest level of input that is significant to the fair value measurement:
Schedule of consolidated balance sheet at
fair value on a recurring basis | |
| | | |
| | | |
| | |
| |
Fair Value Measurements at Reporting Date Using |
| |
Quoted Prices in Active Markets for Identical Assets Inputs | |
Significant Other Observable Inputs | |
Significant Other Unobservable Inputs |
| |
(Level 1) | |
(Level 2) | |
(Level 3) |
| |
| |
| |
|
The roll forward of the contingent consideration liability is as follows: | |
| | | |
| | | |
| | |
Balance June 30, 2023 | |
| — | | |
| — | | |
$ | — | |
Contingent consideration in Acquisition | |
| — | | |
| — | | |
| 20,557,500 | |
Fair value adjustment | |
| — | | |
| — | | |
| (486,500 | ) |
Contingent Consideration Liability at March 31, 2024 | |
| — | | |
| — | | |
$ | 20,071,000 | |
NOTE 5 — PROPERTY AND EQUIPMENT
Property and equipment consisted of the following:
Schedule of property and equipment | |
| |
| |
|
| |
Useful Life | |
March 31, 2024 | |
June 30, 2023 |
Lab Equipment and Instruments | |
| 4-7 | | |
$ | 617,882 | | |
$ | 576,298 | |
Leasehold Improvements | |
| 10 | | |
| 224,629 | | |
| 224,629 | |
Furniture, Fixtures and Equipment | |
| 4-7 | | |
| 194,398 | | |
| 172,861 | |
Total | |
| | | |
| 1,036,909 | | |
| 973,788 | |
Less Accumulated Depreciation | |
| | | |
| (547,994 | ) | |
| (464,799 | ) |
Net Property and Equipment | |
| | | |
$ | 488,915 | | |
$ | 508,989 | |
Depreciation expense amounted to
$29,526 and $83,203 for the three and nine months ended March 31, 2024, respectively, and $26,662 and $80,915 for the three and nine months
ended March 31, 2023, respectively.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 — INTANGIBLE ASSETS AND GOODWILL
At March 31, 2024, and June 30,
2023, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes
of $31,042 and $39,676, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization
expense for the three and nine months ended March 31, 2024, was $779 and $7,524, respectively. Amortization expense for the three and
nine months ended March 31, 2023, was $1,580 and $4,572, respectively.
At March 31, 2024, and 2023, indefinite
life intangible assets consisted of In-Process Research and Development (“IPR&D”), which
is not amortizable until the intangible asset provides economic benefit.
At March 31, 2024, and June 30,
2023, definite and indefinite-life intangible assets consisted of the following:
Schedule of intangible assets | |
| |
| |
| |
| |
| |
| |
|
| |
Useful Life | |
June 30, 2023 | |
Additions | |
Amortization | |
Impairment | |
Translation Adjustment | |
March 31, 2024 |
Definite Life Intangible Assets | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Patents | |
20 Years | |
$ | 290,936 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | (3,856 | ) | |
$ | 287,080 | |
Less Accumulated Amortization | |
| |
| (251,260 | ) | |
| — | | |
| (7,524 | ) | |
| — | | |
| 2,746 | | |
| 256,038 | |
Net Definite-Life Intangible Assets | |
| |
$ | 39,676 | | |
$ | — | | |
$ | (7,524 | ) | |
$ | — | | |
$ | (1,110 | ) | |
$ | 31,042 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Indefinite Life Intangible Assets and Goodwill | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Goodwill | |
| |
| 11,640,000 | | |
| 151,536,444 | | |
| — | | |
| — | | |
| 1,010,408 | | |
| 164,186,852 | |
IPR&D | |
| |
$ | 42,611,000 | | |
| 10,684,091 | | |
| — | | |
| (42,611,000 | ) | |
| 71,164 | | |
| 10,755,255 | |
Total Indefinite Life Intangible Assets and Goodwill | |
| |
$ | 54,251,000 | | |
$ | 162,220,535 | | |
$ | — | | |
$ | (42,611,000 | ) | |
$ | 1,081,572 | | |
$ | 174,942,107 | |
Expected future amortization expense
is as follows:
Schedule of expected future amortization expense | |
|
Year ending June 30, | |
|
| 2024 | | |
$ | 1,942 | |
| 2025 | | |
| 9,700 | |
| 2026 | | |
| 9,700 | |
| 2027 | | |
| 9,700 | |
| Total | | |
$ | 31,042 | |
During February 2018, the Company
acquired IPR&D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale,
import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of
and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&D intangible
asset was classified as an indefinite life asset that was tested annually for impairment.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 — INTANGIBLE
ASSETS AND GOODWILL (Continued)
On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement. As part of the acquisition of Renovaro
Cube, the Company acquired IPR&D assets valued at $10,684,091.
Impairment – On
March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between
Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated
February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 in the period ended
March 31, 2024.
NOTE 7 — LEASES
Operating
Leases — On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.
On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. Renovaro subleased the space as
of June 25, 2022 through April 30, 2023. (See subsection below “Sublease Agreement” for details.)
Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase.
The Company identified and assessed
the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:
Expected lease term
— The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company’s leases have a remaining lease term of 41 and 23 months. As of
March 31, 2024, the weighted-average remaining term is 2.77 years.
Incremental borrowing rate
— The Company’s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of March 31, 2024, the weighted-average
discount rate is 5.16%.
Lease and non-lease components
— In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 — LEASES (Continued)
Below are the lease commitments
for the next 5 years:
| Schedule of
lease commitments | | |
| | |
Year Ending June 30th | |
Lease Expense |
| 2024 | | |
| 286,252 | |
| 2025 | | |
| 557,851 | |
| 2026 | | |
| 349,204 | |
| 2027 | | |
| 309,491 | |
| 2028 | | |
| 59,439 | |
| Sub-total | | |
| 1,562,237 | |
| Less imputed interest | | |
| (108,658 | ) |
| Total | | |
$ | 1,453,579 | |
Sublease Agreement
On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.
In accordance with ASC Topic 842,
the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease.
The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement
date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease,
as it did not meet the criteria of a sales-type or direct financing lease.
On
April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed
to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $139,460 along with the security
deposit of $35,540 for a total termination fee of $175,000, to permit early termination of the sublease.
The Company recognized operating
income from the sublease on a straight-line basis in its statements of operations over the sublease term.
During the three and nine months
ended March 31, 2024 and 2023, the net operating lease expenses were as follows:
Schedule of net operating
lease expenses | |
| | | |
| | | |
| | | |
| | |
| |
For the Three Months Ended | |
For the Nine Months Ended |
| |
March 31, | |
March 31, |
| |
2024 | |
2023 | |
2024 | |
2023 |
| |
| |
| |
| |
|
Operating Lease Expense | |
$ | 106,790 | | |
$ | 99,099 | | |
$ | 236,455 | | |
$ | 239,759 | |
Sub lease Income | |
| — | | |
| (53,310 | ) | |
| — | | |
| (159,930 | ) |
| |
| | | |
| | | |
| | | |
| | |
Total Net Lease Expense | |
$ | 106,790 | | |
$ | 45,789 | | |
$ | 236,455 | | |
$ | 79,829 | |
Lease expense charged to general
and administrative expenses for the three and nine months ended March 31, 2024, amounted to $106,790 and $236,455, respectively. Lease
expense charged to general and administrative expenses for the three and nine months ended March 31, 2023, amounted to $45,789 and
$79,829, respectively. During the three and nine months ended March 31, 2024, the Company paid $108,441 and $232,237 under operating
leases, respectively. During the three and nine months ended March 31, 2023, the Company paid $98,950 and $339,993 under operating
leases, respectively. The difference between the operating lease expense for the nine months ended March 31, 2023 in the amount of $79,829
and the cash paid of $339,993, is primarily made up of the release of an accrual of $77,242 related to the termination of the Plaza Medical
Office Building, LLC lease.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 — DEBT
Convertible Notes Payable —
March 2024 Note —
On March 14, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount
of $500,000 (the “March 2024 Note”). The March 2024 Note bears an interest rate of 10% per annum and shall mature on March
15, 2025. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the issue date prior to the maturity of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest
may accrue on this Note on a quarterly basis. The March 2024 Note is convertible either at the option of the holder after a qualified
offering. If no qualified offering occurs prior to the maturity date, the March 2024 Note is to be repaid in cash.
The 2024 Notes —
On January 11, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the “January
2024 Note I”) in the amount of $460,000. The January 2024 Note I bears an interest rate of 12% per annum and shall mature on January
11, 2025. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the Issue Date prior to the maturity of the Notes. Notwithstanding the immediately foregoing, at the option of the Holder, interest may
accrue on this Note on a quarterly basis. The January 2024 Note I is convertible either at the option of the Holder or automatically upon
maturity into shares of the Company’s Common Stock at the conversion price of $3.38. On January 12, 2024, the Company entered into
Subscription Agreements with an investor (the “Investor”) to issue a Convertible Promissory Note for an aggregate principal
amount of $125,000 (the “January 2024 Note II”, and collectively with the January 2024 Note I, the “January 2024 Notes”).
The Company received a total of $125,000 in gross proceeds. The January 2024 Note II bears an interest rate of 12% per annum and
shall mature on December 29, 2024 (the “Maturity Date”). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2024 Notes. The January 2024
Note II is convertible either at the option of the Holder or automatically upon maturity into shares of the Company’s Common Stock
at the Note Conversion Price of $3.38. The January 2024 Notes principal balance at March 31, 2024, is $585,000.
December 2023 Notes — Between December
1, 2023, and December 29, 2023, the Company entered into Subscription Agreements with two investors to purchase Convertible Promissory
Notes for an aggregate principal amount of $560,000 (the “December Notes”). The Company received a total of $560,000 in gross
proceeds from the private placement prior to the end of the quarter ending December 31, 2023, and it subsequently received $20,000 in
January 2024. The December Notes bear an interest rate of 12% per annum and shall mature one year after their respective dates of
issuance (the “Maturity Date”). The Company is required to pay interest quarterly, in arrears, in cash, on the first day of
each quarter of each year following the Issue Date prior to the maturity of the December Notes. Notwithstanding the immediate foregoing,
at the option of the Holder, interest may accrue on the December Notes on a quarterly basis. The December Notes are convertible into shares
of the Company’s Common Stock in whole or in part at any time and from time to time, after the Original Issue Date and prior to
the Maturity Date, at a conversion price of $3.38 per share. The December Notes will be accounted for under ASC 470-20, and all proceeds
received from the issuance will be recognized as a liability on the balance sheet. The December Notes principal balance at March 31, 2024,
is $560,000.
As of March 31, 2024, the Company
accrued interest expense of $37,463 related to the 2024 Notes and December 2023 Notes. The 2024 Notes and December 2023 Notes balance
at March 31, 2024 was $1,645,000.
The 2023 Notes — Between
September 5, 2023, and October 5, 2023, the Company entered into Subscription Agreements with five investors to purchase 5% Original Issue
Discount Convertible Promissory Notes (the “2023 Notes”) for an aggregate principal amount of $2,105,263. The Company received
a total of $2,000,000 in gross proceeds from the private placement, after taking into account the 5% original issue discount. The
discount of $105,263 will be accreted over the life of the 2023 Notes. The 2023 Notes bear an interest rate of 12% per annum and shall
mature on September 5, 2024 (the “Maturity Date”). The Company is required to pay interest quarterly, in arrears, in cash,
on the first day of each quarter of each year following the Issue Date prior to the maturity of the 2023 Notes. Notwithstanding the immediately
foregoing, at the option of the Holder, interest may accrue on the Notes on a quarterly basis. The 2023 Notes are convertible into shares
of the Company’s Common Stock upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 — DEBT (Continued)
The 2023 Notes are subject to mandatory
conversion (“Mandatory Conversion”) in the event the Company closes an offering of its Common Stock and receives gross proceeds
of not less than $10,000,000 (“Qualified Offering”). The conversion price per share of Common Stock in the case of a Mandatory
Conversion shall be 95% of the offering price per share in the Qualified Offering, subject to a floor of $4.50 per share. In addition,
if no Qualified Offering occurs prior to the Maturity Date, the 2023 Notes shall automatically convert into shares of Common Stock on
the Maturity Date at a conversion price per share equal to the closing sale price of the Common Stock on the Maturity Date, subject to
a floor of $4.50 per share.
On January 11, 2024, the Company
entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional
conversion at a conversion price of $3.38 per share. All other terms of the Promissory Note remained the same. The Company treated this
as a modification for accounting purposes.
For the three and nine months ended
March 31, 2024, discount amortization of $26,316 and $55,694 was charged to interest expense, respectively. As of March 31, 2024, the
Company accrued interest expense of $134,719. The 2023 Notes balance, net of discount at March 31, 2024 is $2,055,694.
The Convertible Notes —
On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to Paseco ApS (the “Holder”),
a Danish limited company and an existing stockholder of the Company, each with a face value amount of $600,000, convertible into shares
of Common Stock. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis of twelve 30-day months, and was
compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as
of such compound date. The interest was payable in cash on a semi-annual basis.
The
conversion price was equal to $12.00 per share of Common Stock. The Holder did not exercise its conversion feature that expired on
February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded
conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily
convertible into cash. All proceeds received from the issuance were recognized as a liability on the balance sheet.
Effective December 30, 2022
(the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured
Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February
28, 2024. The Amended and Restated Secured Notes are convertible by the Holder if the Company consummates a
public offering or private placement of Common Stock or securities convertible into Common Stock. The conversion price shall be the
price being paid by the investors in such offering. The interest rate was increased to twelve percent (12%)
per annum, which was prepaid by the Company in full on the date of amendment through the issuance of 198,439
shares of the Company’s Common Stock: 29,419
shares for accrued interest up to the Effective Date and 169,020
shares related to the prepayment of interest through the extension date of the Amended and Restated Secured Notes using the closing
market price on the Effective Date, of $1.03.
The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the
“Security Agreement”). The Company evaluated the Amended and Restated Secured Notes and conversion feature to determine
the appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480- Distinguishing Liabilities
from Equity, the Company determined that the Amended and Restated Secured Notes embody an obligation that may require the Company to
settle with the issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a
fixed monetary amount of $1,200,000
known at inception. Accordingly, the Company recorded the Amended and Restated Secured Notes as share settled debt. The total value
of the shares issued was $204,392
which included $174,090
of prepaid interest and $30,302
for accrued interest as of December 30, 2022. On June 26, 2023, the Holder notified the
Company that it wished to elect to exercise its conversion right triggered by a private placement. Therefore, all outstanding $1,200,000
Amended and Restated Secured Notes were converted into 2,264,150 shares of Common Stock and 1,132,075
warrants. There were no Amended and Restated Secured Notes outstanding after the foregoing conversion.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 — DEBT (Continued)
Notes Payable—
Bridge Loans — On
March 26, 2024, the Company issued Paseco ApS a Promissory Note in the principal amount of $160,000. The Note bears an interest rate of
10% per annum and was to mature on May 1, 2024. On May 1, 2024, the Company and Paseco ApS entered into an amendment to the Promissory
Note to extend the maturity date to July 1, 2024 (the “Maturity Date”). The Company is required to pay interest on the maturity
date. The Notes Payable will be accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized as a liability
on the balance sheet. As of March 31, 2024, the Company accrued $215 of interest expense that is included in accrued expenses on the balance
sheet. The Note balance at March 31, 2024 is $160,000.
On February 5, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by our Chairman, Rene Sindlev (“RS Bio”) to issue a
5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263. The Company received $100,000 in gross proceeds
after taking into account the 5% original issue discount. The Note bears an interest rate of 12% per annum and matured on March 1, 2024
(the “Maturity Date”). The obligations under this Note are secured by the Amended and Restated Security Agreement (discussed
below). The Company is required to pay interest on the maturity date. The Notes Payable will be accounted for under ASC 470-20, and all
proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. For the three and nine months
ended March 31, 2024, discount amortization of $5,263 was charged to interest expense, respectively. As of March 31, 2024, the Company
accrued $3,158 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March
31, 2024 was $105,263.
On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315
(the “January 2024 Note”). The Company received a total of $500,000 in gross proceeds after taking into account the 5% original
issue discount. The January 2024 Note bears an interest rate of 12% per annum and matured on March 1, 2024 (the “Maturity Date”).
The Company is required to pay interest on the maturity date. The Notes Payable will be accounted for under ASC 470-20, and all proceeds
received from the issuance will be recognized as a liability on the balance sheet net of discount. For the three and nine months ended
March 31, 2024, discount amortization of $26,315 was charged to interest expense, respectively. As of March 31, 2024, the Company accrued
$15,789 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March 31,
2024 was $526,315. In connection with the entry into the January 2024 Note, the Company and Paseco ApS agreed to amend and restate the
Security Agreement (see Note 8) to add the Company’s obligations under the November 2023 Note and the January 2024 Note to the Secured
Obligations (as defined in the Amended and Restated Security Agreement).
On November 22, 2023, Renovaro
Cube entered into a loan agreement where the holder agreed to loan the Company up to £500,000 (approximately $624,000 USD). The note
has a repayment date occurring the first business day after the first anniversary of the draw down of the loan. The first draw down of
£250,000 occurred on November 27, 2023, and the second draw down of £249,994 occurred on December 13, 2023. The Company will
pay interest on the loan at the rate of 10% per annum. Interest is accrued quarterly in arrears on the last business day of March, June,
September, and December and is payable on the repayment date. As of March 31, 2024, the Company accrued $10,545 of interest expense that
is included in accrued expenses on the balance sheet. The total amount of the note at March 31, 2024, is $639,544.
On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5%
Original Issue Discount Promissory Note for the principal amount of $1,000,000
(the “November 2023 Note”). The Company received a total of $950,000
in gross proceeds after taking into account the 5%
original issue discount. The discount of $50,000
will be accreted over the life of the Note. The November 2023 Note bears an interest rate of 12%
per annum and was due to mature on January
1, 2024 (the “Maturity Date”). On January 1, 2024, the Company entered into an amendment with RS Bio for the November
3, 2023, $1,000,000
Note Payable bridge loan to extend the maturity date until March
1, 2024. The Company is required to pay interest on the maturity date. The Notes Payable will be accounted for under ASC 470-20,
and all proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. On February 16, 2024,
the Company received notice from the holder to exercise 471,699
warrants outstanding at $0.53
per share and apply $250,000
of the note balance to the exercise price of the warrants. For the three and nine months ended March 31, 2024, discount amortization
of zero 0
and $50,000
was charged to interest expense, respectively. As of March 31, 2024, the Company accrued $46,583
of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March 31,
2024 is $750,000.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 — DEBT (Continued)
Promissory Note — On
March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $5,000,000 (the “Promissory
Note”) to the Holder. The principal amount of the Promissory Note was originally payable on November 30, 2021 (the “Maturity
Date”). The Promissory Note bore interest at a fixed rate of 6% per annum, computed based on the number of days between the Issuance
Date and the Maturity Date, and the interest was prepaid by the Company in full on the Issuance Date through the issuance of 188,485
shares of the Company’s Common Stock based on the closing market price on that date for a total value of $501,370. The Company
evaluated the Promissory Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20,
proceeds received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding
discount of $493,192, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective
interest method. The discount of $493,192 will be accreted over the life of the Promissory Note.
On February 11, 2021, the Company
entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory
Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6% per annum, which was
prepaid by the Company in full on the date of the amendment through the issuance of 74,054 shares of the Company’s Common Stock
based on the closing market price on that date for a total value of $298,178.
On May 17, 2022, the Company entered
into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 and increased the interest rate from
6% to 12% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year
of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022
until May 30, 2023 on the date of the amendment through the issuance of 47,115 shares of the Company’s Common Stock based on the
closing market price on that date for a total value of $299,178. All other accrued interest payable from May 30, 2023 to the Maturity
Date was required to be paid by the Company on May 30, 2023, at the option of the Holder in either (i) cash or (ii) shares of the Company’s
Common Stock, valued at the closing sale price of the Common Stock on the Nasdaq Capital Market on May 30, 2023. The Holder elected the
interest be paid in cash (the “Interest Payment”).
Effective December 30, 2022, the
Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under
the Promissory Note were secured by the Security Agreement. To secure the Company’s obligations under each of the Amended and Restated
Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted
a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined
in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession
of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.
On June 12, 2023, the Holder notified
the Company that it wanted to apply the Interest Payment due to it towards the Company’s next private placement. Therefore, on June
26, 2023, in conjunction with the Company’s private placement, the Company issued (i) 567,588 shares of its Common Stock, par value
$0.0001 per share and (ii) warrants to purchase 283,794 shares of Common Stock at a purchase price of $0.53 per share and applied the
Interest Payment of $300,822 it owed to the Holder.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 — DEBT (Continued)
On July 31, 2023, the Company
and the Holder agreed to amend the Promissory Note (the “Fourth Amendment”) to provide the Holder with limited conversion
rights in connection with the Company’s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to
convert $2 million of the outstanding principal balance of the Promissory Note into the Units being offered in a private placement at
the price per Unit being paid by the investors in the private placement (the “Conversion Right”). On August 1, 2023, the Holder
notified the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of
the Promissory Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible
Preferred Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of
$0.65 per share. The Series A Convertible Preferred Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common
Stock. A $3 million principal balance remains outstanding under the Promissory Note after the foregoing conversion. The Company concluded
that in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value
of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded
in Other Income/Loss in the Statement of Operations. On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note
(the “Fifth Amendment”) to where the Company and the Holder extended the maturity of the Original Note until February 29,
2024. In addition, all interest payable from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company
as of November 30, 2023. On February 16, 2024, the Company received notice from the holder to exercise 2,953,700 warrants outstanding
ranging from $0.53 to $0.65 per share and apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29,
2024, the Company and the Holder agreed to amend the Promissory Note (the “Sixth Amendment”) to where the Company and the
Holder extended the maturity of the Original Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend the Promissory
Note (the “Seventh Amendment”) to extend the maturity of the Original Note until May 1, 2024. For the three and nine months
ended March 31, 2024, discount amortization of $72,500 and $357,536 was charged to interest expense. For the three and nine months ended
March 31, 2023, discount amortization of $74,621 and $223,863 was charged to interest expense. The Promissory Note balance, net of discount
at March 31, 2024 is $1,237,500.
Finance Agreement —
On November 30, 2023, the
Company entered into a premium finance agreement (the “Agreement”) related to insurance, which
resulted in the recognition of a liability and prepaid expense with a principal amount of $906,834 at 7.90%
interest per annum, which is reflected on the consolidated balance sheet under “other current liabilities” and
“prepaid assets and other assets”, respectively. The repayment of the Agreement will be made in nine equal monthly
installments of $77,127 after
a down payment of $235,000. For
the three and nine months ended March 31, 2024 the Company made payments of $223,945 and
$646,128,
respectively. For the three and nine months ended March 31, 2023, under a similar arrangement, the Company made payments of
$374,367 and
$840,992,
respectively. For the three and nine months ended March 31, 2024, the Company recorded total interest expense in the amount of 7,436
and $12,692 related
to the Agreement. This amount is reflected in other income and expenses.
Total interest expense recorded
for the three and nine months ended March 31, 2024, was $303,802 and $758,057, respectively. Interest
expense recorded for the three and nine months ended March 31, 2023, was $122,289 and $310,766, respectively.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 — STOCKHOLDERS’ EQUITY
Preferred Stock —
The Company has 10,000,000
authorized shares of Preferred Stock, par value $0.0001
per share, of which 1,000,000
shares have been designated as Series A Convertible Preferred Stock. At March 31, 2024, and June 30, 2023, there were zero
0 shares
of Series A Convertible Preferred Stock issued and outstanding.
Voting — Holders of
Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
Holder’s shares of Preferred Stock could then be converted in accordance with conversion rights.
Dividends — The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.
Liquidation Rights —
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all Shares held by such holder. The Series A Preferred Stock is not participating preferred.
Conversion Rights — On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a “Series A Election
Notice”) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
“Conversion Ratio”).
Common Stock —During the period ended March 31, 2024, the Company increased its authorized
shares of Common Stock. The
Company has 350,000,000 authorized shares of Common Stock, par value $0.0001 per share. At March 31, 2024, and June 30, 2023, there were
147,488,598 and 63,698,144 shares issued and outstanding, respectively.
Voting — Holders of
Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.
Dividends — Holders
of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available.
Liquidation Rights —
In the event of any liquidation, dissolution, or winding up of affairs of the Company, after payment of all debts and liabilities and
preferences to holders of preferred stock, the holders of Common Stock will be entitled to share ratably in the distribution of any of
the remaining assets.
Purchase Agreement with Lincoln Park Capital
On June
20, 2023, the Company entered into a purchase agreement (the “2023 Purchase Agreement”) with Lincoln Park Capital Fund, LLC
(“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $20,000,000 of shares of Common Stock over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 — STOCKHOLDERS’
EQUITY (Continued)
In consideration for entering into
the 2023 Purchase Agreement, the Company issued 696,021 shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.
During the three and nine months
ended March 31, 2024, no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.
Preferred Stock Issuances
On August 1, 2023, the Company
closed a private placement of 280,505 units (the “Units”), each consisting of (i) one share of the Company’s
Series A Convertible Preferred Stock, (the “Preferred Stock”) and (ii) one Common Stock purchase warrant (each, a “Warrant”,
and together with the Units and the shares of Preferred Stock, the “Securities”) to purchase five shares of the Company’s
Common Stock, at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $2,000,000 in cash. In addition, the Company
issued 280,505 Units in connection with the conversion of $2,000,000 of the Promissory Note (see Note 8.)
The Company issued an aggregate
of 561,010 shares of Preferred Stock, which are initially convertible into an aggregate of 5,610,100 shares of Common Stock. In connection
with the Private Placement, the Company sold Warrants to purchase an aggregate of 2,805,050 shares of Common Stock. The Warrants are exercisable
for five years from the date of issuance and have an exercise price of $0.65 per share, payable in cash.
On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the 561,010
shares of Preferred Stock were converted into an aggregate of 5,610,100
shares of Common Stock. As of March 31, 2024 there were zero shares of 0 Preferred
Stock outstanding.
Common Stock Issuances
Between July 28, 2023 and September
28, 2023, the Company issued 2,000,000 shares of Common Stock for consulting services.
On October 23, 2023 the
Company issued 1,000,000
shares of Common Stock for advisory services to Avram Miller, a member of the Company’s board of directors.
On December 4, 2023 the Company
issued 525,945 shares of Common Stock pursuant to warrants exercised for cash proceeds of $341,865.
On
February 13, 2024 the Company issued 70,834,183 shares of Common Stock pursuant to the Stock Purchase Agreement of Renovaro Cube.
On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the 561,010 shares of Preferred Stock were converted into an aggregate of 5,610,100 shares of Common
Stock.
On
February 15, 2024 the Company closed a private placement of 344,827 shares of Common Stock, $0.0001 par value, at $2.90 per share for
aggregate proceeds to the Company of $1,000,000 in cash.
On February 15, 2024 the Company
issued 50,000 shares of Common Stock for consulting services.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 — STOCKHOLDERS’
EQUITY (Continued)
On February 20, 2024, 2,953,700
warrants outstanding were exercised ranging from $0.53 to $0.65 per share and the aggregate $1,750,000 of a promissory note held by the
holder was applied to the exercise price of the warrants (see Note 8).
On February 20, 2024, 471,699
warrants outstanding were exercised ranging at $0.53 per share and $250,000 of a promissory note held by the holder was applied to the
exercise price of the warrants (see Note 8).
Acquisition of Renovaro
Denmark — At March 31, 2024, and June 30, 2023, the Company maintained a reserve of 17,414
shares of Common Stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”), all of which are
reflected as issued and outstanding in the accompanying consolidated financial statements. The Escrow Shares are reserved to acquire
the shares of Renovaro Denmark held by non-consenting shareholders of Renovaro Denmark on both March 31, 2024, and June 30, 2023, in
accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been 167,639
shares of Common Stock issued to non-consenting shareholders of Renovaro Denmark as of March 31, 2024. During the three and nine
months ended March 31, 2024, the Company issued zero 0
shares of Common Stock to such non-consenting shareholders of Renovaro Denmark. There is no impact on outstanding shares as these
shares are reflected as issued and outstanding.
Stock-based Compensation
The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated
on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of
the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended March 31, 2024:
Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted | |
| | |
| |
Renovaro Inc. |
Expected term (in years) | |
| 5.0 – 6.5 | |
Volatility | |
| 84.33% – 108.79 | % |
Risk free interest rate | |
| 3.12% – 4.83 | % |
Dividend yield | |
| 0 | % |
On
February 13, 2024, the Company repriced 3,849,931 eligible employee and consultant options from the original issued exercise price to
$1.92 per share, the closing price of the Company’s Common Stock on February 13, 2024. The Company recognized stock-based compensation
expense related to the repricing of options of $886,849
for the period ended March 31, 2024.
In total, the Company recognized
stock-based compensation expense related to options of $1,326,592 and $2,775,793 for the three and nine months ended March 31, 2024, respectively.
The Company recognized stock-based compensation expense related to options of $1,076,203 and
$2,922,166 for the three and nine months ended March 31, 2023, respectively. At March 31, 2024, the Company had approximately
$579,305 of unrecognized compensation cost related to non-vested options.
Plan Options
On February 6, 2014, the Board
adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 shares of
Common Stock for issuance in accordance with the terms of the 2014 Plan.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 — STOCKHOLDERS’
EQUITY (Continued)
On October 30, 2019, the Board
approved and on October 31, 2019, the Company’s stockholders adopted its 2019 Equity Incentive Plan (the “2019 Plan”),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company’s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.
Effective July 21, 2023, the
Company adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan replaced the
2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject to and will be
available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire, terminate,
or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2023
Plan.
The Company granted options
to purchase zero
0 and 366,500
shares of Common Stock to employees with a three-year vesting period during the three and nine months ended March 31, 2024,
respectively under the 2019 and 2023 Plan. The Company granted options to purchase 15,000
and 193,000
shares of Common Stock to employees with a three-year vesting period during the three and nine months ended March 31, 2023,
respectively under the 2019 Plan.
During the three and nine
months ended March 31, 2024, respectively, the Company granted options to purchase zero
0 shares of Common Stock to employees with a six-month vesting period under the 2023 Plan. During the three and nine
months ended March 31, 2023, the Company granted options to purchase zero 0
and 184,800
issued and 0 18,960
forfeited shares of Common Stock to employees with a six-month vesting period, respectively under the 2019 Plan.
During the three and nine
months ended March 31, 2024, respectively, the Company granted options to purchase zero 0
shares of Common Stock to employees with a one-year vesting period under the 2023 Plan. During the three and nine months ended March
31, 2023, the Company granted options to purchase zero 0
and 73,200
issued and 0 12,640
forfeited shares of Common Stock to employees with a one-year vesting period, respectively under the 2019 Plan.
During the three and nine months
ended March 31, 2024, the Company granted options to purchase 28,196 and 371,595 shares of Common Stock, to the Board of Directors and
Scientific Advisory Board Members with a one-year vesting period under the 2023 Plan and the 2019 Plan, respectively. During
the three and nine months ended March 31, 2023, the Company granted options to purchase 64,655 and 275,572 shares
of Common Stock, to the Board of Directors and Scientific Advisory Board Members with a one-year vesting period under the 2019 Plan, respectively.
During the three and nine months
ended March 31, 2024, the Company granted options to purchase zero and 26,000 shares, respectively of Common Stock for Scientific Advisory
Board members with immediate vesting under the 2023 Plan. During the three and nine months ended
March 31, 2023, the Company did not grant options to Scientific Advisory Board members to purchase
shares of Common Stock with immediate vesting.
During
the three and nine months ended March 31, 2024, the Company granted options to purchase 10,000 shares of Common Stock to a consultant
with ten months vesting. During the three and nine months ended March 31, 2024, the Company forfeited zero and 7,000 options, respectively,
to purchase shares of Common Stock to a consultant with immediate vesting.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 — STOCKHOLDERS’
EQUITY (Continued)
All of the above options
are exercisable at the market price of the Company’s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931 eligible employee
and consultant options from the original issued exercise price to $1.92 per share, the closing price of the Company’s Common Stock
on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $886,849 for the period ended March 31, 2024.
To date the Company has granted
options under the 2014, 2019 and 2023 Plans (“Plan Options”) to purchase 6,306,275 shares of Common Stock. At March 31, 2024,
the Company has 4,875,419 options available to be issued under the 2023 Plan.
A summary of the status of the
Plan Options outstanding at March 31, 2024, is presented below:
Schedule of stock options outstanding | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Options Outstanding | |
Options Exercisable |
| |
Exercise Price Ranges | |
Number Outstanding | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price | |
Number Exercisable | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price |
| | |
$ | 0.45–4.50 | | |
| 4,885,441 | | |
| 7.43 | | |
$ | 1.91 | | |
| 3,410,589 | | |
| 7.10 | | |
$ | 1.98 | |
| | |
$ | 4.51–6.50 | | |
| 167,634 | | |
| 6.73 | | |
$ | 5.33 | | |
| 135,376 | | |
| 6.06 | | |
$ | 5.49 | |
| | |
$ | 6.51–12.00 | | |
| 115,231 | | |
| 4.91 | | |
$ | 7.63 | | |
| 111,585 | | |
| 4.82 | | |
$ | 7.61 | |
Total | | |
| | | |
| 5,168,306 | | |
| 7.35 | | |
$ | 2.15 | | |
| 3,657,550 | | |
| 6.99 | | |
$ | 2.28 | |
A summary of the status of the
Plan Options at March 31, 2024, and changes since July 1, 2023, are presented below:
Schedule of stock option activity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
Weighted Average Exercise Price |
|
Average Remaining Life |
|
Weighted Average Intrinsic Value |
|
|
|
|
|
|
|
|
|
Outstanding at beginning of period |
|
|
|
4,401,211 |
|
|
$ |
4.78 |
|
|
|
7.82 |
|
|
$ |
— |
|
Granted |
|
|
|
4,624,026 |
|
|
$ |
1.97 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Expired/Canceled |
|
|
|
(3,856,931 |
) |
|
$ |
4.94 |
|
|
|
|
|
|
|
|
|
Outstanding at end of period |
|
|
|
5,168,306 |
|
|
$ |
2.15 |
|
|
|
7.35 |
|
|
$ |
— |
|
Exercisable at end of period |
|
|
|
3,657,550 |
|
|
$ |
2.28 |
|
|
|
6.99 |
|
|
$ |
3,839,725 |
|
At March 31, 2024, the Company had Plan Options to purchase 3,657,550 shares
of common stock that were exercisable. The total intrinsic value of options exercisable at March 31, 2024, was $3,839,725. Intrinsic value
is measured using the fair market value at the date of exercise (for shares exercised) and at March 31, 2024 (for outstanding options),
less the applicable exercise price.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 — STOCKHOLDERS’
EQUITY (Continued)
Common Stock Purchase Warrants
A summary of the status of the
Common Stock Purchase Warrants outstanding at March 31, 2024, is presented below:
Schedule of common stock purchase warrants outstanding | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Warrants Outstanding | |
Warrants Exercisable |
| |
Exercise Price | |
Number Outstanding | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price | |
Number Exercisable | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price |
| | |
$ | 0.53 | | |
| 471,698 | | |
| 1.41 | | |
| | | |
| 471,698 | | |
| 1.41 | | |
| | |
| | |
$ | 0.65 | | |
| 741,274 | | |
| 3.25 | | |
| | | |
| 741,274 | | |
| 3.25 | | |
| | |
| | |
$ | 1.14 | | |
| 1,189,036 | | |
| 3.98 | | |
| | | |
| 1,189,036 | | |
| 3.98 | | |
| | |
Total | | |
| | | |
| 2,402,008 | | |
| 3.25 | | |
$ | 0.87 | | |
| 2,402,008 | | |
| 3.25 | | |
$ | 0.87 | |
A summary of the warrants outstanding at March 31, 2024, and changes since
July 1, 2023, are presented below:
Schedule of warrants outstanding | |
| | | |
| | | |
| | |
| |
Shares | |
Weighted Average Exercise Price | |
Weighted Average Remaining Life |
| |
| |
| |
|
Outstanding at beginning of period | |
| 3,548,302 | | |
$ | 0.73 | | |
| 4.80 | |
Granted | |
| 2,805,050 | | |
$ | 0.65 | | |
| 3.25 | |
Exercised | |
| (3,951,344 | ) | |
$ | 0.59 | | |
| — | |
Cancelled/Expired | |
| — | | |
$ | — | | |
| — | |
Outstanding and exercisable at end of period | |
| 2,402,008 | | |
$ | 0.87 | | |
| 3.25 | |
At March 31, 2024, the Company had 2,402,008 exercisable Common Stock Purchase
Warrants outstanding. The total intrinsic value of warrants exercisable at March 31, 2024, was $4,277,992. Intrinsic value is measured
using the fair market value at the date of exercise (for shares exercised) and at March 31, 2024 (for outstanding warrants), less the
applicable exercise price.
Restricted Stock Awards (RSA)
The Company recognized stock-based compensation expense related to RSAs of
$535,009 and $1,068,865 for the three and nine months ended March 31, 2024, respectively. The restricted stock awards are related to a
grant of 1,000,000 shares of restricted stock with a 3-year vesting period made to a director as consideration for advisory
services, with a total value of $2,760,000. At March 31, 2024, the Company had $1,691,135 of unrecognized stock-based compensation expense
remaining to be amortized.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 — COMMITMENTS AND CONTINGENCIES
Commitments
On July 9, 2018, the Company entered
into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company
with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration of HIV in humans,
and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including
but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20
months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of the 20 months, the monthly consulting
fee of $25,000 continued for scientific consulting and knowledge transfer on existing HIV experiments until the services were no longer
being rendered or the G-Tech Agreement is terminated. As of May 25, 2022, the consultant was no longer able to render services; therefore,
no expense was incurred for the three and nine months ended March 31, 2024 and 2023.
On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech, and
G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute
(“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license
(the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV)
infections.
The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24 month period, and provides for an up-front payment of $1.2 million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a 2% royalty to G-Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $1.2 million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.
The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement in the three and nine months ended March 31, 2024, and 2023.
The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies
sub-section below).
On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the “License Development Agreement”), by and among the Company, G-Tech
and SRI (collectively, the “Licensors”), whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development
License”) to research, develop, and commercialize certain formulations which were aimed at preventing and treating pan-coronavirus
or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza
(the “Prevention and Treatment”).
The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides
for an up-front payment of $10,000,000 and a $760,000 payment for expenditures to date prior to the effective date related to research
towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional payments
upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement, in each
case subject to the terms of the Development License Agreement.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 — COMMITMENTS AND CONTINGENCIES (Continued)
The Development License Agreement
provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates
that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license
(see Contingencies sub-section below).
On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”) with Serhat
Gümrükcü and SRI (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $600,000 and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $600,000.
G-Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.
Shares held for
non-consenting shareholders – The 17,414
remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have
been reflected as issued and outstanding in the accompanying financial statements. There were zero shares of Common Stock issued
to such non-consenting stockholders during the three and nine months ended March 31, 2024 (see Note 9.)
Service Agreements –The
Company maintains employment agreements with certain senior staff in the ordinary course of business.
Contingencies
Securities Class Action Litigation.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the “Chow Action” and the latter, the
“Manici Action”) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company’s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company’s relationship
with Serhat Gümrükcü and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice, but the Chow action remains pending. On October
22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead plaintiff filed an amended complaint on December 15, 2023.
The Company has filed a motion to dismiss the amended complaint, but expresses no opinion as to the likelihood of a favorable outcome.
Federal Derivative Litigation.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District
Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action
Litigation. The actions, filed on behalf of the Company, name Serhat Gümrükcü and certain of the Company’s current
and former directors as defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections
14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification,
aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution,
and other costs and expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the
Koenig matter pending resolution of the defendants’ anticipated motion to dismiss in the Securities Class Action Litigation. On
April 6, 2023, the United States District Court for the District of Delaware stayed the Solak matter pending resolution of the defendants’
anticipated motion to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to either complaint. The
Company intends to contest these matters but expresses no opinion as to the likelihood of favorable outcomes.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 — COMMITMENTS AND CONTINGENCIES (Continued)
State Derivative Litigation.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting
similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names
Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The action also names the
Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution and indemnification, aiding and
abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other
costs and expenses. On January 20, 2023, the Court stayed the Midler matter pending resolution of the defendants’ anticipated motion
to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to the complaint. The Company intends to contest
this matter but expresses no opinion as to the likelihood of a favorable outcome.
On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
Gümrükcü, William Anderson Wittekind (“Wittekind”), G Tech Bio LLC (“G Tech”), SG & AW Holdings,
LLC, and Seraph Research Institute (“SRI”) (collectively, the “Defendants”). The Complaint alleges that the Defendants
engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the Defendants’ conduct, the
Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.”
On April 21, 2023, defendants Wittekind, G Tech, SG & AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company’s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.
On December
4, 2023, the Defendants answered the Company’s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, inter
alia, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work & License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently scheduled
to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while pursuing
its claims against the Defendants.
On March 1, 2021, the Company’s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the Court partially granted the Company’s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29,
2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24,
2023, the Court denied the motion for summary judgment. Trial is currently scheduled to begin on July 15, 2024. The Company denies the
allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.
On June
7, 2023, Weird Science LLC (“Weird Science”), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the “Trusts”)
(collectively, “Plaintiffs”) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the “Investor Rights Agreement”). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all “Holders” of “Registrable Securities” at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 — COMMITMENTS AND CONTINGENCIES (Continued)
On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (“FAC”). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys’ fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Company denies Plaintiffs’ allegations and intends to vigorously defend against the claims.
On August 24, 2023, counsel on behalf of Weird Science,
Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company’s books and records (the
“Demand”) pursuant to Delaware General Corporation Law, § 220 (“Section 220”). The Demand seeks the
Company’s books and records in connection with various issues identified in the Demand. The Company takes its obligations under
Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those obligations.
On January
23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District
of California against certain officers, directors, and investors of the Company, as well as other defendants. The Verified Stockholder
Derivative Complaint (“Derivative Complaint”) alleges, among other claims, violations of Section 13(d) and 14(a) and Rules
10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary duty, corporate
waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory, exemplary and punitive
damages and certain injunctive relief. Simultaneously with the Derivative Complaint, Weird Science and Wittekind filed an emergency Ex
Parte Application for Temporary Restraining Order (“Application”) asking the Court to enjoin a special meeting of the
Company’s stockholders noticed for January 25, 2024. As the basis for the Application, Weird Science and Wittekind recited many
of the same allegations as in the Derivative Complaint. The Court denied the Application on January 24, 2024. The defendants have not
yet responded to the Derivative Complaint. The Company denies the allegations in the Derivative Complaint and intends to vigorously defend
against the claims asserted therein.
NOTE 11 — RELATED PARTY TRANSACTIONS
As of March 31, 2024, the
Company has accrued $111,750
of compensation related expenses for the Company’s Chief Executive Officer, Mark Dybul, related to budget constraints.
On March 26, 2024, the Company
issued a Promissory Note to Paseco ApS, a Danish entity and greater than 5% shareholder, in the principal amount of $160,000. The Note
bears an interest rate of 10% per annum and was to mature on May 1, 2024. On May 1, 2024, the Company and Paseco ApS entered into an amendment
to the Promissory Note to extend that maturity to July 1, 2024 (the “Maturity Date”). The Company is required to pay interest
on the maturity date. As of March 31, 2024, the Company accrued $215 of interest expense that is included in accrued expenses on the balance
sheet. The Note balance at March 31, 2024 is $160,000 (see Note 8.)
On February 16, 2024, the Company received an exercise
notice from RS Bio to exercise 471,699 warrants outstanding at an exercise price of $0.53 per share. The holder applied $250,000 of one
of its outstanding note payable balance to the exercise price (see Note 8.)
On February 16, 2024, the Company
received an exercise notice from Paseco ApS to exercise 2,953,700
warrants outstanding with exercise prices ranging from $0.53
to $0.65
per share. The proceeds of $1,750,000
were immediately applied to the outstanding note payable balance (see Note 8.)
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 11 — RELATED PARTY TRANSACTIONS (Continued)
On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263.
The Company received $100,000 in gross proceeds after taking into account the 5% original issue discount. The Note bears an interest rate
of 12% per annum and matured on March 1, 2024 (the “Maturity Date”). The obligations under this Note are secured by the Amended
and Restated Security Agreement (discussed below). The Company is required to pay interest on the maturity date. For the three and nine
months ended March 31, 2024, discount amortization of $5,263 was charged to interest expense. As of March 31, 2024, the Company accrued
$3,158 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March 31, 2024
is $105,263 (see Note 8.)
On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315
(the “January 2024 Note”). The Company received a total of $500,000 in gross proceeds after taking into account the 5% original
issue discount. The January 2024 Note bears an interest rate of 12% per annum and shall mature on March 1, 2024 (the “Maturity
Date”). The Company is required to pay interest on the maturity date. For the three and nine months ended March 31, 2024, discount
amortization of $26,315 was charged to interest expense. As of March 31, 2024, the Company accrued $15,789 of interest expense
that is included in accrued expenses on the balance sheet. The January 2024 Note balance, net of discount at March 31, 2024 is $526,315
(see Note 8.) In connection with the entry into the January 2024 Note, the Company and Paseco ApS agreed to amend and restate the Security
Agreement (see Note 8) to add the Company’s obligations under the November 2023 Note and the January 2024 Note to the Secured Obligations
(as defined in the Amended and Restated Security Agreement).
On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000 (the
“November 2023 Note”). The Company received a total of $950,000 in gross proceeds after taking into account the 5% original
issue discount. The discount of $50,000 will be accreted over the life of the Note. The Note bears an interest rate of 12% per annum
and shall mature on January 1, 2024 (the “Maturity Date”). The Company is required to pay interest on the maturity date (see
Note 8.)
On
October 10, 2023, the Board of Directors of the Company (the “Board”) appointed Avram Miller to the Board, effective October
11, 2023, to fill a vacancy. Mr. Miller will serve until the Company’s 2024 Annual Meeting of Stockholders subject to this re-election
or until his successor has been duly elected and qualified. In addition to Mr. Miller’s appointment to the Board, Mr. Miller, the
co-founder of Intel Capital, entered into an advisory agreement with the Company (the “Advisory Agreement”), pursuant
to which Mr. Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation,
business development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will
issue Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will
vest in 2026, subject to Mr. Miller’s continued service through each applicable vesting date.
On August 1, 2023, RS Bio, purchased
in a Private Placement 70,126 of the Company’s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of
$500,000. Mr. Rene Sindlev, the Chairman of the Company’s Board of Directors, holds the sole
voting and disposition power of the shares owned by RS Bio. The Board of Directors (excluding Mr. Sindlev) approved the participation
of certain officers and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement
(see Note 8.)
On August 1, 2023, Paseco ApS,
in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company’s Units at a price
per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company’s Units at a price per
Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS
was deemed to be an affiliate of the Company (see Note 8.)
RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 11 — RELATED PARTY TRANSACTIONS (Continued)
The Company currently has a consulting
agreement with Paseco ApS for business advisory services since December of 2019. For the three and nine months ended March 31, 2024 the
Company issued zero and 1,000,000 restricted common shares as payment for services rendered thereunder.
The Company currently has a consulting agreement with
Paseco for business advisory services that commenced in December of 2019. For the three and nine months ended March 31, 2024 the Company
issued zero and 1,000,000 restricted common shares, respectively, for services provided.
The information
set forth above in Note 8—Debt—Notes Payable—Promissory Note relating to the Promissory Note issued to Paseco ApS is
incorporated herein by reference.
NOTE
12 — ACQUISITION
On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GEDi Cube Intl Ltd.,
a private company formed under the laws of England and Wales (“GEDi Cube”) to acquire 100% of the equity interests
of GEDi Cube from its equity holders (the “Sellers”). On September 28, 2023, the Board of Directors of the Company,
and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and on January 25, 2024, the shareholders of the Company
approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement. The acquisition adds complementary product candidates and technologies
from GEDi Cube and may accelerate the Company's product development and therapeutic approaches for cancer and other diseases.
On February
13, 2024 (the “Closing Date”), the Company consummated the previously announced acquisition of GEDi Cube and the other transactions
contemplated by the Stock Purchase Agreement (collectively, the “Transaction”). As a result of the Transaction, GEDi Cube
became a wholly-owned subsidiary of the Company.
Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a “GEDi Cube Share” and, collectively, the “GEDi Cube Shares”)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller’s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”), which represents the
67,224,089 shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously
issued to a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director
of the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the “Closing
Consideration”) plus 5,610,100 shares of Common Stock representing the Seller’s Earnout Shares (defined below) resulting
from the automatic conversion of the Company’s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller’s
pro rata percentage of the shares of Common Stock (the “Earnout Shares” and, together with the Closing Consideration, the
“Exchange Consideration”) to be issued to the Sellers upon the exercise or conversion of any of the Company’s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the “Closing Derivative Securities”).
Each Seller’s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.
The
transaction was accounted for in accordance with the provisions of ASC 805-10 - Business Combinations. As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.
RENOVARO
INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
12 — ACQUISITION (Continued)
The
assets acquired and liabilities assumed are recognized provisionally in the accompanying condensed consolidated balance sheets at
their estimated fair values as of the acquisition date. The initial accounting for the business combination is not complete as the
Company is in the process of obtaining additional information for the valuation of acquired intangible assets and deferred tax
liabilities. The provisional amounts are subject to change to the extent that additional information is obtained about the facts and
circumstances that existed as of the acquisition date. Under U.S. GAAP, the measurement period shall not exceed one year from the
acquisition date and the Company will finalize these amounts no later than February 13, 2025. The estimated fair values as of the
acquisition date are based on information that existed as of the acquisition date. During the measurement period the Company may
adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that the Company has
subsequently obtained regarding facts and circumstances that existed as of the acquisition date.
The
acquisition-date fair value of the consideration transferred totaled approximately $156 156,559,131
million, which consisted of the following:
Schedule
of acquisition date fair value | |
| | |
Common stock | |
$ | 136,001,631 | |
Contingent consideration | |
| 20,557,500 | |
Total consideration transferred | |
$ | 156,559,131 | |
The
fair value of the Company’s common shares issued as consideration was based on the closing price of the Company’s common
stock as of the Acquisition Date. The fair value determination of the contingent consideration is further detailed in Note 4 to
these condensed consolidated financial statements.
The following
table details the provisional fair values of the assets acquired and liabilities assumed at the acquisition date:
Schedule of fair values of the assets acquired and liabilities assumed | |
| | |
Cash | |
$ | 65,851 | |
Prepaid & Other Assets | |
| 151,544 | |
Fixed Assets | |
| 16,243 | |
Operating lease ROU | |
| 624,366 | |
In-process research and development | |
| 10,684,091 | |
Total Assets Acquired: | |
| 11,542,095 | |
| |
| | |
Accounts Payable | |
| 583,577 | |
Accrued Expenses | |
| 722,509 | |
Operating Lease liability | |
| 624,367 | |
Notes Payable | |
| 1,832,460 | |
Deferred tax liabilities | |
| 2,756,495 | |
Total Liabilities Assumed | |
| 6,519,408 | |
Net Assets Acquired | |
| 5,022,687 | |
| |
| | |
Goodwill | |
| 151,536,444 | |
Total Consideration | |
$ | 156,559,131 | |
The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.
The
fair values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach
valuation methodology used for the intangible assets acquired makes use of Level 3 inputs.
RENOVARO
INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
12 — ACQUISITION (Continued)
The in-process
research and development acquired represents know-how and intellectual property being developed by GEDi Cube pertaining to its diagnostic
platform currently being developed. The fair value of this asset was determined based on a cash flow model with forecasted revenues and
expenses specifically tied to the diagnostic platform. Those cash flows were then discounted at 19.2% over the life of the projections.
The discount rate was determined by the use of a weighted average return on assets analysis.
The
Company recognized approximately $1.2
million of acquisition related costs that were expensed during the period ended March 31, 2024. These costs are included in
“selling, general and administrative expenses” in the accompanying condensed consolidated statements of operations.
The amounts
of revenue and loss of GEDi Cube, included in the Company’s consolidated statements of operations from the Closing Date through
March 31, 2024 are as follows:
Schedule of consolidated
statements of operations |
|
|
|
|
Revenues |
|
$ |
— |
|
Net loss |
|
$ |
(398,597 |
) |
Consolidated unaudited pro forma information:
The following consolidated pro forma information assumes
that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the nine-month period ended March
31, 2024. These amounts have been estimated after applying the Company’s accounting policies:
Schedule of consolidated
proforma information | |
| | |
Revenues | |
$ | — | |
Net loss | |
$ | (33,622,997 | ) |
NOTE 13 — SUBSEQUENT EVENTS
On April 5, 2024, the Company issued 33,760 shares of common
stock for consulting services valued at $94,190.
On April 9, 2024, the Company
issued a Promissory Note to Paseco ApS in the principal amount of $150,000. The Note bears an interest rate of 10% per annum and shall
mature on June 1, 2024 (the “Maturity Date”). The Company is required to pay interest on the Maturity Date.
From April 15, 2024, to May 7,
2024, the Company issued Promissory Notes to Paseco ApS in the aggregate principal amount of $855,149. The Company received $855,149 in
proceeds. The Notes bear an interest rate of 10% per annum and shall mature on July 1, 2024 (the “Maturity Date”). The Company
is required to pay interest on the Maturity Date.
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations.
Forward-Looking Statement Notice
Certain statements made in this
Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform
Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance, or achievements of Renovaro Inc. (“Renovaro,”
and together with its subsidiaries, the “Company”, “we” or “us”) to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included
herein are based on current expectations that involve numerous risks and uncertainties. Our actual future results and trends may differ
materially depending on a variety of factors, including, but not limited to, the risks and uncertainties discussed in Part I, Item 1A,
“Risk Factors” in our Annual Report on Form 10-K as filed with the SEC on October 2, 2023. The Company’s plans and objectives
are based, in part, on assumptions involving the continued expansion of the business. Assumptions relating to the foregoing involve judgments
with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its
assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there
can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as
a representation by the Company or any other person that the objectives and plans of the Company will be achieved.
Our Business
Renovaro
Inc. operates in two subsidiaries, Renovaro Biosciences and RenovaroCube. RenovaroCube was created upon our acquisition of GediCube Itnl.
Ltd. and its wholly-owned subsidiary GediCube, BV, which closed on February 13, 2024.
Renovaro Biosciences
Renovaro
Biosciences is a biotechnology company committed to developing advanced allogeneic cell and gene therapies to promote stronger immune
system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or
cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infections. As a result of our
acquisition of GEDi Cube on February 13, 2024, we have also expanded our technology pipeline to include diagnostic related services with
an early emphasis on the detection of cancer.
Our Product
Development strategy related to our allogeneic cell and gene therapies is anchored in the use of “non-self” or allogeneic
cells that enhance the immune response that we seek to elicit.
Over the past several years, Renovaro
Biosciences has evolved from a company with a single product candidate as a potential cure for HIV (RENB-HV12 and RENB-HV21), a pipeline
for Hepatitis B Virus (HBV) (RENB-HB01), and with a significant expansion into cancer immune therapies to address high unmet needs from
difficult-to-treat solid tumors (RENB-DC11.)
The oncology platform is now at
the forefront of our development activities, beginning with pancreatic cancer and other solid tumors with poor life expectancy, such as
triple negative breast, second-line liver, head, neck, and oral among other possible targets.
Many operational aspects of our
platforms can be quickly adapted to multiple disease states from a single therapeutic approach, potentially streamlining and accelerating
development, and regulatory process, as well as manufacturing operations. Moreover, because our product candidates do not require specialized
delivery devices and surgical procedures, our potentially groundbreaking interventions could have worldwide applicability.
Renovaro Biosciences responds quickly
to new data and perceived development opportunities and risk assessments. Based on the maturation of our pipelines, the Company makes
business decisions to prioritize the programs that could move more rapidly through development and commercial processes.
Therapeutic Platforms
Renovaro Bioscience’s general
approach with gene- and/or cell-therapy is to train the immune system to allow a person to better fight diseases. Our vision is for a
world free from toxic chemotherapy and healthy longevity for those with cancer and other diseases. Renovaro Biosciences is leveraging
general principles and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote the recognition
and elimination of diseased cells.
Advanced Allogeneic Cell Therapy
The strategic benefit of cell therapy
platforms is to potentially allow for manufacture of large, “off-the-shelf” banks of therapeutic cells that could be accessed
on demand by health care professionals to potentially decrease the time between diagnosis and treatment.
In addition, because we focus on
cells from donors, the strategy could potentially enhance the ability of the therapeutic candidates to induce a more robust response once
injected into patients. The human immune system is designed to recognize and distinguish “self” from “non-self”
and destroy “otherness” such as bacteria, viruses, and damaged or diseased cells such as cancer cells. Alloreactivity (reacting
against another person’s cells) is the most powerful response the immune system generates. Several of our technologies take advantage
of the alloreactivity to hyper stimulate a person’s immune response to better attack a chronic infection (e.g., HIV) or solid tumor.
In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are sometimes genetically modified to introduce signaling molecules that are designed to
enhance the ability of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or
virus infected cells.
We believe that the combination
of off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, could potentially generate
therapeutic candidates that have unique attributes that will increase the likelihood of clinical success.
HBV Gene Therapy
Renovaro Biosciences is exploring
various approaches for gene therapy design elements to potentially eliminate virus-infected cells with an innovative molecular mechanism
that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection to exacerbate
disease.
Oncology:
RENB-DC11: Genetically modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors – Starting with Pancreatic
Cancer
Allogeneic Cell Therapy Platform
– Advanced Pre-Clinical
Based
on learnings from literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we have
designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission from some of the
deadliest solid tumors. The survival rate in pancreatic cancer is currently only 5 to 10 percent at 5 years.
Initial
preclinical in vitro and proof of concept in vivo studies have been compelling. The platform is designed to enable broad
immune enhancements that are combined with cancer specific antigens that could be applicable to a wide range of solid tumors. We initially
plan to target pancreatic cancer. Other potential targets for later development could include triple-negative breast cancer, liver or
mesothelioma amongst many. Similar to our approach with HIV, RENB-DC11 would potentially allow for outpatient therapy without wiping out
or significantly impairing the patient’s immune system often associated with standard of care chemotherapies.
Renovaro Biosciences has initiated
a collaboration with Dr. Anahid Jewett from UCLA to study further the in vitro and in vivo effectiveness of the approach
in pancreatic cancer. Dr. Jewett created an innovative pancreatic cancer mouse model that comprises the human immune system repertoire
in combination with human cancer cells implanted in the corresponding anatomical location found in human cancer. Multiple experiments
in different humanized mouse models are consistently showing with only one regimen cycle of therapy (2 injections in mice, likely 5-6
in human) - what Dr. Jewett calls “the Holy Grail of cancer research” with now seven independent animal studies:
|
1. |
Consistent superior therapeutic effect compared to mainstream cancer vaccine approach and other control dendritic cell therapies |
|
2. |
Significant infiltration of effector immune cells into the tumor |
|
3. |
Significant peripheral T and NK cell immune activation |
|
4. |
Primary tumor reduction and no metastases |
|
5. |
Effective in early stage and late-stage cancer |
The confirming reproducibility
and robustness of the therapeutic response in an aggressive form of human pancreatic cancer in several models is promising. We received
FDA input from pre-IND interactions which helped solidify our IND-enabling plan as well as our investigational plan. We are now fully
committed to process development/improvements and IND-enabling activities. We believe that we can complete IND-enabling activities in
the second half of 2024 which if successful, would enable the start of clinical trials in humans during the first half of 2025. The investigational
plan discussed with the FDA includes phase 1 safety testing broadly in all solid tumor types, followed by a phase 2a focusing on a few
solid tumor types that are difficult to treat and have poor life expectancy, for example triple negative breast, second-line liver, and
head and neck cancers. Phase 2b would expand cohorts in cancers with the strongest response in phase 2a.
RENB-DC-12--XX: Genetically
modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Additional Indications
The technology is a platform that
could potentially be adapted to other solid tumors first line and/or salvage therapy, by itself or, potentially, in combination with other
cancer treatments. Additional cancer vaccine designs are being evaluated strategically to balance risk and opportunity to advance therapeutic
development quickly in cancer indications with few treatment options.
Infectious Diseases:
HIV:
RENB-HV12: HIV Therapeutic Vaccines for Potential
Long-term Remission/Cure
Allogeneic Cell Therapy Platform
- Advanced Pre-Clinical Stage; Non-Human Primate Studies Ongoing.
In persons living with HIV who
are controlling the spread of virus with anti-retroviral (ARV) treatment, boosting the immune system in a different way than the virus
already has through infection, could allow for control of HIV after stopping ARVs.
Renovaro
Biosciences is developing RENB-HV12 that utilizes a novel cellular and immunotherapy approach that could potentially provide therapeutic
vaccines for HIV. A non-human study of the therapeutic vaccine in primates at the Fred Hutchinson Cancer Research Center is ongoing. Animals
began receiving the first injections of the potential therapeutic vaccine in August, 2023. Preliminary results assessment may potentially
be available in the second half of 2024. A Pre-IND request could be submitted in the first half of 2025, with IND submission and the beginning
of Phase I clinical trials by mid- to end-2025.
RENB-HV21: Immunotherapy with Allogeneic NK/GDT Cells
Allogeneic Cell Therapy Platform - Pre-IND conducted
- Advanced Pre-Clinical with Human Data through a Collaboration
We are also exploring RENB-HV21,
an innovative treatment for HIV with allogeneic Natural Killer (NK) and Gamma Delta T-Cells (GDT). It is believed that the GDT cells,
a small subset of immune cells that can be infected with HIV, could both be infected by, and be a key factor in controlling the virus.
The initial scientific findings were presented during the American Society of Gene & Cell Therapy (ASCGT) Annual Meeting in 2021.
We have an exclusive license to use the underlying patent to develop RENB-HV21 for potential treatment or cure of HIV. A successful investigator-initiated
Pre-IND was completed in October 2021. However, due to a shift in priorities to the Oncology pipeline, Renovaro Biosciences does not plan
to pursue the IND and potential clinical trial in the medium- to long-term.
HBV:
RENB-HB01: Potential Cure for
HBV
HBV Gene Therapy - Pre-Clinical
RENB-HB01 is in an early pre-clinical
phase as we explore various approaches for gene therapy design elements. If those explorations are successful, it is possible we could
begin the regulatory process at the earliest in the second half of 2024. However, our highest priority is currently the oncology platform,
beginning with pancreatic cancer and other solid tumors with poor life expectancy.
Renovaro Cube
Renovaro Cube (“RenCube”)
is an artificial intelligence driven healthcare technology company focused on developing diagnostic tests and test kits that would analyze
samples derived from non-invasive liquid biopsy procedures for the early detection of cancer, disease recurrence, treatment selection
and monitoring of treatment in cancer. RenCube is developing a proprietary platform that will analyze genetic information using “Explainable
AI” (as defined below) to provide earlier and more accurate cancer diagnosis. This platform applies a multi-omics approach to search
for individual biomarkers that are present even in asymptomatic patients. RenCube’s process also generates biomarker panels, which
are used for training models per cancer type and per clinical application, and are integrated into a machine learning library referred
to as a “Cube” to facilitate accurate diagnosis. The “Cube” will become more effective and accurate over time
due to retraining of its models on the enriched database of molecular data.
RenCube also aims to utilize and
commercialize its proprietary platform RenCube for use in developing products and services by third parties aimed at (i) early cancer
characterization, (ii) personalized treatment selection, (iii) tracking response to therapies, (iv) recurrence detection, and (v) ultimately,
drug discovery.
As part of RenCube’s dedication to the development
of early cancer detection blood tests it expects to develop partnerships with third-party laboratories across the United Kingdom, the
Netherlands, Europe and the United States. In particular, RenCube is focused on developing diagnostic tests and test kits that make use
of non-invasive liquid biopsy samples.
Renovaro Cube’s Strategy
RenCube’s product development
focuses on four core areas:
|
● |
Early Detection. Multi-cancer
early detection (“MCED”) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the
bloodstream. These tests specifically look for genetic mutations, epigenetic alterations, cell-free DNA fragment patterns, gene expressions,
proteomic patterns or other genetic alterations of these tumor-derived molecules, which can indicate the presence of cancer cells.
By examining the molecules shed from cancer cells, MCED tests aim to detect cancer at an early stage employing a non-invasive blood
test. |
|
● |
Recurrence of cancer.
A recurrence refers to the return of cancer after a period of remission. A cancer recurrence happens because, in spite of the efforts
to eradicate the cancer, some cells may remain, which grow and eventually cause symptoms. In rare instances, a patient may develop
a new cancer that’s completely unrelated to the originally diagnosed cancer, which is referred to as a second primary cancer.
|
|
|
|
|
● |
Response to treatment.
Most cancer treatments that are currently available are only effective in 30-40% of the cases. In life threatening cases these
patients only have one option and therefore reduce their chances of survival significantly. Particularly, in patients with cancer,
it is critical to be the ‘first time right’. RenCube aims to develop a new array of diagnostic products that can accurately
identify patients that are going to respond or fail to a certain drug thereby facilitating personalized treatment. |
|
|
|
|
● |
Treatment monitoring.
Current imaging modalities, while valuable, may not be sensitive enough to capture subtle changes in tumor size to guide treatment
adjustments effectively. Furthermore, the cost and availability of these imaging techniques can pose barriers to frequent monitoring,
potentially delaying necessary interventions. RenCube aims to develop non-invasive liquid biopsy tests that will provide real-time
accurate feedback on tumor response thereby empowering clinicians to personalize treatment plans, optimize outcomes, and minimize
unnecessary interventions, ultimately improving patient care and quality of life. |
Renovaro Cube’s Technology
and Techniques
RenCube’s AI technology aims
to address three critical facets of medical needs within the domain of cancer diagnosis:
|
● |
type-specific cancer detection; |
|
|
|
|
● |
pan-cancer detection; and |
|
|
|
|
● |
personalized treatment |
The foundational architecture of
RenCube’s AI technology will be engineered to facilitate comprehensive pan-cancer analysis through its extensive record of informative
biomarkers discovered across a diverse array of cancer types. This comprehensive repository empowers RenCube’s technology to swiftly
cross-reference biomarkers and explore molecular commonalities and distinctions that span multiple tumor categories.
Uses of RenCube’s AI Technology
RenCube’s AI platform will
be an enterprise software platform that is distinguished from its competitors’ technology by its core attributes encompassing AI-guided
analysis and meticulous record-keeping of data handling procedures within audit trails, logs, and data discoveries. RenCube is designing
this technology to support and validate every phase of the process, from the initial handling of raw data to the creation of essential
biomarker panels. RenCube’s AI platform may also facilitate the integration of data originating from diverse sources, including
public databases and collaborative partnership data.
AI-Assisted Diagnostics
The process of biomarker discovery
facilitated by RenCube’s AI technology has yielded a set of biomarkers that enables scrutiny of the genomic distinctions and commonalities
inherent in diverse cancer types. This biomarker set may support the diagnosis of cancers when their type or origin remains unidentified.
In addition to this role in biomarker
discovery and the development of diagnostic tests, RenCube’s AI technology will integrate AI-guided molecular profiling of patient
samples to generate diagnostic patient reports. These diagnostic reports reflect the outcomes of molecular profiling, coupled with interpretations
provided by RenCube’s team, to facilitate the process of cancer diagnostics by a qualified healthcare provider, who can consider
these reports in the context of a patient’s medical history, clinical signs, and symptoms, among other factors.
Panel Mining
The unique panel mining technique
in RenCube’s technology repeatedly investigates genes to identify relevant biomarkers. The proprietary technique in RenCube’s
technology not only searches for individual biomarkers, but also integrates validated panels for different cancer types into the “Cube”
machine learning library. This process enables precision diagnosis, by including one cancer and excluding others on the basis of statistically,
scientifically and clinically validated machine-learning panels.
Explainable AI
The term “Explainable AI”
refers to the ability of an artificial intelligence system or model to provide human-understandable explanations for its decision-making
process or predictions. This feature aims to bridge the gap between the “black box” nature of many AI algorithms and the need
for transparency, interpretability, and accountability in AI applications.
RenCube believes that Explainable
AI is crucial for ensuring transparency, fairness, and accountability in AI systems. RenCube’s AI platform includes Explainable
AI by design. All data points, calculations and results are traceable, and all calculations are verifiable and reproducible with the same
result.
Differential Diagnosis
Diseases like cancer are very homogenous,
meaning that markers like TP53 or BRCA are expressed with multiple cancers. To address this homogeneity, differential diagnosis distinguishes
between two or more conditions or diseases that share similar signs, symptoms or characteristics. The goal of differential diagnosis is
to consider and evaluate all possible diagnoses for the patient’s symptoms to determine the most likely cause. Differential diagnosis
therefore aims to identify the underlying condition accurately and guide appropriate treatment and management strategies.
Corporate History
We were incorporated under the
laws of the State of Delaware on January 18, 2011, under the name Putnam Hills Corp. and in 2014 we merged with and changed our name to
DanDrit Biotech USA, Inc. In 2018, we acquired Enochian Biopharma and changed our name to Enochian BioSciences Inc. In August 2023, the
Company changed its corporate name to Renovaro Biosciences Inc. On February 13, 2024, the Company changed its corporate name to Renovaro
Inc. On February 13, 2024, Renovaro Inc. acquired Renovaro Cube Intl Ltd and its subsidiaries, in which Renovaro Cube became a wholly-owned
subsidiary of Renovaro Inc.
Going Concern and Management’s Plans
The financial statements included
elsewhere herein for the period ended March 31, 2024, were prepared under the assumption that we would continue our operations as a going
concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. As of
March 31, 2024, we had cash and cash equivalents of $312,697, an accumulated deficit of $308,947,816 and a working capital deficit of
$19,654,098 and total liabilities of $43,683,784. We have incurred significant losses from continuing operations, have used cash in our
continuing operations, and are dependent on additional financing to fund operations. These conditions raise substantial doubt about our
ability to continue as a going concern for one year after the date the financial statements are issued. The financial statements included
elsewhere herein do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets
or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
Management has reduced overhead
and administrative costs by streamlining the organization to focus around two of its therapies (oncology and a HIV therapeutic vaccine)
and investment in the development and validation of our AI driven cancer diagnostics platform. The Company has tailored its workforce
to focus on these therapies. In addition, the Company intends to attempt to secure additional required funding through equity or debt
financing. However, there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding
may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant
additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted
and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business,
stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained.
If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that
could result in our stockholders losing some or all of their investment in us.
Funding that we may receive during
the fiscal year 2024 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products and conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.
Results of Operations as restated for the three and nine months ended
March 31, 2024, compared to the three and nine months ended March 31, 2023
During the preparation of the
Company’s response to an SEC comment letter dated July 12, 2024, the Company’s management identified an error in the March
31, 2024 financial statements resulting from an error in the method used to measure the impairment charge associated with the termination
of a license agreement with Weird Science, LLC. The error resulted in, among other things, an overstatement of the Company's assets and
an understatement of the Company's net loss and net loss per share for the three and nine months ended March 31, 2024. Refer to “Note
2 - Restatement of Previously Issued Financial Statements” for additional information.
The following table sets forth
our revenues, expenses and net loss for the three and nine months ended March 31, 2024 and 2023. The financial information below is derived
from our restated unaudited condensed consolidated financial statements.
|
|
For the Three Months Ended |
|
|
|
|
|
For the Nine Months Ended |
|
|
|
|
|
|
March 31, |
|
Increase/(Decrease) |
|
March 31, |
|
Increase/(Decrease) |
|
|
2024 |
|
2023 |
|
$ |
|
% |
|
2024 |
|
2023 |
|
$ |
|
% |
|
|
(As Restated) |
|
|
|
|
(As Restated) |
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
$ |
7,652,379 |
|
|
$ |
3,796,057 |
|
|
$ |
3,856,322 |
|
|
|
102 |
% |
|
$ |
19,558,981 |
|
|
$ |
12,365,960 |
|
|
$ |
7,193,021 |
|
|
|
58 |
% |
Research and development |
|
|
1,087,156 |
|
|
|
239,137 |
|
|
|
848,019 |
|
|
|
355 |
% |
|
|
2,274,321 |
|
|
|
3,170,471 |
|
|
|
(896,150 |
) |
|
|
(28 |
)% |
Intangible assets impairment |
|
|
42,611,000 |
|
|
|
— |
|
|
|
42,611,000 |
|
|
|
100 |
% |
|
|
42,611,000 |
|
|
|
— |
|
|
|
42,611,000 |
|
|
|
100 |
% |
Depreciation and amortization |
|
|
30,305 |
|
|
|
28,242 |
|
|
|
2,063 |
|
|
|
7 |
% |
|
|
90,727 |
|
|
|
85,487 |
|
|
|
5,240 |
|
|
|
6 |
% |
Total Operating Expenses |
|
|
51,380,840 |
|
|
|
4,063,436 |
|
|
|
47,317,404 |
|
|
|
1,164 |
% |
|
|
64,535,029 |
|
|
|
15,621,918 |
|
|
|
48,913,111 |
|
|
|
313 |
% |
LOSS FROM OPERATIONS |
|
|
(51,380,840 |
) |
|
|
(4,063,436 |
) |
|
|
(47,317,404 |
) |
|
|
1,164 |
% |
|
|
(64,535,029 |
) |
|
|
(15,621,918 |
) |
|
|
(48,913,111 |
) |
|
|
313 |
% |
Other Income (Expenses) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
% |
|
|
(120,018 |
) |
|
|
— |
|
|
|
(120,018 |
) |
|
|
100 |
% |
Loss on extinguishment of contingent consideration liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
% |
|
|
— |
|
|
|
(419,182 |
) |
|
|
419,182 |
|
|
|
(100 |
)% |
Change in fair value of contingent consideration |
|
|
486,500 |
|
|
|
— |
|
|
|
486,500 |
|
|
|
100 |
% |
|
|
486,500 |
|
|
|
— |
|
|
|
486,500 |
|
|
|
100 |
% |
Interest expense |
|
|
(303,802 |
) |
|
|
(122,289 |
) |
|
|
(181,513 |
) |
|
|
148 |
% |
|
|
(758,057 |
) |
|
|
(310,766 |
) |
|
|
(447,291 |
) |
|
|
144 |
% |
Interest and other income (expense) |
|
|
(16,272 |
) |
|
|
(142,571 |
) |
|
|
126,299 |
|
|
|
(89 |
)% |
|
|
8,041 |
|
|
|
(133,938 |
) |
|
|
141,979 |
|
|
|
(106 |
)% |
Total Other Income (Expense) |
|
|
166,426 |
|
|
|
(264,860 |
) |
|
|
431,286 |
|
|
|
(163 |
)% |
|
|
(383,534 |
) |
|
|
(863,886 |
) |
|
|
480,352 |
|
|
|
(56 |
)% |
NET LOSS |
|
$ |
(51,214,414 |
) |
|
$ |
(4,328,296 |
) |
|
$ |
(46,886,118 |
) |
|
|
1,083 |
% |
|
$ |
(64,918,563 |
) |
|
$ |
(16,485,804 |
) |
|
$ |
(48,432,759 |
) |
|
|
294 |
% |
Revenues
We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.
Expenses
Our operating expenses for the
three months ended March 31, 2024 and 2023, were $51,380,840 and $4,063,436 respectively, representing
an increase of $47,317,404 or approximately 1,164%. The increase in operating expenses primarily relates to the increase in general
and administrative expenses of $3,856,322, the increase in research and development expenses of $848,019 and an indefinite life intangible
assets impairment charge of $42,611,000.
Our operating expenses for the
nine months ended March 31, 2024 and 2023, were $64,535,029 and $15,621,918 respectively, representing
an increase of $48,913,111, or approximately 313%. The increase in operating expenses primarily relates to the increase in general
and administrative expenses of $7,193,021, and the indefinite life intangible assets impairment charge of $42,611,000, partially offset
by the decrease in research and development expenses of $896,150.
General and administrative expenses
for the three months ended March 31 2024, and 2023, were $7,652,379 and $3,796,057, respectively, representing an increase of $3,856,322
or approximately 102%. The variance is related to an increase in legal expenses of $1,552,970, non-cash stock-based compensation of $785,396,
non-cash consulting fees of $544,657, accrued expenses related to the GEDi Cube acquisition of $797,203, investor relations expenses of
$264,344, marketing expenses of $148,827, and compensation and related expenses of $97,528, partially offset by a decrease in accounting
fees of $466,145.
General and administrative expenses
for the nine months ended March 31, 2024, and 2023, were $19,558,981 and $12,365,960, respectively, representing an increase of $7,193,021
or approximately 58%. The variance is related to an increase in non-cash consulting fees of $4,570,000, non-cash stock-based compensation
of $922,492, accrued expenses related to the GEDi Cube acquisition of $797,203, legal expenses of $693,473, investor relations expenses
of $505,395, consulting expenses of $447,407, marketing expenses of $270,010, rent expenses of $156,626, and insurance expenses of $127,628,
partially offset by a decrease in accounting fees of $403,538.
Research and development expenses
for the three months ended March 31, 2024, and 2023, were $1,087,156 and $239,137, respectively, representing an increase of $848,019
or approximately 355%. The variance is primarily driven by an increase of $584,912 in collaborating partner expenses with
CDMO and CROs, $115,616 in consumables related to pre-clinical testing and $150,811 in consulting expenses related to regulatory
and outsourced consultants.
Research and development expenses
for the nine months ended March 31, 2024, and 2023, were $2,274,321 and $3,170,471, respectively, representing a decrease of $896,150
or approximately 28%. The variance is primarily driven by a decrease of $1,603,896 in collaborating partner expenses with
CDMO and CROs related to discontinued product candidates, partially offset by an increase in consumables of $355,235 and consulting expenses
of $351,466.
Intangible assets impairment
expense for the three and nine months ended March 31, 2024, was $42,611,000. This was due to the
termination of the license agreement with Weird Science, LLC in March 2024 as that resulted in the Company abandoning the development
of certain technology included in its in-process research and development and recording an impairment of $42,611,000 in the period ended
March 31, 2024.
The Company recorded other income of $166,426 for the three months ended March 31, 2024, compared to other
expense of $264,860 for the three months ended March 31, 2023, representing a decrease in other expense of $431,286 or 163%. The variance
is primarily due to an increase of $486,500 in change in fair value of contingent consideration following the acquisition of GEDi Cube.
The Company recorded other expense
of $383,534 for the nine months ended March 31, 2024, compared to other expense of $863,886 for the nine months ended March 31, 2023,
representing a decrease in other expense of $480,352 or 56%. The variance is primarily due to the loss on extinguishment of contingent
consideration liability of $419,182 in the prior period, and an increase of $486,500 in change in fair value of contingent consideration
in the current period, partially offset by an increase of $447,291 in interest expense in the current period.
Net Loss
Net loss for the three months ended
March 31, 2024, and 2023, was $51,214,414 and $4,328,296, respectively, representing an increase in net loss of $46,886,118 or approximately
1,083%. The increase in net loss was primarily due to the indefinite life intangible assets impairment charge of $42,611,000 and an increase
in general and administrative expenses of $3,856,322.
Net loss for the nine months ended
March 31, 2024, and 2023, was $64,918,563 and $16,485,804, respectively, representing an increase in net loss of $48,432,759 or approximately
294%. The increase in net loss was primarily due to the indefinite life intangible assets impairment charge of $42,611,000 and an increase
in general and administrative expenses of $7,193,021.
Liquidity and Capital Resources
We have historically satisfied
our capital and liquidity requirements through funding from stockholders, the sale of our Common Stock and warrants, and debt financing.
We have never generated any sales revenue to support our operations and we expect this to continue until our therapies or products are
approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved for
sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may never be
profitable.
As noted above under the heading
“Going Concern and Management’s Plans,” through March 31, 2024, we have incurred substantial losses. We will need additional
funds for (a) research and development, (b) increases in personnel, (c) the purchase of equipment, specifically to advance towards an
Investigational New Drug Application (IND) following Pre-IND readouts from the FDA for RENB-DC11, RENB-HV12, RENB-HV21 and RENB-HB01 and
(d) investment in the development and validation of our AI driven cancer diagnostics platform. The availability of any required additional
funding cannot be assured. In addition, an adverse outcome in legal or regulatory proceedings in which we are currently involved or in
the future may be involved could adversely affect our liquidity and financial position. We may raise such funds from time to time through
public or private sales of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our
failure to raise capital when needed could materially adversely affect our growth plans and our financial condition and results of operations.
As of March 31, 2024, the Company
had $312,697 in cash and working capital of $(19,654,098) as compared to $1,874,480 in cash and working capital of $(8,457,693) as of
June 30, 2023, a decrease of 83% and 132%, respectively.
Assets
Total assets at March 31, 2024,
were $178,089,340 compared to $58,300,796 as of June 30, 2023. The increase in total assets was primarily due to the increase in goodwill
of $152,546,852 from the acquisition of Renovaro Cube.
Liabilities
Total liabilities at March 31,
2024, were $43,683,784 compared to $11,798,685 as of June 30, 2023. The increase in total liabilities was primarily related to increases
of $20,071,000 in contingent consideration liability, $3,031,803 in accrued expenses, $2,693,808 in accounts payable, $3,700,694 in convertible
notes payable, net of discount and $2,774,856 in deferred tax liability offset by a decrease of $1,206,326 in notes payable, net of discount.
The following is a summary of the
Company’s cash flows (used in) or provided by operating, investing, and financing activities:
| |
Nine Months Ended March 31, 2024 | |
Nine Months Ended March 31, 2023 |
Net Cash Used in Operating Activities | |
$ | (8,557,649 | ) | |
$ | (9,512,937 | ) |
Net Cash Used in Investing Activities | |
| (1,206,806 | ) | |
| (23,633 | ) |
Net Cash Provided by Financing Activities | |
| 8,050,737 | | |
| 3,267,008 | |
Effect of exchange rates on cash | |
| 151,935 | | |
| 45,462 | |
Change in Cash and Cash Equivalents | |
$ | (1,561,783 | ) | |
$ | (6,224,100 | ) |
Cash Flows
Cash used in operating activities
for the nine months ended March 31, 2024, and 2023 was ($8,557,649) and ($9,512,937), respectively. Cash used in operating activities
during the current period primarily related to the net loss including $2,274,321 in research and development expenses for CDMO and CRO
costs, along with approximately $10,477,101 in general and administrative expenses, net of non-cash items, partially offset by an increase
in accounts payable of $2,693,808 and accrued expenses of $3,031,803 due to the timing of cash payments and a $216,293 increase in prepaid
expenses.
Cash used in investing activities
for the nine months ended March 31, 2024, and 2023 was ($1,206,806) and ($23,633), respectively. Cash used in investing activities during
the current period primarily related to the issuance of notes receivable prior to the acquisition of Renovaro Cube totaling $1,193,000
in principal and $32,779 of interest accrued as of February 13, 2024.
Cash provided by financing activities
for the nine months ended March 31, 2024, was $8,050,737 as compared to cash provided by financing activities of $3,267,008 during the
nine months ended March 31, 2023. During the nine months ended March 31, 2024, the Company received net proceeds of $5,355,000 from issuance
of notes payable, $3,000,000 from private placements and $341,865 from Common Stock warrants exercised, that were partially offset by
$646,128 in repayment of a finance agreement.
Off-Balance Sheet Arrangements
The Company does not have any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material
to investors.
Significant Accounting Policies and Critical Accounting
Estimates
The methods, estimates, and judgments
that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some
of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding
matters that are inherently uncertain.
For a summary of our accounting
policies, see Note 1 to the unaudited condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk.
As a “smaller reporting company”
as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this
Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and
Chief Financial Officer (the “Certifying Officers”) are responsible for establishing and maintaining disclosure controls and
procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material information
is made known to them, particularly during the period in which this Report was prepared.
The Certifying Officers are responsible
for establishing and maintaining adequate internal control over financial reporting for the Company and used the “Internal Control
over Financial Reporting Integrated Framework” issued by the Committee of Sponsoring Organizations (“COSO”) to conduct
an extensive review of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act, Rules 13a-15(e)
and 15-d-15(e)) as of the end of each of the periods covered by this Report (the “Evaluation Date”). Based upon that evaluation,
the Certifying Officers concluded that, as of March 31, 2024, our disclosure controls and procedures were not effective in ensuring that
the information we were required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended,
is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. The deficiency is attributed
to the Company not having adequate resources to address complex accounting matters. This control deficiency will be monitored, and attention
will be given to this matter as we grow.
The Certifying Officers based their
conclusion on the fact that the Company has identified a material weakness in controls over financial reporting, detailed above. We expect
to be deficient in our disclosure controls and procedures until sufficient capital is available to hire the appropriate internal accounting
staff.
Changes in Internal Controls
There have been no changes in our
internal controls over financial reporting during the three months ended March 31, 2024, that have materially affected or are reasonably
likely to materially affect our internal controls.
PART II — OTHER INFORMATION
Item 1. Legal Proceedings.
Securities Class Action Litigation.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the “Chow Action” and the latter, the
“Manici Action”) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company’s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company’s relationship
with Serhat Gümrükcü and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice, but the Chow action remains pending. On October
22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead plaintiff filed an amended complaint on December 15, 2023.
The Company has filed a motion to dismiss the amended complaint, but expresses no opinion as to the likelihood of a favorable outcome.
Federal Derivative Litigation.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District
Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action
Litigation. The actions, filed on behalf of the Company, name Serhat Gümrükcü and certain of the Company’s current
and former directors as defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections
14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification,
aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution,
and other costs and expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the
Koenig matter pending resolution of the defendants’ anticipated motion to dismiss in the Securities Class Action Litigation. On
April 6, 2023, the United States District Court for the District of Delaware stayed the Solak matter pending resolution of the defendants’
anticipated motion to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to either complaint. The
Company intends to contest these matters but expresses no opinion as to the likelihood of favorable outcomes.
State Derivative Litigation.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting
similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names
Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The action also names the
Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution and indemnification, aiding and
abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other
costs and expenses. On January 20, 2023, the Court stayed the Midler matter pending resolution of the defendants’ anticipated motion
to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to the complaint. The Company intends to contest
this matter but expresses no opinion as to the likelihood of a favorable outcome.
On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
Gümrükcü, William Anderson Wittekind (“Wittekind”), G Tech Bio LLC (“G Tech”), SG & AW Holdings,
LLC, and Seraph Research Institute (“SRI”) (collectively, the “Defendants”). The Complaint alleges that the Defendants
engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the Defendants’ conduct, the
Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.”
On April 21, 2023, defendants Wittekind, G Tech, SG & AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company’s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.
On December
4, 2023, the Defendants answered the Company’s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, inter
alia, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work & License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently scheduled
to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while pursuing
its claims against the Defendants.
On March 1, 2021, the Company’s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the Court partially granted the Company’s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29,
2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24,
2023, the Court denied the motion for summary judgment. Trial is currently scheduled to begin on July 15, 2024. The Company denies the
allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.
On June
7, 2023, Weird Science LLC (“Weird Science”), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the “Trusts”)
(collectively, “Plaintiffs”) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the “Investor Rights Agreement”). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all “Holders” of “Registrable Securities” at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.
On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (“FAC”). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys’ fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Company denies Plaintiffs’ allegations and intends to vigorously defend against the claims.
On August 24, 2023, counsel on behalf of Weird Science,
Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company’s books and records (the
“Demand”) pursuant to Delaware General Corporation Law, § 220 (“Section 220”). The Demand seeks the
Company’s books and records in connection with various issues identified in the Demand. The Company takes its obligations under
Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those obligations.
On January
23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District
of California against certain officers, directors, and investors of the Company, as well as other defendants. The Verified Stockholder
Derivative Complaint (“Derivative Complaint”) alleges, among other claims, violations of Section 13(d) and 14(a) and Rules
10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary duty, corporate
waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory, exemplary and punitive
damages and certain injunctive relief. Simultaneously with the Derivative Complaint, Weird Science and Wittekind filed an emergency Ex
Parte Application for Temporary Restraining Order (“Application”) asking the Court to enjoin a special meeting of the
Company’s stockholders noticed for January 25, 2024. As the basis for the Application, Weird Science and Wittekind recited many
of the same allegations as in the Derivative Complaint. The Court denied the Application on January 24, 2024. The defendants have not
yet responded to the Derivative Complaint. The Company denies the allegations in the Derivative Complaint and intends to vigorously defend
against the claims asserted therein.
Item 1A. Risk Factors.
Risk factors that may affect our
business and financial results are discussed within Item 1A. “Risk Factors” of our annual report for the fiscal year ended
June 30, 2023, on Form 10-K (“2023 Form 10-K”) filed with the SEC on October 2, 2023.
The following risk factors are
in addition to the risks referenced above. The effects of the events and circumstances described in the following risk factors may heighten
the risks contained in the Company’s Annual Report on Form 10-K.
Risks Related to Renovaro Cube
Risks
Related to Renovaro Cube’s Limited Operating History, Financial Position and Capital Requirements
Renovaro Cube is an
artificial intelligence (“AI”)-driven healthcare technology company operating in a rapidly evolving field and has a limited
operating history, which makes it difficult to evaluate Renovaro Cube’s current business and predict Renovaro Cube’s future
performance.
Renovaro
Cube is an AI-driven healthcare technology company operating in a rapidly evolving field and, having commenced operations in 2013,
has a limited operating history. Renovaro Cube shifted its business from the financial technology (or FinTech) industry to cancer diagnostics
only in 2018. Renovaro Cube does not currently have a commercial product for sale. Renovaro Cube has never generated any revenue relating
to its cancer diagnostics AI platform. Renovaro Cube’s short operating history as a company makes any assessment of its current
business or future success and viability subject to significant uncertainty. Renovaro Cube expects to encounter risks and difficulties,
including those frequently experienced by early-stage companies in rapidly evolving fields. If Renovaro Cube does not address
these risks and difficulties successfully, its business will suffer.
Renovaro Cube has a
history of net losses and anticipates that it may continue to incur net losses for the foreseeable future.
Grace
Systems (Renovaro Cube’s predecessor) has primarily incurred net losses since its inception in 2013 and has never generated any
revenue relating to its cancer diagnostics AI platform. Renovaro Cube anticipates that it may continue to incur primarily net losses in
the foreseeable future. Renovaro Cube has invested significant financial resources in research and development activities, including to
develop its technology and investigational products and plan for commercial launch of its AI platform. The amount of Renovaro Cube’s
future net losses will depend, in part, on the level of Renovaro Cube’s future expenditures and its ability to generate revenue
following the commercialization of its AI platform. Moreover, Renovaro Cube’s net losses may fluctuate significantly from quarter
to quarter and year to year, such that a period-to-period comparison of Renovaro Cube’s results of operations may not
be a good indication of Renovaro Cube’s future performance.
Renovaro
Cube expects to continue to incur significant expenses and operating losses for the foreseeable future if, and as, it:
|
● |
attracts, hires, and retains qualified personnel; |
|
● |
continues its research and development activities; |
|
● |
initiates and conducts additional clinical validation to support the development and commercialization of its products; |
|
● |
expands its technological and operating capabilities and introduces laboratory capacity as Renovaro Cube prepares for commercial scale; |
|
● |
seeks regulatory approvals and any other marketing authorizations or clearances that may be necessary or desired for its products; |
|
● |
establishes sales, marketing and distribution infrastructure to commercialize its products; |
|
● |
acquires or in-licenses additional intellectual property and technologies; |
|
● |
makes milestone, royalty, or other payments due under any license or collaboration agreements; |
|
● |
obtains, maintains, protects and enforces its intellectual property portfolio, including intellectual property obtained through license agreements; |
|
● |
provides additional infrastructure to support its continued research and development operations and any planned commercialization efforts in the future; |
|
● |
as part of the combined company following the Closing, meets the requirements and demands of being a public company; and |
|
● |
defends against any product liability claims or other lawsuits related to its products. |
Renovaro Cube has never
generated revenue from its cancer diagnostics AI platform, and does not expect any near-term revenue to offset Renovaro Cube’s
ongoing operating expenses, and may never be able to maintain profitability.
Renovaro
Cube’s ability to generate revenue from product sales and maintain profitability in the future depends on its ability to commercialize
its products. While Renovaro Cube plans to commercially launch its AI platform in the European Union and United Kingdom in 2024, Renovaro
Cube cannot assure you that it will successfully be able to do so as planned, if at all, and Renovaro Cube’s failure to do so would
prevent Renovaro Cube from generating revenue. Furthermore, even if Renovaro Cube is able to launch its AI platform or other products
in a timely manner, Renovaro Cube may not be able to generate sufficient revenue to offset its costs and maintain profitability. Renovaro
Cube’s ability to generate future revenue from product sales depends heavily on its success in:
|
● |
completing
clinical development and additional validation of Renovaro Cube’s products and continuing to improve product performance and expand
product features over time; |
|
● |
seeking,
obtaining and maintaining marketing approvals, clearances, licenses, or exemptions that may be necessary or desired for any future products
that Renovaro Cube develops; |
|
● |
establishing
a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner
sufficient to launch and commercialize its products; |
|
● |
obtaining
market acceptance by consumers, including self-insured employers, integrated health systems, healthcare providers, patients
and third-party payors; |
|
● |
establishing
and maintaining supply and manufacturing relationships with third parties that can timely and consistently provide adequate, in both
amount and quality, products and services to support clinical development and the market demand for Renovaro Cube’s future products; |
|
● |
achieving
adequate coverage or reimbursement recognition from governments, health insurance organizations and other third-party payors
for products that Renovaro Cube launches; |
|
● |
addressing
any technological and market developments, including competing products; |
|
● |
negotiating
favorable terms in any collaboration, licensing, or other arrangements into which Renovaro Cube may enter, and maintaining such existing
or future arrangements; |
|
● |
achieving
general adoption and acceptance of Renovaro Cube’s products by the medical community; |
|
● |
maintaining,
protecting and expanding Renovaro Cube’s portfolio of intellectual property rights, including patents, trade secrets, know-how and
trademarks; |
|
● |
defending
against third-party interference or infringement claims, if any; and |
|
● |
attracting,
hiring and retaining qualified personnel. |
Renovaro
Cube anticipates incurring substantial costs to commercialize Renovaro Cube’s products. Renovaro Cube’s expenses could increase
beyond expectations if it is required by the U.S. Food and Drug Administration (the “FDA”), the European Medicines Agency
(the “EMA”), the Medicines and Healthcare products Regulatory Agency (“MHRA”) or other regulatory agencies to
delay its launch, narrow or change its intended use or product claims, modify or expand its clinical validation, perform future additional
clinical validation, either pre- or post-approval, or conduct clinical trials. Even if Renovaro Cube is able to generate
revenue from the sale of any products, Renovaro Cube may not become profitable and may need to obtain additional funding to continue its
operations.
Renovaro Cube will
require additional financing in order to start its commercialization efforts and develop additional products.
To date,
Renovaro Cube has financed its operations primarily through the sale of its equity securities and cash flow from consulting services previously
provided by Renovaro Cube. Renovaro Cube’s product development and clinical validation activities are expensive, and Renovaro Cube
expects to start to spend substantial amounts as it prepares for the launch and commercialization of its AI platform, continues to enhance
its AI platform, broadens the applications of its AI platform and develops new products. In addition, obtaining any necessary or desirable
regulatory approvals and clearances from the FDA, the MHRA, or the EMA for Renovaro Cube’s products will require substantial additional
funding.
Renovaro
Cube will require additional capital for the development of its AI platform and future products. Renovaro Cube’s future capital
requirements depend on many additional factors, including:
|
● |
the cost of development and commercialization activities for Renovaro Cube’s products, including marketing, sales and distribution costs; |
|
● |
the timing of, and the costs involved in, obtaining any required or desired regulatory approvals and clearances for Renovaro Cube’s products; |
|
● |
the timing, scope, progress, results and costs of developing additional products, and of conducting additional clinical validation or future clinical studies, if required; |
|
● |
the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent and other intellectual property rights and claims, including litigation costs and the outcome of such litigation; |
|
● |
the timing and amount of sales of Renovaro Cube’s products, if any, and collection of related receivables; |
|
● |
the extent to which Renovaro Cube’s products are eligible for coverage and/or reimbursement from third-party payors; |
|
● |
the emergence of new technologies or any competing tests, products, or services and other adverse market developments; and |
|
● |
other potential adverse developments. |
Risks Related to Renovaro
Cube’s Business Operations, Products and Industry
Renovaro Cube’s
products may not perform as expected, which could materially and adversely affect Renovaro Cube’s business, financial condition,
results of operations and growth prospects.
Renovaro
Cube does not currently have a commercial product. Renovaro Cube’s success depends on the market’s confidence that it can
provide reliable, high-quality products. Assuming successful launch, Renovaro Cube’s products may not perform as expected.
If this were to occur, Renovaro Cube’s business, financial condition, results of operations and growth prospects would suffer.
Renovaro
Cube’s AI platform requires a number of complex and sophisticated biochemical and bioinformatics processes, many of which are highly
sensitive to external factors. An operational or technological failure in one of these complex processes or fluctuations in external variables
may result in sensitivity and specificity rates that are lower than Renovaro Cube anticipates or that vary between test runs or in a higher
than anticipated number of tests that fail to produce consistent results. In addition, Renovaro Cube regularly evaluates and refines its
algorithms and other processes under development. These refinements may inadvertently result in unanticipated issues that may reduce Renovaro
Cube’s sensitivity and specificity rates or otherwise adversely affect the performance of the tests supported by Renovaro Cube’s
AI platform and the results of such tests.
Further,
Renovaro Cube plans to iterate and improve, enhancing product performance, offerings, scalability and/or cost of goods. However, Renovaro
Cube may not be successful in transitioning its AI platform to a new or enhanced version or iteration. Product development involves a
lengthy and complex process and Renovaro Cube may be unable to commercialize, validate, or improve performance of any of its AI platform
or products on a timely basis, or at all. Renovaro Cube’s failure to successfully develop new and/or improved products (including
new versions of its existing platform and other products) on a timely basis could have a material adverse effect on Renovaro Cube’s
results of operations and business.
Even if Renovaro Cube
commercially launches its AI platform and other products, they may fail to achieve the degree of market acceptance necessary for commercial
success.
The commercial
success of Renovaro Cube’s AI platform and other future products will depend upon the degree of market acceptance by consumers,
including self-insured employers, integrated health systems, healthcare providers, patients and, over the long-term, third-party payors.
The degree of market acceptance of Renovaro Cube’s products will depend on a number of factors, including:
|
● |
the performance
and clinical utility of its products as demonstrated in clinical validation and published in peer-reviewed journals; |
|
● |
Renovaro
Cube’s ability to demonstrate the clinical utility of its products and their potential advantages to the medical community; |
|
● |
the ability
of Renovaro Cube’s products to demonstrate the same performance in real-world intended use populations as in clinical
validation; |
|
● |
the willingness
of consumers, including self-insured employers, integrated health systems, healthcare providers, patients and others in the
medical community to utilize Renovaro Cube’s products; |
|
● |
the willingness
of commercial third-party payors and government payors to cover and reimburse for Renovaro Cube’s products, the scope
and amount of which will likely affect an individual’s willingness or ability to pay for Renovaro Cube’s products and likely
heavily influence healthcare providers’ decisions to recommend Renovaro Cube’s products; |
|
● |
with respect
to products under development that Renovaro Cube intends to launch for use in a broad asymptomatic population, the concern that such
products could lead to over-diagnosis or a high false-positive rate and unnecessary medical procedures and costs; |
|
● |
the introduction
of competing products, including the expansion of the capabilities of existing products; |
|
● |
the market
acceptance of existing competitive products, including tests that are currently reimbursed; |
|
● |
publicity
concerning Renovaro Cube’s products or competing products; and |
|
● |
the strength
of Renovaro Cube’s marketing and distribution support. |
The failure
of Renovaro Cube’s AI platform, once introduced, to be listed in physician guidelines or of any future clinical validation to produce
favorable results or to be published in peer-reviewed journals could limit the adoption of its AI platform. In addition, healthcare
providers and third-party payors, including Medicare, may rely on physician guidelines issued by industry groups, medical societies
and other key organizations, such as the U.S. Preventive Services Task Force, before utilizing or reimbursing the cost of any diagnostic
or screening test. Although Renovaro Cube has conducted prior clinical validation of its AI platform, this platform is not yet, and may
never be, listed in any such guidelines.
Further,
if Renovaro Cube’s products and the technology underlying them do not receive sufficient favorable exposure in peer-reviewed publications,
the rate of physician and market acceptance of Renovaro Cube’s products and positive reimbursement or coverage decisions for Renovaro
Cube’s products could be negatively affected. The publication of clinical data in peer-reviewed journals is a crucial
step in commercializing and obtaining reimbursement or coverage for Renovaro Cube’s products, and Renovaro Cube’s inability
to control when, if ever, results are published may delay or limit Renovaro Cube’s ability to derive sufficient revenues from any
of its products that is developed using data from a clinical study.
Failure
to achieve broad market acceptance of Renovaro Cube’s products, once launched, would materially harm Renovaro Cube’s business,
financial condition and results of operations.
Renovaro Cube may be
unable to develop and commercialize new products.
Renovaro
Cube continues to expand its research and development efforts to use its proprietary AI platform to develop new products, including in
disease areas beyond cancer. The commercialization of any new products will require the completion of certain clinical development activities,
regulatory activities and the expenditure of additional cash resources. Renovaro Cube cannot assure you that it can successfully complete
the clinical development of any such products.
Renovaro
Cube also cannot assure you that it will be able to reduce its expenditures sufficiently, generate sufficient revenue from products that
it successfully commercializes or otherwise mitigate the risks associated with its business to raise enough capital to develop and commercialize
new products. In addition, once Renovaro Cube’s development efforts for a product are completed, commercialization efforts, including
allocation of resources necessary to comply with applicable laws and regulations, will require significant expenditures. Any failure by
Renovaro Cube to develop and commercialize new products could have a material adverse effect on Renovaro Cube’s ability to implement
its strategy and grow its business.
One of the key elements
of Renovaro Cube’s strategy is to expand access to its tests by pursuing reimbursement and/or coverage from third-party payors.
If Renovaro Cube’s products do not receive adequate coverage or reimbursement from third-party payors, its ability to
expand access to its tests beyond its initial sales channels and its overall commercial success will be limited.
Renovaro
Cube anticipates that it will not have broad-based coverage or reimbursement at the initial commercial launch. However, a key
element to Renovaro Cube’s strategy is to expand access to its tests by pursuing coverage and/or reimbursement by third-party payors,
including government payors. Coverage and reimbursement by third-party payors, including managed care organizations, private
health insurers and government healthcare programs, such as Medicare and Medicaid in the United States and similar programs in other countries,
for the types of early detection and post-diagnosis service tests that Renovaro Cube provides can be limited and uncertain. Healthcare
providers may not order Renovaro Cube’s products unless third-party payors cover or provide adequate reimbursement for
a substantial portion of the price of Renovaro Cube’s products. If Renovaro Cube is not able to obtain adequate coverage or an acceptable
level of reimbursement for its products from third-party payors, there could be a greater co-insurance or co-payment obligation
for any individual for whom a test is ordered. The individual may be forced to pay the entire cost of a test out-of-pocket, which
could dissuade physicians from ordering Renovaro Cube’s products and, if ordered, could result in delay in, or decreased likelihood
of, Renovaro Cube’s collection of payment. Renovaro Cube believes its revenue and revenue growth will depend on its success in achieving
broad coverage and adequate reimbursement for its products from third-party payors.
Coverage
and reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that a product
is appropriate, medically necessary and cost-effective. Each payor will make its own decision as to whether to establish a policy
or enter into a contract to cover Renovaro Cube’s products and the amount it will reimburse for such products. Any determination
by a payor to cover and the amount it will reimburse for Renovaro Cube’s products would likely be made on an indication-by-indication basis.
For example, because Renovaro Cube intends to cover a broad asymptomatic population with its future products which could potentially generate
a significant number of false-positive results on an absolute basis, Renovaro Cube may face additional scrutiny in obtaining
reimbursement from third-party payors given the additional costs of further diagnostic workup. As a result, obtaining approvals
from third-party payors to cover Renovaro Cube’s products and establishing adequate coding recognition and reimbursement
levels is an unpredictable, challenging, time-consuming and costly process and Renovaro Cube may never be successful. If third-party payors
do not provide adequate coverage or reimbursement for Renovaro Cube’s products, Renovaro Cube’s ability to succeed commercially
will be limited.
Even if
Renovaro Cube establishes relationships with payors to provide its products at negotiated rates, such agreements would not obligate any
healthcare providers to order its products or guarantee that it would receive reimbursement for its products from these or any other payors
at adequate levels. Thus, these payor relationships, or any similar relationships, may not result in acceptable levels of coverage or
reimbursement for Renovaro Cube’s products or meaningful increases in the number of billable tests it sells to healthcare providers.
Renovaro Cube believes it may take several years to achieve coverage or adequate reimbursement with a majority of third-party payors,
including with those payors offering negotiated rates. In addition, Renovaro Cube cannot predict whether, under what circumstances, or
at what payment levels payors will cover or reimburse for its products. If Renovaro Cube fails to establish and maintain broad-based coverage
or reimbursement for its products, its ability to expand access to its products, generate increased revenue and grow its test volume and
customer base will be limited and its overall commercial success will be limited.
If Renovaro Cube’s
products, or the products of its competitors, directly or indirectly result in harm or injury to patients, Renovaro Cube could be subject
to significant reputational and liability risks, and its operating results, reputation and business could suffer.
Renovaro
Cube’s success will depend on the market’s confidence that its developed products can provide reliable, high-quality results,
once such products are launched. Renovaro Cube believes that patients, physicians and regulators are likely to be particularly sensitive
to errors in the use of its products or failure of its products to perform as described, and there can be no guarantee that its products
will meet their expectations. Renovaro Cube’s initial product is intended to be used to detect a cancer signal in patients, but
its results are not diagnostic. If a cancer signal is detected, the product would be used to localize the origin of the cancer signal.
A “cancer signal detected” test result would need to be followed up by appropriate diagnostic methods. Because this product
cannot detect all cancer signals, and may not detect signals for all cancer types, a negative test would not rule out the presence of
cancer. Additionally, a patient undergoing unnecessary diagnostic tests on the basis of a false-positive result or an erroneous
location of cancer signal result could expose Renovaro Cube to significant liability and reputational risks notwithstanding the emotional
and mental health effects to which the patient may be exposed. Similarly, a patient who receives a cancer diagnosis shortly following
a “no cancer signal detected” test result may create negative publicity about Renovaro Cube’s product, which would discourage
adoption. Performance failures could establish a negative perception of Renovaro Cube’s products among physicians, patients and
regulators, jeopardize Renovaro Cube’s ability to successfully commercialize its products, impair Renovaro Cube’s ability
to obtain regulatory approvals or secure favorable coverage or reimbursement, or otherwise result in reputational harm. In addition, Renovaro
Cube may be subject to legal claims arising from any errors in the use, manufacture, design, labelling or performance of its products,
including any false-positive or false-negative results.
In addition,
other companies are developing competing cancer detection tests and technologies focused on improving cancer care with cancer detection
tests and post-diagnostic products. If any tests marketed or being developed by Renovaro Cube’s competitors that are similar
to its products do not perform in accordance with expectations or cause harm or injury to patients, such failure to perform, harm or injury
may result in lower confidence in early disease detection and post-diagnosis tests in general, which could potentially adversely
affect confidence in Renovaro Cube’s products and result in an adverse impact on its operating results and reputation.
If Renovaro Cube’s
facilities or those of its third-party collaborators become inoperable, Renovaro Cube’s ability to provide its products
will be significantly impaired and its business will be harmed.
Renovaro
Cube relies on its third-party collaborators, consultants, contractors, vendors, suppliers and service providers. The facilities
of these partners could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, tornadoes, hurricanes,
fires, extreme weather conditions, medical epidemics, pandemics, global conflict, war and other natural or man-made disasters
or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations and policies,
or withdrawn funding. The occurrence of any of these business disruptions could seriously harm their ability to complete their contracted
services to Renovaro Cube, which may adversely impact its operations and financial condition.
Renovaro Cube’s
business and results of operations will suffer if it fails to compete effectively.
The testing
and diagnostic products industry is intensely competitive. Renovaro Cube has competitors both in Europe and abroad, including Grail, Inc.,
Exact Sciences Corporation, Freenome, Inc. and Thrive Earlier Detection Corp., that have stated that they are developing tests designed
to detect cancer. Renovaro Cube’s competitors have, or may have, substantially greater financial, technical and other resources,
such as larger research and development staff and well-established marketing and sales forces, and they may operate in jurisdictions
where lower standards of evidence are required to bring products to market. Renovaro Cube’s competitors may succeed in developing,
acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than Renovaro Cube’s
products. In addition, established medical technology, biotechnology, or pharmaceutical companies may invest heavily to accelerate the
discovery and development of tests that could make Renovaro Cube’s products less competitive than Renovaro Cube anticipates.
Renovaro
Cube’s ability to compete successfully will depend largely on its ability to:
|
● |
successfully commercialize its products; |
|
● |
demonstrate compelling advantages in the performance and convenience of its products, including on a cost-competitive basis; |
|
● |
achieve market acceptance of its products by consumers, including self-insured employers, integrated health systems, healthcare providers and patients; |
|
● |
achieve adequate coverage or reimbursement by third-party payors for its products; |
|
● |
differentiate its product from the other tests and products of current and potential competitors; |
|
● |
attract qualified scientific, data science, clinical development, product development and commercial personnel; |
|
● |
obtain, maintain, defend and enforce patents and other intellectual property rights and claims as necessary for its products; |
|
● |
obtain and maintain any necessary or desirable clearance or approval from regulators in Europe, the United Kingdom, the United States and other jurisdictions; |
|
● |
successfully collaborate with institutions in the discovery, development and commercialization of its products; and |
|
● |
successfully expand its operations and implement a successful sales and marketing strategy to support commercialization. |
Renovaro
Cube may not be able to compete effectively if Renovaro Cube is unable to accomplish one or more of these or similar objectives.
If Renovaro Cube cannot
enter new collaborations in a timely manner and on acceptable terms, its efforts to develop and commercialize its products could be delayed
or adversely affected.
From time
to time, Renovaro Cube expects to engage in discussions with potential development and/or commercial collaborators that may or may not
lead to collaborations. However, Renovaro Cube cannot guarantee that any discussions will result in development or commercial collaborations.
Further, once news of discussions regarding possible collaborations are known in the general public, regardless of whether the news is
accurate, failure to announce a collaboration agreement, or the entity’s announcement of a collaboration with an entity other than
Renovaro Cube, could result in adverse speculation about Renovaro Cube, its products or its technology, resulting in harm to its reputation
and its business. In addition, establishing collaborations is difficult and time-consuming and may require Renovaro Cube’s
significant financial investment. Potential collaborators may elect not to work with Renovaro Cube based on their assessment of its financial,
regulatory, or intellectual property position. Even if Renovaro Cube establishes new collaborations, they may not result in the successful
development or commercialization of its products or technology.
If Renovaro Cube is
unable to establish sales and marketing capabilities, it may not be successful in commercializing Renovaro Cube’s products.
Renovaro
Cube has only limited sales and marketing infrastructures and no experience as a company in the sale, marketing and distribution of screening
or diagnostic tests. In preparation of a commercial launch, Renovaro Cube is rapidly hiring additional personnel in Renovaro Cube’s
sales and marketing organization.
Factors that may inhibit
Renovaro Cube’s efforts to commercialize any of its products include:
|
● |
its inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs and other support personnel; |
|
● |
the inability of sales personnel to persuade adequate numbers of customers, including healthcare systems and healthcare providers, to use its products; |
|
● |
the inability to price its products at a sufficient price point to ensure an adequate and attractive level of profitability; |
|
● |
its inability to effectively market to, collaborate with, and secure coverage or reimbursement from third-party payors; |
|
● |
its failure to comply with applicable regulatory requirements governing the sale, marketing, reimbursement and commercialization of its products; and |
|
● |
unforeseen costs and expenses associated with creating an independent commercialization organization. |
Renovaro Cube’s
business is subject to economic, political, regulatory and other risks associated with international operations.
Renovaro
Cube’s business is subject to risks associated with conducting business internationally. For example, some of Renovaro Cube’s
suppliers and parties with whom it has collaborative relationships are located outside of the Netherlands, including in the United Kingdom
and Israel. Accordingly, Renovaro Cube’s future results could be harmed by a variety of factors, including:
|
● |
economic
weakness, including inflation, or political instability in particular foreign economies and markets; |
|
● |
challenges
enforcing its contractual and intellectual property rights, especially in those foreign jurisdictions that do not respect and protect
intellectual property rights to the same extent as the Netherlands; |
|
● |
changes
in foreign laws, regulations and customs, tariffs and trade barriers; |
|
● |
changes
in foreign currency exchanges rates; |
|
● |
changes
in a specific country’s or region’s political or economic environment; |
|
● |
negative
consequences from changes in tax laws; |
|
● |
trade
protection measures, import or export licensing requirements or other restrictive actions by the Netherlands or foreign governments; |
|
● |
compliance
with tax, employment, immigration and labor laws for employees living or traveling abroad; |
|
● |
workforce
uncertainty in countries where labor unrest is more common than in the Netherlands; |
|
● |
difficulties
associated with staffing and managing international operations, including differing labor relations; and |
|
● |
business
interruptions resulting from geo-political actions, including war and terrorism, pandemics, or natural disasters, including
earthquakes, typhoons, floods and fires. |
Risks Related to Renovaro
Cube’s Employee Matters and Managing Growth
Renovaro Cube is highly
dependent on its key personnel. If Renovaro Cube is not successful in attracting, motivating and retaining highly qualified personnel,
it may not be able to successfully implement its business strategy.
Renovaro
Cube’s ability to compete in the highly competitive biotechnology industry depends upon its ability to attract, motivate and retain
highly qualified personnel. Renovaro Cube is highly dependent on its executive management team and its scientific, medical, technological
and engineering personnel, all of whom have been working together as a group for only a limited period of time. The loss of the services
provided by any of Renovaro Cube’s executive officers, other key employees and other scientific and medical advisors, and Renovaro
Cube’s inability to find suitable replacements as needed, could result in delays in commercialization of its products and harm its
business. Renovaro Cube does not maintain “key person” insurance policies on the lives of these individuals or the lives of
any of its other employees.
Renovaro
Cube is headquartered in Amsterdam, the Netherlands, a region in which many other healthcare companies, technology companies and academic
and research institutions are headquartered. Competition for personnel is intense and the turnover rate can be high, which may limit Renovaro
Cube’s ability to hire and retain highly qualified personnel on acceptable terms or at all. Renovaro Cube expects that it may need
to recruit talent from outside of its region, and doing so may be costly and difficult. If Renovaro Cube is unable to attract and retain
highly qualified personnel, its ability to develop and commercialize its products may be limited.
If Renovaro Cube is
unable to scale its operations successfully to support demand for its products following the launch of its platform, its business could
suffer.
As and
to the extent demand increases beyond Renovaro Cube’s expectations following the launch of Renovaro Cube’s platform, Renovaro
Cube will likely need to start to ramp up operating capacity. Renovaro Cube will need to implement new infrastructure, data processing
capabilities, customer service, billing and systems processes, and expand Renovaro Cube’s internal quality assurance program and
technology to support operations on a larger scale. Renovaro Cube will also need collaboration arrangements with third-party laboratories
to process its physical tests or, if processing of such tests is not fully outsourced to support demand, will need to obtain equipment
and certified and licensed laboratory personnel to process these physical tests internally. Renovaro Cube may face difficulties increasing
the scale of its operations, including implementing changes in infrastructure or programs or acquiring additional equipment or personnel.
As Renovaro Cube refines its products and develops additional products, Renovaro Cube may need to introduce new equipment, implement
new systems, technology, controls and procedures, and hire personnel with different qualifications, licenses or certifications.
The value
of Renovaro Cube’s products will depend, in part, on Renovaro Cube’s ability to perform tests, whether through a licensed
provider or internally, and return results to providers on a timely basis and at an appropriate quality standard, and on Renovaro Cube’s
reputation for such timeliness and quality. Failure to establish necessary arrangements with licensed providers, to implement necessary
procedures, to transition to new equipment or processes, or to hire the appropriately qualified personnel could result in higher costs
of processing, longer turnaround times or an inability to meet market demand. There can be no assurance that Renovaro Cube or any such
licensed provider will be able to perform tests on a timely basis at a level consistent with demand, that Renovaro Cube will be able to
maintain the quality of its test results as Renovaro Cube scales its commercial operations, or that Renovaro Cube will be successful in
responding to the potential growing complexity of its operations, including the related data analysis requirements.
In addition,
Renovaro Cube’s growth may place a significant strain on its management, operating and financial systems, research and development,
and its sales, marketing, and administrative resources. As a result of Renovaro Cube’s growth, its operating costs may escalate
even faster than planned, and some of its internal systems may need to be enhanced or replaced. If Renovaro Cube cannot effectively manage
its expanding operations and its costs, Renovaro Cube may not be able to grow successfully or it may grow at a slower pace, and its business
could be adversely affected.
Renovaro Cube will
need to grow the size and capabilities of its organization, and it may experience difficulties in managing this growth.
As of
February 13, 2024, Renovaro Cube had 11 full-time employees and four independent contractors, including two full-time. As Renovaro Cube’s
growth plan and strategies develop, it must add a significant number of additional managerial, operational, financial and other personnel.
Future growth will impose significant added responsibilities on members of management, including:
|
● |
identifying,
recruiting, integrating, retaining and motivating additional employees; |
|
● |
managing
its internal development efforts effectively, including creating compliant programs and processes, and managing the regulatory requirements
for its products, while complying with its contractual obligations to contractors and other third parties; |
|
● |
expanding
its operational, financial and management controls, reporting systems and procedures; and |
|
● |
managing
the increasing complexity associated with a larger organization and expanded operations. |
Renovaro
Cube’s future financial performance and its ability to commercialize its products will depend, in part, on its ability to effectively
manage any future growth. Renovaro Cube’s management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to manage these growth activities. Renovaro Cube’s ability to successfully manage its expected growth is uncertain given
the fact that Renovaro Cube has been in full operation as an independent company focusing on cancer diagnostics AI only since 2018. Renovaro
Cube’s executive management team’s lack of long-term experience working together may adversely impact their ability
to effectively manage its business and growth.
If Renovaro
Cube is not able to effectively expand its organization by hiring new employees, it may not be able to successfully implement the tasks
necessary to commercialize its products, which would have a negative impact on Renovaro Cube’s business and result of operations.
Risks Related to Renovaro
Cube’s Legal Compliance and Litigation
Changes in funding
or disruptions at the EMA, the MRHA, and other government agencies caused by funding shortages or global health concerns could hinder
Renovaro Cube’s ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from
being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business
functions on which the operation of Renovaro Cube’s business may rely, which could negatively impact its business.
The ability
of the EMA, the MRHA, and, in the future, the FDA and other government agencies to review and clear or approve new products or changes
to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and
policy changes, the agency’s ability to hire and retain key personnel and accept the payment of user fees, government shutdowns
and other events that may otherwise affect the agency’s ability to perform routine functions. For example, average review times
at the FDA have fluctuated in recent years as a result of such factors. In addition, government funding of other government agencies that
fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions
at the EMA, the MRHA, and, in the future, the FDA and other agencies may also slow the time necessary for new medical devices or modifications
to cleared or approved medical devices to be reviewed and/or approved by necessary government agencies, which would adversely affect Renovaro
Cube’s business.
If Renovaro Cube is
sued for product or professional liability, it could face substantial liabilities that exceed its resources.
Renovaro
Cube’s business depends upon its ability to obtain reliable and accurate test results that incorporate rapidly evolving understanding
of how to interpret minute signals detected by Renovaro Cube’s assays as indications of potential presence of disease. Actual or
perceived errors resulting from laboratory or reporting errors, false positive or false negative test results, or the manufacture, design,
or labelling of Renovaro Cube’s products, could subject Renovaro Cube to product liability or professional liability claims. A product
liability or professional liability claim against Renovaro Cube could result in substantial damages and be costly and time-consuming to
defend. Any liability claim brought against Renovaro Cube, with or without merit, could increase its insurance rates or prevent it from
securing insurance coverage in the future. Additionally, any liability lawsuit could damage Renovaro Cube’s reputation or force
it to delay or suspend sales of its products. The occurrence of any of these events could have a material adverse effect on Renovaro Cube’s
business, results of operations, financial condition and prospects.
Renovaro Cube’s
employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements.
Renovaro
Cube is exposed to the risk of fraud, misconduct, or other illegal activity by its employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to comply with
the rules and regulations of the Centers for Medicare & Medicaid Services (the “CMS”), the FDA, the EMA, the MRHA and
other comparable regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing
and clinical laboratory standards; comply with healthcare fraud and abuse laws in the United Kingdom, Europe and, in the future, the United
States and similar fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities
to Renovaro Cube. When Renovaro Cube begins commercializing its products in the United Kingdom and Europe and, in the future, the United
States, its potential exposure under such laws will increase significantly, and its costs associated with compliance with such laws are
also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry
are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices, as well as off-label product
promotion. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion,
sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws
also involve the improper use of information obtained in the course of clinical validation, which could result in regulatory sanctions
and cause serious harm to Renovaro Cube’s reputation. Renovaro Cube has adopted a code of business conduct and ethics, but it is
not always possible to identify and deter misconduct by employees and third parties, and the precautions Renovaro Cube takes to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Renovaro Cube from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions
are instituted against Renovaro Cube, and Renovaro Cube is not successful in defending itself or asserting its rights, those actions could
have a significant impact on Renovaro Cube’s business, including the imposition of significant fines or other sanctions. Even if
it is later determined after an action is instituted against Renovaro Cube that Renovaro Cube was not in violation of these laws, Renovaro
Cube may be faced with negative publicity, incur significant expenses defending its actions and have to divert significant management
resources from other matters.
Renovaro Cube’s products, if used
for the diagnosis of disease, could be subject to government regulation, and the regulatory approval and maintenance process for such
products may be expensive, time-consuming, and uncertain both in timing and in outcome.
Renovaro
Cube’s products are not subject to FDA or other government regulatory clearance or approval if they are not intended to be used
for the diagnosis, treatment or prevention of disease. However, as Renovaro Cube expands its product line to encompass products that are
intended to be used for the diagnosis of disease, certain of its products will become subject to regulation by the FDA, or comparable
international agencies, including requirements for regulatory clearance or approval of such products before they can be marketed. Such
regulatory approval processes or clearances may be expensive, time-consuming, and uncertain, and Renovaro Cube’s failure to obtain
or comply with such approvals and clearances could have an adverse effect on its business, financial condition, or operating results.
In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any
time during the development or marketing of Renovaro Cube’s future products, which may negatively affect its ability to obtain or
maintain FDA or comparable regulatory approval of its products, if required.
Diagnostic
products are regulated as medical devices by the FDA and comparable international agencies and may require either clearance from the FDA
or such other comparable agencies following the 510(k) pre-market notification process or pre-market approval from the FDA, in each case
prior to marketing. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. If Renovaro Cube
fails to obtain, or experiences significant delays in obtaining, regulatory approvals for diagnostic products that it develops in the
future, Renovaro Cube may not be able to launch or successfully commercialize such products in a timely manner, or at all.
In addition,
if Renovaro Cube’s products labelled as “For Research Use Only. Not for use in diagnostic procedures,” or RUO, are used,
or could be used, for the diagnosis of disease, the regulatory requirements related to marketing, selling, and supporting such products
could change or be uncertain, even if such use by Renovaro Cube’s customers is without its consent. If the FDA or other regulatory
agencies assert that any of Renovaro Cube’s RUO products are subject to regulatory clearance or approval, Renovaro Cube’s
business, financial condition, or results of operations could be adversely affected.
Regulatory and legislative developments
on the use of AI and machine learning could adversely affect Renovaro Cube’s use of such technologies in its platform and other
products.
As the
regulatory framework for machine learning technology and AI evolves, Renovaro Cube’s business, financial condition, and results
of operations may be adversely affected. The regulatory framework for machine learning technology, AI and automated decision-making is
evolving. It is possible that new laws and regulations will be adopted in the United Kingdom, the European Union, the United States and/or
other foreign jurisdictions, or that existing laws and regulations may be interpreted in ways that would affect the operation of Renovaro
Cube’s AI platform and data analytics and the way in which Renovaro Cube uses AI and machine learning technology. Further, the cost
to comply with such laws or regulations could be significant and would increase Renovaro Cube’s operating expenses, which could
adversely affect its business, financial condition and results of operations.
For example,
in Europe, on April 21, 2021, the European Commission proposed a regulation seeking to establish a comprehensive, risk-based governance
framework for AI in the European Union market. The proposed legislation is intended to apply to companies that develop, use and/ or provide
AI in the European Union and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human
oversight, security and accuracy, and proposes fines for breach of up to 6% of worldwide annual turnover. In addition, on September 28,
2022, the European Commission proposed the AI Liability Directive and the revised Product Liability Directive seeking to establish a harmonized
civil liability regime for AI in the European Union in order to facilitate civil claims in respect of harm caused by AI and to include
AI-enabled products within the scope of the European Union’s existing product liability regime. If enacted, this regulatory framework
is expected to have a material impact on the way AI is regulated in the European Union, and together with developing guidance and/or decisions
in this area, may affect Renovaro Cube’s use of AI and its ability to provide and to improve its services, require additional compliance
measures and changes to its operations and processes, result in increased compliance costs and potential increases in civil claims against
Renovaro Cube, and could adversely affect its business, operations and financial condition.
Risks Related to Renovaro
Cube’s Technology and Intellectual Property
Issues in the development and use of AI,
including machine learning and computer vision, in Renovaro Cube’s AI platform may result in reputational harm or liability.
AI is
integrated into Renovaro Cube’s platform and is a significant element of its business offerings going forward. As with many developing
technologies, AI presents risks, challenges and unintended consequences that could affect its further development, adoption, and use,
and therefore Renovaro Cube’s business. AI algorithms and training methodologies may be flawed. Data sets may be insufficient, of
poor quality, or contain biased information. Inappropriate or controversial data practices by data scientists, engineers, and end-users of
Renovaro Cube’s systems could impair the acceptance of AI solutions. If the analyses that AI applications assist in producing are
deficient or inaccurate, Renovaro Cube could be subjected to competitive harm, potential legal liability, and brand or reputational harm.
Some uses of AI present ethical issues, and Renovaro Cube’s judgment as to the ethical concerns may not be perceived as accurate.
While Renovaro Cube aims to develop and use AI responsibly and attempts to identify and mitigate ethical and legal issues presented by
its use, Renovaro Cube may be unsuccessful in identifying or resolving issues before they arise. If Renovaro Cube uses AI as part of its
platform in a manner that is controversial or perceived as unethical, this may lead to adverse results for Renovaro Cube’s financial
condition and operations or the financial condition and operations of its collaborators or vendors, which may further lead to Renovaro
Cube experiencing competitive harm, legal liability and brand or reputational harm. In addition, AI-related issues, deficiencies and/or
failures could give rise to legal and/or regulatory action, including with respect to proposed legislation regulating AI in jurisdictions
such as the European Union and others, and as a result of new applications of existing data protection, privacy, intellectual property,
and other laws.
Failure of, or defects
in, Renovaro Cube’s machine learning and cloud-based computing infrastructure, or increased regulation in the machine
learning space, could impair Renovaro Cube’s ability to process its data, develop products, or provide test results, and harm its
business and results of operations.
The design,
development, maintenance and operation of Renovaro Cube’s technology over time is expensive and complex, and may involve unforeseen
difficulties including material performance problems, undetected defects or errors. Overcoming technical obstacles and correcting defects
or errors could prove to be impossible or impracticable, and the costs incurred may be substantial and adversely affect Renovaro Cube’s
results of operations. Additionally, regulation in the machine learning space is constantly evolving and may make it difficult for Renovaro
Cube to continue using its machine learning approach. If Renovaro Cube’s technology does not function reliably, fails to meet expectations
in terms of performance, or cannot be fully utilized due to increasing regulation, Renovaro Cube may be unable to provide, or its customers
may stop using, its products.
Renovaro
Cube currently hosts all of its data on, and conducts its data analysis through, local hosting facilities. Any technical problems
or outages that may arise in connection with these hosting facilities could result in the loss of Renovaro Cube’s data or delayed
or ineffective data processing. A variety of factors, including infrastructure changes, human or software errors, viruses, malware, security
attacks, fraud, spikes in customer usage, or denial of service issues could cause interruptions in Renovaro Cube’s service. Such
service interruptions may reduce or inhibit Renovaro Cube’s ability to provide its products, delay any further clinical validation
and any future clinical studies, and damage its relationships with its customers. Renovaro Cube could also be exposed to potential lawsuits,
liability claims or regulatory actions, if, for example, Renovaro Cube’s local servers experienced a data privacy breach. If Renovaro
Cube was required to transfer its data to an alternative hosting provider, the transfer and acclimation to the new provider could result
in significant business delays and require additional resources.
Real or perceived errors, failures, or bugs
in Renovaro Cube’s platform and future products could adversely affect its business, results of operations, financial condition,
and growth prospects.
Renovaro Cube’s platform
is, and its future products will be, complex, and therefore, undetected errors, failures, bugs, or defects may be present in such platform
or products or occur in the future in its platform or products, its technology or software or the technology or software Renovaro Cube
licenses from third parties, including open source software, especially when updates or new products are released. Such software and technology
is used in information technology (“IT”) environments with different operating systems, system management software, devices,
databases, servers, storage, middleware, custom and third-party applications, and equipment and networking configurations, which may cause
errors, failures, bugs, or defects in the IT environment into which such software and technology is deployed. This diversity increases
the likelihood of errors, failures, bugs, or defects in those IT environments. Some of the features in Renovaro Cube’s platform
are powered by machine learning and AI, which depend on datasets and algorithms that could be flawed, including through inaccurate,
insufficient, outdated, or biased data. Despite testing by Renovaro Cube, real or perceived errors, failures, bugs, or defects may not
be found until Renovaro Cube’s customers use its products. Real or perceived errors, failures, bugs, or defects in Renovaro Cube’s
products could result in negative publicity, loss of or delay in market acceptance of its platform or future products and harm to its
brand, loss of investor confidence, weakening of its competitive position, claims by customers for losses sustained by them, or failure
to meet the stated service level commitments in its customer agreements. In such an event, Renovaro Cube may be required, or may choose,
for customer relations or other reasons, to expend significant additional resources in order to help correct the problem. Any real or
perceived errors, failures, bugs, or defects in Renovaro Cube’s products could also impair its ability to attract new customers,
retain existing customers, or expand their use of its products, which would adversely affect Renovaro Cube’s business, results of
operations and financial condition.
Renovaro Cube may also be subject
to liability claims for damages related to real or perceived errors, failures, bugs, or defects in its platform or future products. A
material liability claim or other occurrence that harms Renovaro Cube’s reputation or decreases market acceptance of its platform
or future products may harm its business and results of operations. Finally, since some of Renovaro Cube’s customers use its products
for compliance reasons, any errors, failures, bugs, defects, disruptions in service or other performance problems with Renovaro Cube’s
products may damage its customers’ businesses and could hurt its reputation.
Renovaro Cube’s
internal computer systems, or those expected to be used by its third-party research institution collaborators or other contractors or
consultants, may fail or suffer security breaches.
Despite
the implementation of security and back-up measures, Renovaro Cube’s internal computer, server and other information technology
systems as well as those of its third-party collaborators, consultants, contractors, suppliers and service providers, may be
vulnerable to damage from physical or electronic break-ins, computer viruses, malware, ransomware, denial of service and other cyber-attacks or
disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive and/or proprietary
data, including personal and health information, and could subject Renovaro Cube to significant liabilities, regulatory and enforcement
actions and reputational damage. For example, the loss of clinical study data from future clinical studies could result in delays in any
regulatory clearance or approval efforts and significantly increase Renovaro Cube’s costs to recover or reproduce the data, and
subsequently commercialize its future products. If Renovaro Cube or its third-party collaborators, consultants, contractors,
suppliers or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or
disclosure of personal or health information, Renovaro Cube may have to notify physicians, patients, partners, collaborators, government
authorities and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions and litigation,
any of which could harm Renovaro Cube’s business and reputation. Likewise, Renovaro Cube relies on its third-party research
institution collaborators and other third parties to conduct clinical validation, and similar events relating to their computer systems
could also have a material adverse effect on Renovaro Cube’s business. To the extent that any disruption or security breach were
to result in a loss of, or damage to, Renovaro Cube’s data or systems, or inappropriate or unauthorized access to or disclosure
or use of confidential, proprietary, or other sensitive, personal, or health information, Renovaro Cube could incur liability and suffer
reputational harm, and the development and commercialization of its products could be delayed.
Renovaro
Cube’s insurance policies may not be adequate to compensate it for the potential losses arising from such disruptions, failure,
or security breach. In addition, such insurance may not be available to Renovaro Cube in the future on economically reasonable terms,
or at all. Further, Renovaro Cube’s insurance may not cover all claims made against it and defending a suit, regardless of its merit,
could be costly, divert management attention and harm Renovaro Cube’s reputation.
If Renovaro Cube is
unable to protect the confidentiality of its trade secrets, Renovaro Cube’s business and competitive position would be harmed.
Renovaro
Cube relies on trade secrets and confidentiality agreements to protect its know-how, technology, data and other proprietary information
and to maintain its competitive position. Trade secrets and know-how can be difficult to protect. Renovaro Cube expects its
trade secrets and know-how to, over time, be disseminated within the industry through independent development, the publication
of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions.
Renovaro
Cube seeks to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality
agreements with parties who have access to them, such as Renovaro Cube’s employees, directors, corporate collaborators, outside
scientific collaborators, contract research organizations (“CROs”), contract manufacturers, suppliers, service providers,
consultants, advisors and other third parties. Renovaro Cube also enters into confidentiality and invention or patent assignment agreements
with its employees and consultants, and reminds departing employees when they leave their employment of their continuing confidentiality
obligations. Renovaro Cube cannot guarantee that it has entered into such agreements with each party that may have, or have had, access
to Renovaro Cube’s trade secrets or proprietary technology and processes. Despite Renovaro Cube’s efforts, any of these parties
may breach the agreements and disclose Renovaro Cube’s proprietary information, including Renovaro Cube’s trade secrets, and
Renovaro Cube may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. Some courts outside The Netherlands
are less willing or unwilling to protect trade secrets. For example, in China, claims regarding infringement or misappropriation of trade
secrets are difficult to prove, and consequently plaintiffs are rarely successful in bringing these claims. If any of Renovaro Cube’s
trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, Renovaro Cube would have no
right to prevent them from using that technology or information to compete with Renovaro Cube. If any of Renovaro Cube’s trade secrets
were to be misappropriated by, disclosed to, or independently developed by a competitor or other third party, Renovaro Cube’s competitive
position could be materially and adversely harmed.
Renovaro
Cube has and may enter into collaboration, license, contract research and/or manufacturing relationships with contract organizations that
operate in certain countries that are at heightened risk of theft of technology, data and intellectual
property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors.
Accordingly, Renovaro Cube’s efforts to protect and enforce Renovaro Cube’s intellectual property rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that Renovaro Cube develops or licenses,
and Renovaro Cube may be at heightened risk of losing its proprietary intellectual property rights around the world, including outside
of such countries, to the extent such theft or intrusion destroys the proprietary nature of its intellectual property.
Renovaro Cube depends
on its information technology and telecommunications systems and those of third parties, the failure or disruption of which could harm
its business.
Renovaro
Cube depends on information technology and telecommunications systems, including those provided by third parties and their vendors, for
significant elements of its operations, such as its information management systems, research and development, scientific and medical data
analysis and general administrative activities. In addition, Renovaro Cube’s third-party service providers depend upon
technology and telecommunications systems provided by outside vendors. Following the Closing, Renovaro Cube expects that the combined
company will expand and strengthen a number of enterprise software systems that affect a broad range of business processes and functions,
including, for example, systems handling human resources, financial controls and reporting, customer relationship management, regulatory
compliance, security controls and other infrastructure operations. These expansions may prove more difficult than Renovaro Cube expects
and could cause disruptions in its operations or additional expense.
Information
technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network
failures, malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of Renovaro
Cube’s servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive
events. Despite the precautionary measures Renovaro Cube has taken to detect and prevent or solve problems that could affect its information
technology and telecommunications systems, failures or significant downtime of these systems or those used by its third-party service
providers and their vendors could prevent Renovaro Cube from conducting tests, preparing and providing reports to future customers, billing
payors, conducting research and development activities, maintaining its financial controls and other reporting functions, and managing
the administrative aspects of its business. Any disruption or loss of information technology or telecommunications systems on which critical
aspects of Renovaro Cube’s operations depend could have an adverse effect on its business.
If Renovaro Cube’s
trademarks and trade names are not adequately protected, Renovaro Cube may not be able to build name recognition in its markets of interest
and its business may be adversely affected.
Renovaro
Cube uses certain unregistered trademarks and trade names in its business. These trademarks or trade names may be challenged, infringed
or declared generic or determined to be infringing on other marks. Renovaro Cube may not be able to protect its rights to these trademarks
and trade names in the future, which Renovaro Cube views as valuable to building name recognition among potential partners and customers
in its markets of interest. At times, competitors or other third parties have adopted or may adopt trade names or trademarks similar to
Renovaro Cube’s trade names and/or trademarks, thereby impeding its ability to build brand identity and possibly leading to market
confusion and/or litigation. In addition, there could be potential trade name or trademark infringement claims brought by owners of registered
trademarks or trademarks that incorporate variations of Renovaro Cube’s unregistered trademarks or trade names. Over the long term,
if Renovaro Cube is unable to establish name recognition based on its trademarks and trade names, then Renovaro Cube may not be able to
compete effectively and Renovaro Cube’s business may be adversely affected. Renovaro Cube’s efforts to enforce, protect or
defend its proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion
of resources and could adversely affect Renovaro Cube’s business, financial condition, results of operations and prospects.
Intellectual property
litigation may lead to unfavorable publicity that harms Renovaro Cube’s reputation.
During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions and other interim proceedings in the litigation. Such announcements could harm Renovaro Cube’s
reputation, the perceived value of Renovaro Cube’s intellectual property or the potential market for its products, which could have
a material adverse effect on its business.
Renovaro Cube’s
success depends on its ability to develop and commercialize its technology without infringing, misappropriating, or otherwise violating
the intellectual property of third parties. Third parties may initiate legal proceedings alleging that Renovaro Cube is infringing their
intellectual property rights, and if they prevail, could block sales of Renovaro Cube’s products and force Renovaro Cube to make
large damages and/or royalty payments, which could have a material adverse effect on the success of its business.
Renovaro
Cube’s commercial success in part depends upon its ability, and the ability of its collaborators, to market, sell and distribute
Renovaro Cube’s products and use Renovaro Cube’s proprietary technologies without infringing, misappropriating or otherwise
violating the proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology,
diagnostic and pharmaceutical industries. Renovaro Cube may become party to, or threatened with, future adversarial proceedings or litigation
regarding intellectual property rights with respect to its products, including interference proceedings before the United Kingdom Intellectual
Property Office, the European Patent Office, the United States Patent and Trademark Office and similar bodies in other jurisdictions.
Third parties may assert infringement claims against Renovaro Cube based on existing patents or patents that may be issued in the future.
If Renovaro
Cube is found to infringe, misappropriate, or otherwise violate a third party’s intellectual property rights, it could be required
to obtain a license from such third party to continue developing, marketing, selling and distributing Renovaro Cube’s products,
or to cease using the infringing technology. However, Renovaro Cube may not be able to obtain any required license on commercially reasonable
terms or at all. Even if Renovaro Cube were able to obtain a license, it could be non-exclusive, thereby giving Renovaro Cube’s
competitors access to the same technologies licensed to Renovaro Cube. In addition, Renovaro Cube could be found liable for monetary damages,
including treble damages if it is found to have willfully infringed a patent and attorneys’ fees if the court finds the case to
be exceptional. A finding of infringement, misappropriation, or other violation could prevent Renovaro Cube from commercializing its products
or force Renovaro Cube to cease some of its operations, which could materially harm its business. Claims that Renovaro Cube has misappropriated
the confidential information or trade secrets of third parties could have a similar negative impact on Renovaro Cube’s business.
Even if
resolved in Renovaro Cube’s favor, litigation or other legal proceedings relating to intellectual property claims may cause Renovaro
Cube to incur significant expenses and could distract Renovaro Cube’s personnel from their normal responsibilities. Such litigation
or proceedings could substantially increase Renovaro Cube’s operating losses and reduce the resources available for development
activities or any future sales, marketing, or distribution activities. Renovaro Cube may not have sufficient financial or other resources
to conduct such litigation or proceedings adequately. Some of Renovaro Cube’s competitors may be able to sustain the costs of such
litigation or proceedings more effectively than Renovaro Cube can because of their greater financial resources and more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could have a material adverse effect on Renovaro Cube’s ability to compete in the market place.
Renovaro Cube’s
use of open-source software could subject Renovaro Cube’s proprietary technology to unwanted open-source license
conditions that could negatively impact its business.
A portion
of Renovaro Cube’s technology capabilities incorporates open-source software, and Renovaro Cube may incorporate open-source software
into other offerings or products in the future. If an author or other third party that distributed such open-source software
to Renovaro Cube were to allege that Renovaro Cube had not complied with the conditions of one or more of these licenses, Renovaro Cube
could be required to incur significant legal expenses defending against such allegations. Further, the outcome of such litigation may
be particularly uncertain in some cases, because there is little legal precedent governing the interpretation of certain terms of common
open source licenses. In addition, if Renovaro Cube combines its proprietary software with open-source software in a certain
manner and makes it available to others, under some open-source licenses, it could be required to license or make available
the source code of its proprietary software, which could substantially help its competitors develop products that are similar to or better
than Renovaro Cube’s and harm its business.
The success and growth
of Renovaro Cube’s business depends upon its ability to continuously innovate and develop new products and technologies.
Renovaro
Cube’s solution is a technology-driven platform that relies on innovation to remain competitive. The process of developing new technologies
and products is complex, and Renovaro Cube has built and seeks to further develop its own technology using the latest in AI and
machine learning, cloud-based technologies and other tools to differentiate Renovaro Cube’s products and technologies. In addition,
Renovaro Cube’s dedication to incorporating technological advancements into its AI platform requires significant financial and personnel
resources and talent. Renovaro Cube’s development efforts with respect to these initiatives could distract management from current
operations and could divert capital and other resources from other growth initiatives important to Renovaro Cube’s business. Renovaro
Cube operates in an industry experiencing rapid technological change and frequent product introductions. Renovaro Cube may not be able
to make technological improvements as quickly as demanded by its customers, or Renovaro Cube may not be able to accurately predict the
demand or growth of its technological investments, which could harm its ability to attract customers and have a material and adverse effect
on its business, results of operations, financial condition and future prospects. In addition, Renovaro Cube may not be able to effectively
implement new technology-driven products and services as quickly as its competitors or be successful in marketing these products and services
to potential customers. If Renovaro Cube is unable to successfully and timely innovate, Renovaro Cube could experience reputational damage
and decreased demand for its AI platform and other products and technologies and its growth, business, results of operations, financial
condition and future prospects could be materially and adversely affected.
Renovaro Cube’s
AI platform and other related products may become obsolete due to fast growing technological innovations or the entry of competitors with
more financial and brand power.
AI is a fast growing industry and
Renovaro Cube must successfully adapt and manage technological advancements in AI and AI-related markets, as well as effectively
compete with the emergence of additional competitors in the AI industry in order to maintain and grow Renovaro Cube’s AI business
and products. Thus, the success of Renovaro Cube’s AI platform, other products and business depends in large part on its ability
to keep pace with rapid technological changes in the development and implementation of AI products. For example, the development of groundbreaking
technological innovations in AI, or innovations that would render AI obsolete, would harm Renovaro Cube’s business and make its
platform or other products less durable. Further, the entry of competitors into the AI market that have more financial and brand power
could cause Renovaro Cube’s share of the market to be significantly reduced thereby negatively affecting its business, operating
results and financial condition.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On March 14, 2024, the Company
entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount of $500,000 (the “March
2024 Note”). The March 2024 Note bears an interest rate of 10% per annum and shall mature on March 15, 2025. The Company is required
to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity
of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest may accrue on this Note on a
quarterly basis. The March 2024 Note is convertible either at the option of the holder after a qualified offering. If no qualified offering
occurs prior to the maturity date, the March 2024 Note is to be repaid in cash.
On January 11, 2024, the Company
entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the “January 2024 Note I”)
in the amount of $460,000. The January 2024 Note I bears an interest rate of 12% per annum and shall mature on January 11, 2025. The Company
is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following the Issue Date prior
to the maturity of the Notes. Notwithstanding the immediately foregoing, at the option of the Holder, interest may accrue on this Note
on a quarterly basis. The January 2024 Note I is convertible either at the option of the Holder or automatically upon maturity into shares
of the Company’s Common Stock at the conversion price of $3.38.
On January 12, 2024, the Company
entered into a Subscription Agreement with an investor (the “Investor”) to issue a Convertible Promissory Note for an aggregate
principal amount of $125,000 (the “January 2024 Note II”, and collectively with the January 2024 Note I, the “January
2024 Notes”). The Company received a total of $125,000 in gross proceeds. The January 2024 Note II bears an interest rate of
12% per annum and shall mature on December 29, 2024 (the “Maturity Date”). The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2024 Notes. The
January 2024 Note II is convertible either at the option of the Holder or automatically upon maturity into shares of the Company’s
Common Stock at the Note Conversion Price of $3.38.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Insider Trading Plans
During the quarter ended March 31, 2024, no director
or Section 16 officer adopted, modified, or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading
arrangement” (in each case, as defined in Item 408(a) of Regulation S-K).
Item 6. Exhibits.
Exhibits required by Item 601 of Regulation S-K:
Exhibit No. |
|
Description |
|
|
|
2.1 |
|
Second Amendment to Stock Purchase Agreement, dated February 13, 2024, by and among Renovaro Inc., GEDi Cube Intl Ltd., the sellers party thereto and Yalla Yalla Ltd. (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on February 14, 2024) |
|
|
|
3.1 |
|
Certificate of Incorporation, as amended** (incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed with the SEC on February 14, 2024) |
|
|
|
4.1 |
|
Registration Rights Agreement (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on February 14, 2024) |
|
|
|
10.1 |
|
Consulting Agreement, dated March 11, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 13, 2024) |
|
|
|
31.1** |
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 |
|
|
|
31.2** |
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 |
|
|
|
32.1*** |
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 |
|
|
|
32.2*** |
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 |
|
|
|
101.INS |
|
XBRL Instance Document |
|
|
|
101.SCH |
|
XBRL Taxonomy Extension Schema |
|
|
|
101.CAL |
|
XBRL Taxonomy Extension Calculation Linkbase |
|
|
|
101.DEF |
|
XBRL Taxonomy Extension Definition Linkbase |
|
|
|
101.LAB |
|
XBRL Taxonomy Extension Label Linkbase |
|
|
|
101.PRE |
|
XBRL Taxonomy Extension Presentation Linkbase |
** |
Filed herewith. |
*** |
Furnished herewith. |
SIGNATURES
Pursuant to the requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: August 20, 2024 |
RENOVARO INC. |
|
|
|
|
By: |
/s/ Mark Dybul |
|
|
Mark Dybul |
|
|
Chief Executive Officer |
|
|
(Principal Executive Officer) |
|
|
|
|
By: |
/s/ Simon Tarsh |
|
|
Simon Tarsh |
|
|
Interim Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
66
Exhibit 31.1
OFFICER’S CERTIFICATE
PURSUANT TO SECTION 302
I, Mark Dybul, certify that:
1. I have reviewed this Amendment No. 1 to Quarterly
Report on Form 10-Q/A for the period ended March 31, 2024, of Renovaro Inc.;
2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness
of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report
any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: August 20, 2024 |
By: |
/s/ Mark Dybul |
|
Name: |
Mark Dybul |
|
Title: |
Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.2
OFFICER’S CERTIFICATE
PURSUANT TO SECTION 302
I, Simon Tarsh, certify that:
1. I have reviewed this Amendment No. 1 to Quarterly
Report on Form 10-Q/A for the period ended March 31, 2024, of Renovaro Inc.;
2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness
of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report
any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: August 20, 2024 |
By: |
/s/ Simon Tarsh |
|
Name: |
Simon Tarsh |
|
Title: |
Interim Chief Financial Officer (Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Amendment No. 1 to Quarterly
Report (the “Company”) on Form 10-Q/A for the period ended March 31, 2024 as filed with the U.S. Securities and Exchange
Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1. The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 20, 2024 |
By: |
/s/ Mark Dybul |
|
Name: |
Mark Dybul |
|
Title: |
Chief Executive Officer (Principal Executive Officer) |
A signed original of this written statement required
by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the
Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Amendment No. 1 to Quarterly
Report (the “Company”) on Form 10-Q/A for the period ended March 31, 2024, as filed with the U.S. Securities and Exchange
Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1. The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 20, 2024 |
By: |
/s/ Simon Tarsh |
|
Name: |
Simon Tarsh |
|
Title: |
Interim Chief Financial Officer (Principal Financial Officer) |
A signed original of this written statement required
by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the
Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.
v3.24.2.u1
Cover - shares
|
9 Months Ended |
|
Mar. 31, 2024 |
May 10, 2024 |
Cover [Abstract] |
|
|
Document Type |
10-Q/A
|
|
Amendment Flag |
true
|
|
Amendment Description |
Renovaro Inc. (the “Company”,
“we”, “our”, or “us”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q/A (this
“Amendment”) to amend its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and
Exchange Commission (the “SEC”) on May 15, 2024, (the “Q3 2024 Form 10-Q”) to (i) restate its financial statements
as of and for the periods ended March 31, 2024, which should no longer be relied on and are being restated herein; and (ii) describe the
restatement and its impact on previously reported amounts.
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Mar. 31, 2024
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2024
|
|
Current Fiscal Year End Date |
--06-30
|
|
Entity File Number |
001-38758
|
|
Entity Registrant Name |
Renovaro Inc.
|
|
Entity Central Index Key |
0001527728
|
|
Entity Tax Identification Number |
45-2559340
|
|
Entity Incorporation, State or Country Code |
DE
|
|
Entity Address, Address Line One |
2080 Century Park East
|
|
Entity Address, Address Line Two |
Suite 906
|
|
Entity Address, City or Town |
Los Angeles
|
|
Entity Address, State or Province |
CA
|
|
Entity Address, Postal Zip Code |
90067
|
|
City Area Code |
305
|
|
Local Phone Number |
918-1980
|
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
|
Trading Symbol |
RENB
|
|
Security Exchange Name |
NASDAQ
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
147,504,944
|
X |
- DefinitionDescription of changes contained within amended document.
+ References
+ Details
Name: |
dei_AmendmentDescription |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
|
Mar. 31, 2024 |
Jun. 30, 2023 |
CURRENT ASSETS: |
|
|
Cash |
$ 312,697
|
$ 1,874,480
|
Prepaids and other assets |
907,218
|
690,925
|
Total Current Assets |
1,219,915
|
2,565,405
|
Property and equipment, net |
488,915
|
508,989
|
OTHER ASSETS: |
|
|
Definite life intangible assets, net |
31,042
|
39,676
|
Indefinite life intangible assets |
10,755,255
|
42,611,000
|
Goodwill |
164,186,852
|
11,640,000
|
Deposits and other assets |
21,742
|
21,741
|
Operating lease right-of-use assets |
1,385,619
|
913,985
|
Total Other Assets |
176,380,510
|
55,226,402
|
TOTAL ASSETS |
178,089,340
|
58,300,796
|
CURRENT LIABILITIES: |
|
|
Accounts payable – trade |
7,990,631
|
5,296,823
|
Accrued expenses |
3,754,976
|
723,173
|
Other current liabilities |
519,427
|
184,733
|
Contingent consideration liability, current (Note 4) |
1,006,438
|
0
|
Current portion of operating lease liabilities |
483,226
|
193,422
|
Notes payable, net |
3,418,621
|
4,624,947
|
Convertible notes payable |
3,700,694
|
0
|
Total Current Liabilities |
20,874,013
|
11,023,098
|
NON-CURRENT LIABILITIES: |
|
|
Operating lease liabilities, net of current portion |
970,353
|
775,587
|
Contingent consideration liability, noncurrent (Note 4) |
19,064,562
|
0
|
Deferred tax liability |
2,774,856
|
0
|
Total Non-Current Liabilities |
22,809,771
|
775,587
|
Total Liabilities |
43,683,784
|
11,798,685
|
Commitments and Contingencies (Note 10) |
|
|
STOCKHOLDERS’ EQUITY: |
|
|
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; zero 0 shares issued and outstanding at March 31, 2024 and June 30, 2023 |
0
|
0
|
Common Stock, par value $0.0001, 350,000,000 shares authorized, 147,488,598 shares issued and outstanding at March 31, 2024, and 63,698,144 shares issued and outstanding at June 30, 2023 |
14,750
|
6,371
|
Additional paid-in capital |
442,304,652
|
290,554,875
|
Accumulated deficit |
(308,947,816)
|
(244,029,253)
|
Accumulated other comprehensive income (loss) |
1,033,970
|
(29,882)
|
Total Stockholders’ Equity |
134,405,556
|
46,502,111
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
$ 178,089,340
|
$ 58,300,796
|
X |
- References
+ Details
Name: |
RENB_ContingentConsiderationLiabilityCurrent |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_ContingentConsiderationLiabilityNoncurrent |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_DeferredTaxLiabilityNonCurrent |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_NotesPayableNet |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8
+ Details
Name: |
us-gaap_AccountsPayableTradeCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DepositsAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_OtherPrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
|
Mar. 31, 2024 |
Jun. 30, 2023 |
Statement of Financial Position [Abstract] |
|
|
Preferred stock, par value |
$ 0.0001
|
$ 0.0001
|
Preferred stock, shares authorized |
10,000,000
|
10,000,000
|
Preferred stock, shares issued |
0
|
0
|
Preferred stock, shares outstanding |
0
|
0
|
Common stock, par value |
$ 0.0001
|
$ 0.0001
|
Common stock, shares authorized |
350,000,000
|
350,000,000
|
Common Stock, shares issued |
147,488,598
|
63,698,144
|
Common stock, shares outstanding |
147,488,598
|
63,698,144
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
|
3 Months Ended |
9 Months Ended |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Operating Expenses |
|
|
|
|
General and administrative |
$ 7,652,379
|
$ 3,796,057
|
$ 19,558,981
|
$ 12,365,960
|
Research and development |
1,087,156
|
239,137
|
2,274,321
|
3,170,471
|
Intangible asset impairment (Note 6) |
42,611,000
|
0
|
42,611,000
|
0
|
Depreciation and amortization |
30,305
|
28,242
|
90,727
|
85,487
|
Total Operating Expenses |
51,380,840
|
4,063,436
|
64,535,029
|
15,621,918
|
LOSS FROM OPERATIONS |
(51,380,840)
|
(4,063,436)
|
(64,535,029)
|
(15,621,918)
|
Other Income (Expense) |
|
|
|
|
Change in fair value of contingent consideration (Note 4) |
486,500
|
0
|
486,500
|
0
|
Loss on extinguishment of debt |
0
|
0
|
(120,018)
|
0
|
Loss on extinguishment of contingent consideration liability |
0
|
0
|
0
|
(419,182)
|
Interest expense |
(303,802)
|
(122,289)
|
(758,057)
|
(310,766)
|
Interest and other income (expense) |
(16,272)
|
(142,571)
|
8,041
|
(133,938)
|
Total Other Income (Expense) |
166,426
|
(264,860)
|
(383,534)
|
(863,886)
|
NET LOSS |
$ (51,214,414)
|
$ (4,328,296)
|
$ (64,918,563)
|
$ (16,485,804)
|
BASIC LOSS PER SHARE |
$ (0.48)
|
$ (0.08)
|
$ (0.82)
|
$ (0.30)
|
DILUTED LOSS PER SHARE |
$ (0.48)
|
$ (0.08)
|
$ (0.82)
|
$ (0.30)
|
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC |
107,480,475
|
55,974,605
|
79,168,663
|
55,524,511
|
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED |
107,480,475
|
55,974,605
|
79,168,663
|
55,524,511
|
X |
- References
+ Details
Name: |
RENB_ChangeInFairValueOfContingentConsideration |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_InterestAndOtherIncomeExpense |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_LossOnExtinguishmentOfDebt |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4
+ Details
Name: |
us-gaap_AssetImpairmentCharges |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest expense classified as nonoperating.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_InterestExpenseNonoperating |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
|
3 Months Ended |
9 Months Ended |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Income Statement [Abstract] |
|
|
|
|
Net Loss |
$ (51,214,414)
|
$ (4,328,296)
|
$ (64,918,563)
|
$ (16,485,804)
|
Other Comprehensive Income (Loss) |
|
|
|
|
Foreign currency translation, net of taxes |
1,061,201
|
(2,110)
|
1,063,852
|
(1,949)
|
Comprehensive Loss |
$ (50,153,213)
|
$ (4,330,406)
|
$ (63,854,711)
|
$ (16,487,753)
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
|
Series A Preferred Stocks [Member] |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
AOCI Attributable to Parent [Member] |
Total |
Beginning balance, value at Jun. 30, 2022 |
|
$ 5,302
|
$ 276,989,179
|
$ (204,345,197)
|
$ (30,436)
|
$ 72,618,848
|
Beginning balance, shares at Jun. 30, 2022 |
|
53,007,082
|
|
|
|
|
Stock issued pursuant to warrants exercised |
|
$ 125
|
1,624,875
|
|
|
1,625,000
|
Stock issued pursuant to warrants exercised, shares |
|
1,250,000
|
|
|
|
|
Contingent shares issued pursuant to acquisition agreement |
|
$ 125
|
2,762,375
|
|
|
2,762,500
|
Contingent shares issued pursuant to acquisition agreement, shares |
|
1,250,000
|
|
|
|
|
Stock-based compensation |
|
|
1,026,008
|
|
|
1,026,008
|
Net loss |
|
|
|
(7,699,760)
|
|
(7,699,760)
|
Foreign currency translation adjustment |
|
|
|
|
(7,754)
|
(7,754)
|
Ending balance, value at Sep. 30, 2022 |
|
$ 5,552
|
282,402,437
|
(212,044,957)
|
(38,190)
|
70,324,842
|
Ending balance, shares at Sep. 30, 2022 |
|
55,507,082
|
|
|
|
|
Beginning balance, value at Jun. 30, 2022 |
|
$ 5,302
|
276,989,179
|
(204,345,197)
|
(30,436)
|
72,618,848
|
Beginning balance, shares at Jun. 30, 2022 |
|
53,007,082
|
|
|
|
|
Net loss |
|
|
|
|
|
(16,485,804)
|
Ending balance, value at Mar. 31, 2023 |
|
$ 5,800
|
286,985,739
|
(220,831,001)
|
(32,385)
|
66,128,153
|
Ending balance, shares at Mar. 31, 2023 |
|
57,983,591
|
|
|
|
|
Beginning balance, value at Sep. 30, 2022 |
|
$ 5,552
|
282,402,437
|
(212,044,957)
|
(38,190)
|
70,324,842
|
Beginning balance, shares at Sep. 30, 2022 |
|
55,507,082
|
|
|
|
|
Shares issued in lieu of interest on $1.2 million notes payable extension |
|
$ 20
|
204,372
|
|
|
204,392
|
Shares issued in lieu of interest on $1.2 million notes payable extension, shares |
|
198,439
|
|
|
|
|
Stock-based compensation |
|
|
819,955
|
|
|
819,955
|
Net loss |
|
|
|
(4,457,748)
|
|
(4,457,748)
|
Foreign currency translation adjustment |
|
|
|
|
7,915
|
7,915
|
Ending balance, value at Dec. 31, 2022 |
|
$ 5,572
|
283,426,764
|
(216,502,705)
|
(30,275)
|
66,899,356
|
Ending balance, shares at Dec. 31, 2022 |
|
55,705,521
|
|
|
|
|
Shares and warrants issued pursuant to private placement offering |
|
$ 218
|
2,482,782
|
|
|
2,483,000
|
Shares and warrants issued pursuant to private placement offering, shares |
|
2,178,070
|
|
|
|
|
Restricted shares issued for services rendered |
|
$ 10
|
107,990
|
|
|
108,000
|
Restricted shares issued for services rendered, shares |
|
100,000
|
|
|
|
|
Stock-based compensation |
|
|
968,203
|
|
|
968,203
|
Net loss |
|
|
|
(4,328,296)
|
|
(4,328,296)
|
Foreign currency translation adjustment |
|
|
|
|
(2,110)
|
(2,110)
|
Ending balance, value at Mar. 31, 2023 |
|
$ 5,800
|
286,985,739
|
(220,831,001)
|
(32,385)
|
66,128,153
|
Ending balance, shares at Mar. 31, 2023 |
|
57,983,591
|
|
|
|
|
Beginning balance, value at Jun. 30, 2023 |
|
$ 6,371
|
290,554,875
|
(244,029,253)
|
(29,882)
|
46,502,111
|
Beginning balance, shares at Jun. 30, 2023 |
|
63,698,144
|
|
|
|
|
Issuance of preferred stock and warrants in private placement |
$ 28
|
|
1,999,972
|
|
|
2,000,000
|
Issuance of preferred stock and warrants in private placement, shares |
280,505
|
|
|
|
|
|
Issuance of preferred stock and warrants for conversion of Note Payable |
$ 28
|
|
1,999,973
|
|
|
2,000,001
|
Issuance of preferred stock and warrants for conversion of Note Payable, shares |
280,505
|
|
|
|
|
|
Restricted shares issued for services rendered |
|
$ 200
|
4,469,800
|
|
|
4,470,000
|
Restricted shares issued for services rendered, shares |
|
2,000,000
|
|
|
|
|
Stock-based compensation |
|
|
983,829
|
|
|
983,829
|
Net loss |
|
|
|
(9,175,028)
|
|
(9,175,028)
|
Foreign currency translation adjustment |
|
|
|
|
(34,601)
|
(34,601)
|
Ending balance, value at Sep. 30, 2023 |
$ 56
|
$ 6,571
|
300,008,449
|
(253,204,281)
|
(64,483)
|
46,746,312
|
Ending balance, shares at Sep. 30, 2023 |
561,010
|
65,698,144
|
|
|
|
|
Beginning balance, value at Jun. 30, 2023 |
|
$ 6,371
|
290,554,875
|
(244,029,253)
|
(29,882)
|
46,502,111
|
Beginning balance, shares at Jun. 30, 2023 |
|
63,698,144
|
|
|
|
|
Net loss |
|
|
|
|
|
(64,918,563)
|
Ending balance, value at Mar. 31, 2024 |
|
$ 14,750
|
442,304,652
|
(308,947,816)
|
1,033,970
|
134,405,556
|
Ending balance, shares at Mar. 31, 2024 |
|
147,488,598
|
|
|
|
|
Beginning balance, value at Sep. 30, 2023 |
$ 56
|
$ 6,571
|
300,008,449
|
(253,204,281)
|
(64,483)
|
46,746,312
|
Beginning balance, shares at Sep. 30, 2023 |
561,010
|
65,698,144
|
|
|
|
|
Stock issued pursuant to warrants exercised |
|
$ 53
|
341,812
|
|
|
341,865
|
Restricted shares issued for advisory services |
|
100
|
(100)
|
|
|
|
Stock-based compensation |
|
|
999,228
|
|
|
999,228
|
Net loss |
|
|
|
(4,529,121)
|
|
(4,529,121)
|
Foreign currency translation adjustment |
|
|
|
|
37,252
|
37,252
|
Ending balance, value at Dec. 31, 2023 |
$ 56
|
$ 6,724
|
301,349,389
|
(257,733,402)
|
(27,231)
|
43,595,536
|
Ending balance, shares at Dec. 31, 2023 |
561,010
|
67,224,089
|
|
|
|
|
Non-cash exercise of warrants |
|
$ 343
|
1,999,657
|
|
|
2,000,000
|
Non-cash exercise of warrants, shares |
|
3,425,399
|
|
|
|
|
Stock issued pursuant to warrants exercised, shares |
|
525,945
|
|
|
|
|
Restricted shares issued for advisory services, shares |
|
1,000,000
|
|
|
|
|
Restricted shares issued for services rendered |
|
$ 5
|
99,995
|
|
|
100,000
|
Restricted shares issued for services rendered, shares |
|
50,000
|
|
|
|
|
Issuance of common stock under private placement offering |
|
$ 34
|
999,966
|
|
|
1,000,000
|
Issuance of common stock under private placement offering, shares |
|
344,827
|
|
|
|
|
Issuance of common stock pursuant to acquisition of GEDi Cube (Note 12) |
|
$ 7,083
|
135,994,548
|
|
|
136,001,631
|
Issuance of common stock pursuant to acquisition of GEDi Cube (Note 11), shares |
|
70,834,183
|
|
|
|
|
Preferred stock converted to common stock pursuant to acquisition of GEDi Cube (Note 12) |
$ (56)
|
$ 561
|
(505)
|
|
|
|
Preferred stock converted to common stock pursuant to acquisition of GEDi Cube (Note 11), shares |
(561,010)
|
5,610,100
|
|
|
|
|
Stock-based compensation |
|
|
1,861,601
|
|
|
1,861,601
|
Net loss |
|
|
|
(51,214,414)
|
|
(51,214,414)
|
Foreign currency translation adjustment |
|
|
|
|
1,061,201
|
1,061,201
|
Ending balance, value at Mar. 31, 2024 |
|
$ 14,750
|
$ 442,304,652
|
$ (308,947,816)
|
$ 1,033,970
|
$ 134,405,556
|
Ending balance, shares at Mar. 31, 2024 |
|
147,488,598
|
|
|
|
|
X |
- References
+ Details
Name: |
RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ContingentSharesIssuedPursuantToAcquisitionAgreementShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_NoncashExerciseOfWarrantsShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_NoncashExerciseOfWarrantsValue |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RestrictedSharesIssuedForAdvisoryServices |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RestrictedSharesIssuedForAdvisoryServicesShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RestrictedSharesIssuedForServicesRenderedShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RestrictedSharesIssuedForServicesRenderedValue |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_SharesAndWarrantsIssuedPursuantToPrivatePlacementOffering |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_SharesAndWarrantsIssuedPursuantToPrivatePlacementOfferingShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_SharesIssuedInLieuOfInterestOnNotesPayableExtension |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_SharesIssuedInLieuOfInterestOnNotesPayableExtensionShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_StockIssuedPursuantToWarrantsExercisedShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_StockIssuedPursuantToWarrantsExercisedValue |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionGainLossBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
|
9 Months Ended |
Mar. 31, 2024 |
Mar. 31, 2023 |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
Net loss |
$ (64,918,563)
|
$ (16,485,804)
|
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: |
|
|
Depreciation and amortization |
90,727
|
85,487
|
Change in fair value of contingent consideration |
(486,500)
|
0
|
Loss on extinguishment of debt |
120,018
|
0
|
Loss on extinguishment of contingent consideration liability |
0
|
419,182
|
Stock based compensation expense |
3,844,658
|
2,922,166
|
Intangible asset impairment |
42,611,000
|
0
|
Restricted shares for services rendered |
4,570,000
|
0
|
Amortization of discount on notes payable |
494,809
|
223,863
|
Changes in assets and liabilities: |
|
|
Other receivables |
0
|
46
|
Prepaid expenses/deposits |
798,741
|
689,273
|
Accounts payable |
2,110,232
|
3,069,487
|
Accrued expenses |
2,194,293
|
(407,433)
|
Other current liabilities |
0
|
(18,520)
|
Operating leases, net |
12,936
|
(10,684)
|
NET CASH USED IN OPERATING ACTIVITIES |
(8,557,649)
|
(9,512,937)
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
Notes receivable prior to acquisition |
(1,225,779)
|
0
|
Cash received from acquisition |
65,851
|
0
|
Purchase of property and equipment |
(46,878)
|
(23,633)
|
NET CASH USED IN INVESTING ACTIVITIES |
(1,206,806)
|
(23,633)
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
Proceeds from issuance of promissory notes |
3,645,000
|
0
|
Repayment of finance agreement |
(646,128)
|
(840,992)
|
Proceeds from private placement |
3,000,000
|
2,483,000
|
Proceeds from notes payable |
1,710,000
|
0
|
Proceeds from exercise of warrants |
341,865
|
1,625,000
|
NET CASH PROVIDED BY FINANCING ACTIVITIES |
8,050,737
|
3,267,008
|
Effect of exchange rates on cash |
151,935
|
45,462
|
NET CHANGE IN CASH |
(1,561,783)
|
(6,224,100)
|
CASH, BEGINNING OF PERIOD |
1,874,480
|
9,172,142
|
CASH, END OF PERIOD |
312,697
|
2,948,042
|
Cash paid during the period for: |
|
|
Interest |
12,692
|
43,627
|
Income taxes |
0
|
0
|
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES |
|
|
Finance agreement entered into in exchange for prepaid assets |
906,834
|
1,139,875
|
Shares in lieu of interest on $1.2 million notes payable extension |
0
|
204,392
|
Common shares issued for contingent earn out liability |
0
|
2,762,500
|
Conversion of note payable for issuance of preferred stock |
2,000,001
|
0
|
Common shares issued upon acquisition |
136,001,631
|
0
|
Contingent consideration issued upon acquisition |
20,557,500
|
0
|
Note payable settled through non-cash exercise of warrants |
2,000,000
|
0
|
Debt discount related to notes payable |
$ 301,841
|
$ 0
|
X |
- References
+ Details
Name: |
RENB_AmortizationOfDiscountOnNotePayable |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_CashPaidDuringPeriodsForAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ChangeInFairValueOfContingentConsideration |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_CommonSharesIssuedForContingentEarnOutLiability |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_CommonSharesIssuedUponAcquisition |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ContingentConsiderationIssuedUponAcquisition |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ConversionOfNotePayableForIssuanceOfPreferredStock |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_LossOnExtinguishmentOfDebt |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_NonCashCompensation |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_NotePayableSettledThroughNoncashExerciseOfWarrants |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RepaymentOfFinanceAgreement |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RestrictedSharesForServicesRendered |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4
+ Details
Name: |
us-gaap_AssetImpairmentCharges |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_CashAcquiredFromAcquisition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current liabilities classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireNotesReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
|
3 Months Ended |
9 Months Ended |
Mar. 31, 2024 |
Dec. 31, 2023 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Sep. 30, 2022 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
Net Income (Loss) |
$ (51,214,414)
|
$ (4,529,121)
|
$ (9,175,028)
|
$ (4,328,296)
|
$ (4,457,748)
|
$ (7,699,760)
|
$ (64,918,563)
|
$ (16,485,804)
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1
+ Details
Name: |
ecd_PvpTable |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.24.2.u1
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a
+ Details
Name: |
ecd_InsiderTradingArrLineItems |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_NonRule10b51ArrAdoptedFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_NonRule10b51ArrTrmntdFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_Rule10b51ArrAdoptedFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_Rule10b51ArrTrmntdFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
9 Months Ended |
Mar. 31, 2024 |
Accounting Policies [Abstract] |
|
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Business
– On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(“Renovaro”, and together with its subsidiaries, the “Company”, “we” or “us”). In
August 2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company engages
in the research and development of pharmaceutical and biological products for the treatment of cancer, HIV, and HBV with the intent
to manufacture said products. On February 13, 2024, Renovaro Inc. acquired Renovaro Cube Intl Ltd and its subsidiaries (“Renovaro Cube”), as a wholly
owned subsidiary pursuant to a stock purchase agreement.
Basis of Presentation
– The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange
Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash
flows at March 31, 2024, and 2023 and for the periods then ended have been made. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying
unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto
included in the Company’s June 30, 2023, audited financial statements. The results of operations for the period ended March
31, 2024 are not necessarily indicative of the operating results for the full year.
Consolidation – For
the three and nine months ended March 31, 2024, and 2023, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.
Accounting Estimates –
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses
during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value of assets
acquired in a business acquisition, contingent consideration, and equity instruments issued for goods or services.
Functional
Currency & Foreign Currency Translation – The functional currency of Renovaro Denmark is the Danish Kroner
(“DKK”) and the functional currency of Renovaro Cube is the Euro (“EUR”). The Company’s reporting
currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated
into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average
exchange rates prevailing during the periods ended March 31, 2024, and 2023. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the
statement of operations as incurred.
Cash and Cash Equivalents –
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.
Concentration of Credit Risk
– Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits
are held. As of March 31, 2024 and June 30, 2023, the Company has not experienced losses on these accounts and management believes the
Company is not exposed to significant risks on such accounts.
Property and Equipment –
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5.)
Intangible Assets – The
Company has both definite and indefinite life intangible assets.
Definite life intangible assets
include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Definite life intangible
assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent
will not be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized
on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.
Indefinite life intangible assets
include in-process research and development (“IPR&D”) and goodwill. The Company accounts for indefinite life intangible
assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. IPR&D represents the fair value of the technology
on the date acquired and is tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying
value may not be recoverable.
Goodwill – Goodwill
is not amortized but is evaluated for impairment annually as of June 30th of each fiscal year or whenever events or changes
in circumstances indicate the carrying value may not be recoverable.
Impairment of Goodwill and Indefinite
Life Intangible Assets – We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. The Company has elected to perform its annual analysis on June 30th.
The annual fair value analysis performed on goodwill supported that goodwill was not impaired as of June 30, 2023. There have been no
events which have caused the Company to conduct an interim evaluation of its goodwill through March 31, 2024 (see Note 6.)
For indefinite life intangible assets, such as IPR&D, on an annual basis
on June 30th we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the
asset over its fair value. For the year ended June 30, 2023, the carrying value of the IPR&D exceeded its fair value. Therefore, the
Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023. During the quarter ended March 31, 2024, the Company
recorded an impairment loss of $42,611,000 related to the termination of the license agreement with Weird Science LLC (see Note 6.).
Impairment of Long-Lived Assets
– Long-lived assets, such as property and equipment, definite and indefinite life intangible assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which
could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes
in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast
of continuing losses associated with the use of the asset; and current expectations that the asset will more likely than not be sold or
disposed of significantly before the end of its estimated useful life.
Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be
generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
Leases – In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.
Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations.
For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on
a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited
condensed consolidated statements of operations.
The Company has elected the practical
expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance,
insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred
(see Note 7.)
Research and Development Expenses
– The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Oncology, HIV and HBV therapies and technologies for use in the prevention,
treatment, amelioration of and/or therapy for Oncology, HIV and HBV. Research and development expenses for the three and nine months ended
March 31, 2024, amounted to $1,087,156, and $2,274,321, respectively. Research and development expenses for the three and nine months
ended March 31, 2023, amounted to $239,137, and $3,170,471, respectively.
Income Taxes – The
Company accounts for income taxes in accordance with FASB ASC Topic 740, “Accounting for Income Taxes”, which requires an
asset and liability approach for accounting for income taxes.
Loss Per Share – The
Company calculates earnings/ (loss) per share in accordance with FASB ASC Topic 260, “Earnings Per Share”. Basic earnings
per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings
per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential
shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted
but have not been exercised and shares issuable upon conversion of convertible preferred stock and convertible notes. Because of the net
loss for the three and nine months ended March 31, 2024, and 2023, the dilutive shares for all periods were excluded from the Diluted
EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 9,522,967 and 5,410,460 potential
shares of Common Stock excluded from the Diluted EPS calculation as of March 31, 2024, and March 31, 2023, respectively.
Fair Value of Financial Instruments
– The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, “Fair Value Measurements”. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of March 31, 2024 and
2023, respectively. Level 3 liabilities held as of March 31, 2024, consisted of a contingent consideration
liability related to the February 13, 2024, acquisition of Renovaro Cube (see Note 4.)
Stock Options and Restricted
Share Units – The Company has granted stock options, restricted share units (“RSUs”) and warrants. The Company accounts
for stock-based awards in accordance with the provisions of FASB ASC Topic 718, “Compensation - Stock Compensation”.
Stock-Based Compensation
– The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation - Stock Compensation”.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for
based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably
measurable. Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized
based on the fair value of the equity instruments issued and are recognized over the required service period, which is generally
the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the three and nine months ended March
31, 2024 were $1,861,601 and $3,844,658, respectively. Stock based compensation costs for the vesting of options and RSUs granted for
the three and nine months ended March 31, 2023 were $1,076,203 and $2,922,166, respectively (See Note 9.)
Recently Adopted Accounting
Pronouncements – Recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material
impact on the Company’s present or future financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
|
9 Months Ended |
Mar. 31, 2024 |
Restatement Of Previously Issued Financial Statements |
|
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS |
NOTE 2 — RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
On July 12, 2024, the Company
received an SEC Comment Letter questioning its accounting for its indefinite life intangible assets impairment related to the
license agreement with Weird Science, LLC which was terminated on March 31, 2024, as described in Note 6.
After further analysis by
management and review of the applicable accounting requirements, the Company determined that its original impairment recognized in
its March 31, 2024 financial statements was not correct and those financial statements should be restated to reflect further
impairment of certain of its indefinite life intangible assets related to the license agreement with Weird Science, LLC.
The impact of the restatement on
these financial statements by line item is as follows:
Schedule
of restatement of previously issued financial statements | |
| |
| |
|
| |
As Reported | |
Change | |
As Rested |
Indefinite
life intangible assets | |
$ | 44,945,255 | | |
$ | (34,190,000 | ) | |
$ | 10,755,255 | |
| |
| | | |
| | | |
| | |
Total
other assets | |
$ | 210,570,510 | | |
$ | (34,190,000 | ) | |
$ | 176,380,510 | |
Total
assets | |
$ | 212,279,340 | | |
$ | (34,190,000 | ) | |
$ | 178,089,340 | |
Accumulated
deficit | |
$ | (274,757,816 | ) | |
$ | (34,190,000 | ) | |
$ | (308,947,816 | ) |
Total
stockholders’ equity | |
$ | 168,595,556 | | |
$ | (34,190,000 | ) | |
$ | 134,405,556 | |
Total
liabilities and stockholders’ equity | |
$ | 212,279,340 | | |
$ | (34,190,000 | ) | |
$ | 178,089,340 | |
Intangible
asset impairment | |
$ | 8,421,000 | | |
$ | 34,190,000 | | |
$ | 42,611,000 | |
Total
operating expenses for the three months ended March 31, 2024 | |
$ | 17,190,840 | | |
$ | 34,190,000 | | |
$ | 51,380,840 | |
Total
operating expenses for the nine months ended March 31, 2024 | |
$ | 30,345,029 | | |
$ | 34,190,000 | | |
$ | 64,535,029 | |
Loss
from operations three months ended March 31, 2024 | |
$ | (17,190,840 | ) | |
$ | (34,190,000 | ) | |
$ | (51,380,840 | ) |
Loss
from operations nine months ended March 31, 2024 | |
$ | (30,345,029 | ) | |
$ | (34,190,000 | ) | |
$ | (64,535,029 | ) |
Net
loss for the three months ended March 31, 2024 | |
$ | (17,024,414 | ) | |
$ | (34,190,000 | ) | |
$ | (51,214,414 | ) |
Net
loss for the nine months ended March 31, 2024 | |
$ | (30,728,563 | ) | |
$ | (34,190,000 | ) | |
$ | (64,918,563 | ) |
Comprehensive
loss for the three months ended March 31, 2024 | |
$ | (15,963,213 | ) | |
$ | (34,190,000 | ) | |
$ | (50,153,213 | ) |
Comprehensive
loss for the nine months ended March 31, 2024 | |
$ | (29,664,711 | ) | |
$ | (34,190,000 | ) | |
$ | (63,854,711 | ) |
Basic
and diluted net loss per share for the three months ended March 31, 2024 | |
$ | (0.16 | ) | |
$ | (0.32 | ) | |
$ | (0.48 | ) |
Basic
and diluted net loss per share for the nine months ended March 31, 2024 | |
$ | (0.39 | ) | |
$ | (0.43 | ) | |
$ | (0.82 | ) |
|
X |
- References
+ Details
Name: |
RENB_DisclosureRestatementOfPreviouslyIssuedFinancialStatementsAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
GOING CONCERN
|
9 Months Ended |
Mar. 31, 2024 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
GOING CONCERN |
NOTE 3 — GOING CONCERN
The Company’s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional
financing to fund operations. The Company incurred a net loss of $51,214,414 and $64,918,563 for the three and nine months ended March
31, 2024, respectively. As of March 31, 2024, the Company had cash and cash equivalents of $312,697 and an accumulated deficit of $308,947,816
and a working capital deficit of $19,654,098. These conditions raise substantial doubt about the Company’s ability to continue as
a going concern for one year after the date the financial statements are issued. The condensed consolidated financial statements do not
include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.
Management has reduced overhead and administrative costs by streamlining the organization
to focus around two of its therapies (oncology and a HIV therapeutic vaccine) and investment in the development and validation of its
AI driven cancer diagnostics platform. The Company has tailored its workforce to focus on these therapies. In addition, the Company intends
to attempt to secure additional required funding through equity or debt financing. However, there can be no assurance that the Company
will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on reasonable terms,
and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders. If we do not obtain
required additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend
operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with
whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations,
we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their
investment in us.
Funding that we may receive during
the fiscal year 2024 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
FAIR VALUE MEASUREMENTS
|
9 Months Ended |
Mar. 31, 2024 |
Fair Value Disclosures [Abstract] |
|
FAIR VALUE MEASUREMENTS |
NOTE 4 — FAIR VALUE MEASUREMENTS
The Company accounts for fair
value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the
guidance establishes a three-tier fair value hierarchy, which
prioritizes the inputs used in measuring fair value as follows:
|
● |
Level 1. Observable inputs
such as quoted prices in active markets for identical assets or liabilities; |
|
● |
Level 2. Inputs, other
than quoted prices in active markets, that are observable either directly or indirectly; and |
|
● |
Level 3. Unobservable inputs
in which there is little or no market data, which require the reporting entity to develop its own assumptions. |
There
were no Level 1, 2 or 3 assets, nor any Level 1 or 2 liabilities as of March 31, 2024.
Level 3 liabilities held as of
March 31, 2024, consisted of a contingent consideration liability related to the February 13, 2014, acquisition of Renovaro
Cube, (the “Acquisition”). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) 70,834,183
shares of Common Stock, and (ii) the right to receive contingent shares pro rata
upon the exercise of convertible notes, options, and warrants, which were outstanding at closing. The contingent consideration liability
was recorded at fair value of $20,557,500
at the time of acquisition and is subsequently remeasured to fair value at the end
of each reporting period. At March 31, 2024, there were 8,474,146
contingent shares issuable in connection with the Acquisition of Renovaro Cube.
The fair value of the
contingent consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model.
The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the
volatility of the Company’s underlying stock. The key inputs to valuing the contingent consideration liability as of March 31,
2024, were:
Schedule of fair value contingent consideration | |
| | |
Stock Price | |
$ | 2.65 | |
Exercise Price | |
| $0.46 - $4.50 | |
Volatility | |
| 109% - 140% | |
Risk Free Rate | |
| 4.11% - 5.26% | |
Expected Dividends | |
| 0 | % |
Discount Rate (Monte-Carlo model only) | |
| 12 | % |
Expected Term (years) | |
| 0.43 – 9.75 | |
At initial recognition of the contingent consideration,
the inputs were:
Stock Price | |
$ | 1.92 | |
Exercise Price | |
| $0.46 - $4.50 | |
Volatility | |
| 107% - 133% | |
Risk Free Rate | |
| 4.22% - 5.14% | |
Expected Dividends | |
| 0 | % |
Discount Rate (Monte-Carlo model only) | |
| 12 | % |
Expected Term (years) | |
| 0.56 – 9.88 | |
Unless otherwise disclosed,
the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable,
accrued expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.
The following table sets forth
the Level 3 liability at March 31, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required,
this liability is classified based on the lowest level of input that is significant to the fair value measurement:
Schedule of consolidated balance sheet at
fair value on a recurring basis | |
| | | |
| | | |
| | |
| |
Fair Value Measurements at Reporting Date Using |
| |
Quoted Prices in Active Markets for Identical Assets Inputs | |
Significant Other Observable Inputs | |
Significant Other Unobservable Inputs |
| |
(Level 1) | |
(Level 2) | |
(Level 3) |
| |
| |
| |
|
The roll forward of the contingent consideration liability is as follows: | |
| | | |
| | | |
| | |
Balance June 30, 2023 | |
| — | | |
| — | | |
$ | — | |
Contingent consideration in Acquisition | |
| — | | |
| — | | |
| 20,557,500 | |
Fair value adjustment | |
| — | | |
| — | | |
| (486,500 | ) |
Contingent Consideration Liability at March 31, 2024 | |
| — | | |
| — | | |
$ | 20,071,000 | |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent
+ Details
Name: |
us-gaap_FairValueMeasurementInputsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
PROPERTY AND EQUIPMENT
|
9 Months Ended |
Mar. 31, 2024 |
Property, Plant and Equipment [Abstract] |
|
PROPERTY AND EQUIPMENT |
NOTE 5 — PROPERTY AND EQUIPMENT
Property and equipment consisted of the following:
Schedule of property and equipment | |
| |
| |
|
| |
Useful Life | |
March 31, 2024 | |
June 30, 2023 |
Lab Equipment and Instruments | |
| 4-7 | | |
$ | 617,882 | | |
$ | 576,298 | |
Leasehold Improvements | |
| 10 | | |
| 224,629 | | |
| 224,629 | |
Furniture, Fixtures and Equipment | |
| 4-7 | | |
| 194,398 | | |
| 172,861 | |
Total | |
| | | |
| 1,036,909 | | |
| 973,788 | |
Less Accumulated Depreciation | |
| | | |
| (547,994 | ) | |
| (464,799 | ) |
Net Property and Equipment | |
| | | |
$ | 488,915 | | |
$ | 508,989 | |
Depreciation expense amounted to
$29,526 and $83,203 for the three and nine months ended March 31, 2024, respectively, and $26,662 and $80,915 for the three and nine months
ended March 31, 2023, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
INTANGIBLE ASSETS AND GOODWILL
|
9 Months Ended |
Mar. 31, 2024 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
INTANGIBLE ASSETS AND GOODWILL |
NOTE 6 — INTANGIBLE ASSETS AND GOODWILL
At March 31, 2024, and June 30,
2023, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes
of $31,042 and $39,676, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization
expense for the three and nine months ended March 31, 2024, was $779 and $7,524, respectively. Amortization expense for the three and
nine months ended March 31, 2023, was $1,580 and $4,572, respectively.
At March 31, 2024, and 2023, indefinite
life intangible assets consisted of In-Process Research and Development (“IPR&D”), which
is not amortizable until the intangible asset provides economic benefit.
At March 31, 2024, and June 30,
2023, definite and indefinite-life intangible assets consisted of the following:
Schedule of intangible assets | |
| |
| |
| |
| |
| |
| |
|
| |
Useful Life | |
June 30, 2023 | |
Additions | |
Amortization | |
Impairment | |
Translation Adjustment | |
March 31, 2024 |
Definite Life Intangible Assets | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Patents | |
20 Years | |
$ | 290,936 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | (3,856 | ) | |
$ | 287,080 | |
Less Accumulated Amortization | |
| |
| (251,260 | ) | |
| — | | |
| (7,524 | ) | |
| — | | |
| 2,746 | | |
| 256,038 | |
Net Definite-Life Intangible Assets | |
| |
$ | 39,676 | | |
$ | — | | |
$ | (7,524 | ) | |
$ | — | | |
$ | (1,110 | ) | |
$ | 31,042 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Indefinite Life Intangible Assets and Goodwill | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Goodwill | |
| |
| 11,640,000 | | |
| 151,536,444 | | |
| — | | |
| — | | |
| 1,010,408 | | |
| 164,186,852 | |
IPR&D | |
| |
$ | 42,611,000 | | |
| 10,684,091 | | |
| — | | |
| (42,611,000 | ) | |
| 71,164 | | |
| 10,755,255 | |
Total Indefinite Life Intangible Assets and Goodwill | |
| |
$ | 54,251,000 | | |
$ | 162,220,535 | | |
$ | — | | |
$ | (42,611,000 | ) | |
$ | 1,081,572 | | |
$ | 174,942,107 | |
Expected future amortization expense
is as follows:
Schedule of expected future amortization expense | |
|
Year ending June 30, | |
|
| 2024 | | |
$ | 1,942 | |
| 2025 | | |
| 9,700 | |
| 2026 | | |
| 9,700 | |
| 2027 | | |
| 9,700 | |
| Total | | |
$ | 31,042 | |
During February 2018, the Company
acquired IPR&D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale,
import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of
and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&D intangible
asset was classified as an indefinite life asset that was tested annually for impairment.
On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement. As part of the acquisition of Renovaro
Cube, the Company acquired IPR&D assets valued at $10,684,091.
Impairment – On
March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between
Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated
February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 in the period ended
March 31, 2024.
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
LEASES
|
9 Months Ended |
Mar. 31, 2024 |
Leases |
|
LEASES |
NOTE 7 — LEASES
Operating
Leases — On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.
On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. Renovaro subleased the space as
of June 25, 2022 through April 30, 2023. (See subsection below “Sublease Agreement” for details.)
Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase.
The Company identified and assessed
the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:
Expected lease term
— The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company’s leases have a remaining lease term of 41 and 23 months. As of
March 31, 2024, the weighted-average remaining term is 2.77 years.
Incremental borrowing rate
— The Company’s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of March 31, 2024, the weighted-average
discount rate is 5.16%.
Lease and non-lease components
— In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.
Below are the lease commitments
for the next 5 years:
| Schedule of
lease commitments | | |
| | |
Year Ending June 30th | |
Lease Expense |
| 2024 | | |
| 286,252 | |
| 2025 | | |
| 557,851 | |
| 2026 | | |
| 349,204 | |
| 2027 | | |
| 309,491 | |
| 2028 | | |
| 59,439 | |
| Sub-total | | |
| 1,562,237 | |
| Less imputed interest | | |
| (108,658 | ) |
| Total | | |
$ | 1,453,579 | |
Sublease Agreement
On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.
In accordance with ASC Topic 842,
the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease.
The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement
date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease,
as it did not meet the criteria of a sales-type or direct financing lease.
On
April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed
to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $139,460 along with the security
deposit of $35,540 for a total termination fee of $175,000, to permit early termination of the sublease.
The Company recognized operating
income from the sublease on a straight-line basis in its statements of operations over the sublease term.
During the three and nine months
ended March 31, 2024 and 2023, the net operating lease expenses were as follows:
Schedule of net operating
lease expenses | |
| | | |
| | | |
| | | |
| | |
| |
For the Three Months Ended | |
For the Nine Months Ended |
| |
March 31, | |
March 31, |
| |
2024 | |
2023 | |
2024 | |
2023 |
| |
| |
| |
| |
|
Operating Lease Expense | |
$ | 106,790 | | |
$ | 99,099 | | |
$ | 236,455 | | |
$ | 239,759 | |
Sub lease Income | |
| — | | |
| (53,310 | ) | |
| — | | |
| (159,930 | ) |
| |
| | | |
| | | |
| | | |
| | |
Total Net Lease Expense | |
$ | 106,790 | | |
$ | 45,789 | | |
$ | 236,455 | | |
$ | 79,829 | |
Lease expense charged to general
and administrative expenses for the three and nine months ended March 31, 2024, amounted to $106,790 and $236,455, respectively. Lease
expense charged to general and administrative expenses for the three and nine months ended March 31, 2023, amounted to $45,789 and
$79,829, respectively. During the three and nine months ended March 31, 2024, the Company paid $108,441 and $232,237 under operating
leases, respectively. During the three and nine months ended March 31, 2023, the Company paid $98,950 and $339,993 under operating
leases, respectively. The difference between the operating lease expense for the nine months ended March 31, 2023 in the amount of $79,829
and the cash paid of $339,993, is primarily made up of the release of an accrual of $77,242 related to the termination of the Plaza Medical
Office Building, LLC lease.
|
X |
- References
+ Details
Name: |
RENB_DisclosureLeasesAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for lessor's operating leases.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-30/tableOfContent
+ Details
Name: |
us-gaap_OperatingLeasesOfLessorDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
DEBT
|
9 Months Ended |
Mar. 31, 2024 |
Debt Disclosure [Abstract] |
|
DEBT |
NOTE 8 — DEBT
Convertible Notes Payable —
March 2024 Note —
On March 14, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount
of $500,000 (the “March 2024 Note”). The March 2024 Note bears an interest rate of 10% per annum and shall mature on March
15, 2025. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the issue date prior to the maturity of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest
may accrue on this Note on a quarterly basis. The March 2024 Note is convertible either at the option of the holder after a qualified
offering. If no qualified offering occurs prior to the maturity date, the March 2024 Note is to be repaid in cash.
The 2024 Notes —
On January 11, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the “January
2024 Note I”) in the amount of $460,000. The January 2024 Note I bears an interest rate of 12% per annum and shall mature on January
11, 2025. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the Issue Date prior to the maturity of the Notes. Notwithstanding the immediately foregoing, at the option of the Holder, interest may
accrue on this Note on a quarterly basis. The January 2024 Note I is convertible either at the option of the Holder or automatically upon
maturity into shares of the Company’s Common Stock at the conversion price of $3.38. On January 12, 2024, the Company entered into
Subscription Agreements with an investor (the “Investor”) to issue a Convertible Promissory Note for an aggregate principal
amount of $125,000 (the “January 2024 Note II”, and collectively with the January 2024 Note I, the “January 2024 Notes”).
The Company received a total of $125,000 in gross proceeds. The January 2024 Note II bears an interest rate of 12% per annum and
shall mature on December 29, 2024 (the “Maturity Date”). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2024 Notes. The January 2024
Note II is convertible either at the option of the Holder or automatically upon maturity into shares of the Company’s Common Stock
at the Note Conversion Price of $3.38. The January 2024 Notes principal balance at March 31, 2024, is $585,000.
December 2023 Notes — Between December
1, 2023, and December 29, 2023, the Company entered into Subscription Agreements with two investors to purchase Convertible Promissory
Notes for an aggregate principal amount of $560,000 (the “December Notes”). The Company received a total of $560,000 in gross
proceeds from the private placement prior to the end of the quarter ending December 31, 2023, and it subsequently received $20,000 in
January 2024. The December Notes bear an interest rate of 12% per annum and shall mature one year after their respective dates of
issuance (the “Maturity Date”). The Company is required to pay interest quarterly, in arrears, in cash, on the first day of
each quarter of each year following the Issue Date prior to the maturity of the December Notes. Notwithstanding the immediate foregoing,
at the option of the Holder, interest may accrue on the December Notes on a quarterly basis. The December Notes are convertible into shares
of the Company’s Common Stock in whole or in part at any time and from time to time, after the Original Issue Date and prior to
the Maturity Date, at a conversion price of $3.38 per share. The December Notes will be accounted for under ASC 470-20, and all proceeds
received from the issuance will be recognized as a liability on the balance sheet. The December Notes principal balance at March 31, 2024,
is $560,000.
As of March 31, 2024, the Company
accrued interest expense of $37,463 related to the 2024 Notes and December 2023 Notes. The 2024 Notes and December 2023 Notes balance
at March 31, 2024 was $1,645,000.
The 2023 Notes — Between
September 5, 2023, and October 5, 2023, the Company entered into Subscription Agreements with five investors to purchase 5% Original Issue
Discount Convertible Promissory Notes (the “2023 Notes”) for an aggregate principal amount of $2,105,263. The Company received
a total of $2,000,000 in gross proceeds from the private placement, after taking into account the 5% original issue discount. The
discount of $105,263 will be accreted over the life of the 2023 Notes. The 2023 Notes bear an interest rate of 12% per annum and shall
mature on September 5, 2024 (the “Maturity Date”). The Company is required to pay interest quarterly, in arrears, in cash,
on the first day of each quarter of each year following the Issue Date prior to the maturity of the 2023 Notes. Notwithstanding the immediately
foregoing, at the option of the Holder, interest may accrue on the Notes on a quarterly basis. The 2023 Notes are convertible into shares
of the Company’s Common Stock upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date.
The 2023 Notes are subject to mandatory
conversion (“Mandatory Conversion”) in the event the Company closes an offering of its Common Stock and receives gross proceeds
of not less than $10,000,000 (“Qualified Offering”). The conversion price per share of Common Stock in the case of a Mandatory
Conversion shall be 95% of the offering price per share in the Qualified Offering, subject to a floor of $4.50 per share. In addition,
if no Qualified Offering occurs prior to the Maturity Date, the 2023 Notes shall automatically convert into shares of Common Stock on
the Maturity Date at a conversion price per share equal to the closing sale price of the Common Stock on the Maturity Date, subject to
a floor of $4.50 per share.
On January 11, 2024, the Company
entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional
conversion at a conversion price of $3.38 per share. All other terms of the Promissory Note remained the same. The Company treated this
as a modification for accounting purposes.
For the three and nine months ended
March 31, 2024, discount amortization of $26,316 and $55,694 was charged to interest expense, respectively. As of March 31, 2024, the
Company accrued interest expense of $134,719. The 2023 Notes balance, net of discount at March 31, 2024 is $2,055,694.
The Convertible Notes —
On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to Paseco ApS (the “Holder”),
a Danish limited company and an existing stockholder of the Company, each with a face value amount of $600,000, convertible into shares
of Common Stock. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis of twelve 30-day months, and was
compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as
of such compound date. The interest was payable in cash on a semi-annual basis.
The
conversion price was equal to $12.00 per share of Common Stock. The Holder did not exercise its conversion feature that expired on
February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded
conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily
convertible into cash. All proceeds received from the issuance were recognized as a liability on the balance sheet.
Effective December 30, 2022
(the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured
Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February
28, 2024. The Amended and Restated Secured Notes are convertible by the Holder if the Company consummates a
public offering or private placement of Common Stock or securities convertible into Common Stock. The conversion price shall be the
price being paid by the investors in such offering. The interest rate was increased to twelve percent (12%)
per annum, which was prepaid by the Company in full on the date of amendment through the issuance of 198,439
shares of the Company’s Common Stock: 29,419
shares for accrued interest up to the Effective Date and 169,020
shares related to the prepayment of interest through the extension date of the Amended and Restated Secured Notes using the closing
market price on the Effective Date, of $1.03.
The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the
“Security Agreement”). The Company evaluated the Amended and Restated Secured Notes and conversion feature to determine
the appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480- Distinguishing Liabilities
from Equity, the Company determined that the Amended and Restated Secured Notes embody an obligation that may require the Company to
settle with the issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a
fixed monetary amount of $1,200,000
known at inception. Accordingly, the Company recorded the Amended and Restated Secured Notes as share settled debt. The total value
of the shares issued was $204,392
which included $174,090
of prepaid interest and $30,302
for accrued interest as of December 30, 2022. On June 26, 2023, the Holder notified the
Company that it wished to elect to exercise its conversion right triggered by a private placement. Therefore, all outstanding $1,200,000
Amended and Restated Secured Notes were converted into 2,264,150 shares of Common Stock and 1,132,075
warrants. There were no Amended and Restated Secured Notes outstanding after the foregoing conversion.
Notes Payable—
Bridge Loans — On
March 26, 2024, the Company issued Paseco ApS a Promissory Note in the principal amount of $160,000. The Note bears an interest rate of
10% per annum and was to mature on May 1, 2024. On May 1, 2024, the Company and Paseco ApS entered into an amendment to the Promissory
Note to extend the maturity date to July 1, 2024 (the “Maturity Date”). The Company is required to pay interest on the maturity
date. The Notes Payable will be accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized as a liability
on the balance sheet. As of March 31, 2024, the Company accrued $215 of interest expense that is included in accrued expenses on the balance
sheet. The Note balance at March 31, 2024 is $160,000.
On February 5, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by our Chairman, Rene Sindlev (“RS Bio”) to issue a
5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263. The Company received $100,000 in gross proceeds
after taking into account the 5% original issue discount. The Note bears an interest rate of 12% per annum and matured on March 1, 2024
(the “Maturity Date”). The obligations under this Note are secured by the Amended and Restated Security Agreement (discussed
below). The Company is required to pay interest on the maturity date. The Notes Payable will be accounted for under ASC 470-20, and all
proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. For the three and nine months
ended March 31, 2024, discount amortization of $5,263 was charged to interest expense, respectively. As of March 31, 2024, the Company
accrued $3,158 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March
31, 2024 was $105,263.
On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315
(the “January 2024 Note”). The Company received a total of $500,000 in gross proceeds after taking into account the 5% original
issue discount. The January 2024 Note bears an interest rate of 12% per annum and matured on March 1, 2024 (the “Maturity Date”).
The Company is required to pay interest on the maturity date. The Notes Payable will be accounted for under ASC 470-20, and all proceeds
received from the issuance will be recognized as a liability on the balance sheet net of discount. For the three and nine months ended
March 31, 2024, discount amortization of $26,315 was charged to interest expense, respectively. As of March 31, 2024, the Company accrued
$15,789 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March 31,
2024 was $526,315. In connection with the entry into the January 2024 Note, the Company and Paseco ApS agreed to amend and restate the
Security Agreement (see Note 8) to add the Company’s obligations under the November 2023 Note and the January 2024 Note to the Secured
Obligations (as defined in the Amended and Restated Security Agreement).
On November 22, 2023, Renovaro
Cube entered into a loan agreement where the holder agreed to loan the Company up to £500,000 (approximately $624,000 USD). The note
has a repayment date occurring the first business day after the first anniversary of the draw down of the loan. The first draw down of
£250,000 occurred on November 27, 2023, and the second draw down of £249,994 occurred on December 13, 2023. The Company will
pay interest on the loan at the rate of 10% per annum. Interest is accrued quarterly in arrears on the last business day of March, June,
September, and December and is payable on the repayment date. As of March 31, 2024, the Company accrued $10,545 of interest expense that
is included in accrued expenses on the balance sheet. The total amount of the note at March 31, 2024, is $639,544.
On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5%
Original Issue Discount Promissory Note for the principal amount of $1,000,000
(the “November 2023 Note”). The Company received a total of $950,000
in gross proceeds after taking into account the 5%
original issue discount. The discount of $50,000
will be accreted over the life of the Note. The November 2023 Note bears an interest rate of 12%
per annum and was due to mature on January
1, 2024 (the “Maturity Date”). On January 1, 2024, the Company entered into an amendment with RS Bio for the November
3, 2023, $1,000,000
Note Payable bridge loan to extend the maturity date until March
1, 2024. The Company is required to pay interest on the maturity date. The Notes Payable will be accounted for under ASC 470-20,
and all proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. On February 16, 2024,
the Company received notice from the holder to exercise 471,699
warrants outstanding at $0.53
per share and apply $250,000
of the note balance to the exercise price of the warrants. For the three and nine months ended March 31, 2024, discount amortization
of zero 0
and $50,000
was charged to interest expense, respectively. As of March 31, 2024, the Company accrued $46,583
of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March 31,
2024 is $750,000.
Promissory Note — On
March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $5,000,000 (the “Promissory
Note”) to the Holder. The principal amount of the Promissory Note was originally payable on November 30, 2021 (the “Maturity
Date”). The Promissory Note bore interest at a fixed rate of 6% per annum, computed based on the number of days between the Issuance
Date and the Maturity Date, and the interest was prepaid by the Company in full on the Issuance Date through the issuance of 188,485
shares of the Company’s Common Stock based on the closing market price on that date for a total value of $501,370. The Company
evaluated the Promissory Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20,
proceeds received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding
discount of $493,192, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective
interest method. The discount of $493,192 will be accreted over the life of the Promissory Note.
On February 11, 2021, the Company
entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory
Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6% per annum, which was
prepaid by the Company in full on the date of the amendment through the issuance of 74,054 shares of the Company’s Common Stock
based on the closing market price on that date for a total value of $298,178.
On May 17, 2022, the Company entered
into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 and increased the interest rate from
6% to 12% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year
of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022
until May 30, 2023 on the date of the amendment through the issuance of 47,115 shares of the Company’s Common Stock based on the
closing market price on that date for a total value of $299,178. All other accrued interest payable from May 30, 2023 to the Maturity
Date was required to be paid by the Company on May 30, 2023, at the option of the Holder in either (i) cash or (ii) shares of the Company’s
Common Stock, valued at the closing sale price of the Common Stock on the Nasdaq Capital Market on May 30, 2023. The Holder elected the
interest be paid in cash (the “Interest Payment”).
Effective December 30, 2022, the
Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under
the Promissory Note were secured by the Security Agreement. To secure the Company’s obligations under each of the Amended and Restated
Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted
a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined
in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession
of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.
On June 12, 2023, the Holder notified
the Company that it wanted to apply the Interest Payment due to it towards the Company’s next private placement. Therefore, on June
26, 2023, in conjunction with the Company’s private placement, the Company issued (i) 567,588 shares of its Common Stock, par value
$0.0001 per share and (ii) warrants to purchase 283,794 shares of Common Stock at a purchase price of $0.53 per share and applied the
Interest Payment of $300,822 it owed to the Holder.
On July 31, 2023, the Company
and the Holder agreed to amend the Promissory Note (the “Fourth Amendment”) to provide the Holder with limited conversion
rights in connection with the Company’s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to
convert $2 million of the outstanding principal balance of the Promissory Note into the Units being offered in a private placement at
the price per Unit being paid by the investors in the private placement (the “Conversion Right”). On August 1, 2023, the Holder
notified the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of
the Promissory Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible
Preferred Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of
$0.65 per share. The Series A Convertible Preferred Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common
Stock. A $3 million principal balance remains outstanding under the Promissory Note after the foregoing conversion. The Company concluded
that in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value
of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded
in Other Income/Loss in the Statement of Operations. On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note
(the “Fifth Amendment”) to where the Company and the Holder extended the maturity of the Original Note until February 29,
2024. In addition, all interest payable from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company
as of November 30, 2023. On February 16, 2024, the Company received notice from the holder to exercise 2,953,700 warrants outstanding
ranging from $0.53 to $0.65 per share and apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29,
2024, the Company and the Holder agreed to amend the Promissory Note (the “Sixth Amendment”) to where the Company and the
Holder extended the maturity of the Original Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend the Promissory
Note (the “Seventh Amendment”) to extend the maturity of the Original Note until May 1, 2024. For the three and nine months
ended March 31, 2024, discount amortization of $72,500 and $357,536 was charged to interest expense. For the three and nine months ended
March 31, 2023, discount amortization of $74,621 and $223,863 was charged to interest expense. The Promissory Note balance, net of discount
at March 31, 2024 is $1,237,500.
Finance Agreement —
On November 30, 2023, the
Company entered into a premium finance agreement (the “Agreement”) related to insurance, which
resulted in the recognition of a liability and prepaid expense with a principal amount of $906,834 at 7.90%
interest per annum, which is reflected on the consolidated balance sheet under “other current liabilities” and
“prepaid assets and other assets”, respectively. The repayment of the Agreement will be made in nine equal monthly
installments of $77,127 after
a down payment of $235,000. For
the three and nine months ended March 31, 2024 the Company made payments of $223,945 and
$646,128,
respectively. For the three and nine months ended March 31, 2023, under a similar arrangement, the Company made payments of
$374,367 and
$840,992,
respectively. For the three and nine months ended March 31, 2024, the Company recorded total interest expense in the amount of 7,436
and $12,692 related
to the Agreement. This amount is reflected in other income and expenses.
Total interest expense recorded
for the three and nine months ended March 31, 2024, was $303,802 and $758,057, respectively. Interest
expense recorded for the three and nine months ended March 31, 2023, was $122,289 and $310,766, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
STOCKHOLDERS’ EQUITY
|
9 Months Ended |
Mar. 31, 2024 |
Equity [Abstract] |
|
STOCKHOLDERS’ EQUITY |
NOTE 9 — STOCKHOLDERS’ EQUITY
Preferred Stock —
The Company has 10,000,000
authorized shares of Preferred Stock, par value $0.0001
per share, of which 1,000,000
shares have been designated as Series A Convertible Preferred Stock. At March 31, 2024, and June 30, 2023, there were zero
0 shares
of Series A Convertible Preferred Stock issued and outstanding.
Voting — Holders of
Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
Holder’s shares of Preferred Stock could then be converted in accordance with conversion rights.
Dividends — The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.
Liquidation Rights —
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all Shares held by such holder. The Series A Preferred Stock is not participating preferred.
Conversion Rights — On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a “Series A Election
Notice”) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
“Conversion Ratio”).
Common Stock —During the period ended March 31, 2024, the Company increased its authorized
shares of Common Stock. The
Company has 350,000,000 authorized shares of Common Stock, par value $0.0001 per share. At March 31, 2024, and June 30, 2023, there were
147,488,598 and 63,698,144 shares issued and outstanding, respectively.
Voting — Holders of
Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.
Dividends — Holders
of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available.
Liquidation Rights —
In the event of any liquidation, dissolution, or winding up of affairs of the Company, after payment of all debts and liabilities and
preferences to holders of preferred stock, the holders of Common Stock will be entitled to share ratably in the distribution of any of
the remaining assets.
Purchase Agreement with Lincoln Park Capital
On June
20, 2023, the Company entered into a purchase agreement (the “2023 Purchase Agreement”) with Lincoln Park Capital Fund, LLC
(“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $20,000,000 of shares of Common Stock over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.
In consideration for entering into
the 2023 Purchase Agreement, the Company issued 696,021 shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.
During the three and nine months
ended March 31, 2024, no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.
Preferred Stock Issuances
On August 1, 2023, the Company
closed a private placement of 280,505 units (the “Units”), each consisting of (i) one share of the Company’s
Series A Convertible Preferred Stock, (the “Preferred Stock”) and (ii) one Common Stock purchase warrant (each, a “Warrant”,
and together with the Units and the shares of Preferred Stock, the “Securities”) to purchase five shares of the Company’s
Common Stock, at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $2,000,000 in cash. In addition, the Company
issued 280,505 Units in connection with the conversion of $2,000,000 of the Promissory Note (see Note 8.)
The Company issued an aggregate
of 561,010 shares of Preferred Stock, which are initially convertible into an aggregate of 5,610,100 shares of Common Stock. In connection
with the Private Placement, the Company sold Warrants to purchase an aggregate of 2,805,050 shares of Common Stock. The Warrants are exercisable
for five years from the date of issuance and have an exercise price of $0.65 per share, payable in cash.
On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the 561,010
shares of Preferred Stock were converted into an aggregate of 5,610,100
shares of Common Stock. As of March 31, 2024 there were zero shares of 0 Preferred
Stock outstanding.
Common Stock Issuances
Between July 28, 2023 and September
28, 2023, the Company issued 2,000,000 shares of Common Stock for consulting services.
On October 23, 2023 the
Company issued 1,000,000
shares of Common Stock for advisory services to Avram Miller, a member of the Company’s board of directors.
On December 4, 2023 the Company
issued 525,945 shares of Common Stock pursuant to warrants exercised for cash proceeds of $341,865.
On
February 13, 2024 the Company issued 70,834,183 shares of Common Stock pursuant to the Stock Purchase Agreement of Renovaro Cube.
On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the 561,010 shares of Preferred Stock were converted into an aggregate of 5,610,100 shares of Common
Stock.
On
February 15, 2024 the Company closed a private placement of 344,827 shares of Common Stock, $0.0001 par value, at $2.90 per share for
aggregate proceeds to the Company of $1,000,000 in cash.
On February 15, 2024 the Company
issued 50,000 shares of Common Stock for consulting services.
On February 20, 2024, 2,953,700
warrants outstanding were exercised ranging from $0.53 to $0.65 per share and the aggregate $1,750,000 of a promissory note held by the
holder was applied to the exercise price of the warrants (see Note 8).
On February 20, 2024, 471,699
warrants outstanding were exercised ranging at $0.53 per share and $250,000 of a promissory note held by the holder was applied to the
exercise price of the warrants (see Note 8).
Acquisition of Renovaro
Denmark — At March 31, 2024, and June 30, 2023, the Company maintained a reserve of 17,414
shares of Common Stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”), all of which are
reflected as issued and outstanding in the accompanying consolidated financial statements. The Escrow Shares are reserved to acquire
the shares of Renovaro Denmark held by non-consenting shareholders of Renovaro Denmark on both March 31, 2024, and June 30, 2023, in
accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been 167,639
shares of Common Stock issued to non-consenting shareholders of Renovaro Denmark as of March 31, 2024. During the three and nine
months ended March 31, 2024, the Company issued zero 0
shares of Common Stock to such non-consenting shareholders of Renovaro Denmark. There is no impact on outstanding shares as these
shares are reflected as issued and outstanding.
Stock-based Compensation
The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated
on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of
the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended March 31, 2024:
Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted | |
| | |
| |
Renovaro Inc. |
Expected term (in years) | |
| 5.0 – 6.5 | |
Volatility | |
| 84.33% – 108.79 | % |
Risk free interest rate | |
| 3.12% – 4.83 | % |
Dividend yield | |
| 0 | % |
On
February 13, 2024, the Company repriced 3,849,931 eligible employee and consultant options from the original issued exercise price to
$1.92 per share, the closing price of the Company’s Common Stock on February 13, 2024. The Company recognized stock-based compensation
expense related to the repricing of options of $886,849
for the period ended March 31, 2024.
In total, the Company recognized
stock-based compensation expense related to options of $1,326,592 and $2,775,793 for the three and nine months ended March 31, 2024, respectively.
The Company recognized stock-based compensation expense related to options of $1,076,203 and
$2,922,166 for the three and nine months ended March 31, 2023, respectively. At March 31, 2024, the Company had approximately
$579,305 of unrecognized compensation cost related to non-vested options.
Plan Options
On February 6, 2014, the Board
adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 shares of
Common Stock for issuance in accordance with the terms of the 2014 Plan.
On October 30, 2019, the Board
approved and on October 31, 2019, the Company’s stockholders adopted its 2019 Equity Incentive Plan (the “2019 Plan”),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company’s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.
Effective July 21, 2023, the
Company adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan replaced the
2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject to and will be
available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire, terminate,
or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2023
Plan.
The Company granted options
to purchase zero
0 and 366,500
shares of Common Stock to employees with a three-year vesting period during the three and nine months ended March 31, 2024,
respectively under the 2019 and 2023 Plan. The Company granted options to purchase 15,000
and 193,000
shares of Common Stock to employees with a three-year vesting period during the three and nine months ended March 31, 2023,
respectively under the 2019 Plan.
During the three and nine
months ended March 31, 2024, respectively, the Company granted options to purchase zero
0 shares of Common Stock to employees with a six-month vesting period under the 2023 Plan. During the three and nine
months ended March 31, 2023, the Company granted options to purchase zero 0
and 184,800
issued and 0 18,960
forfeited shares of Common Stock to employees with a six-month vesting period, respectively under the 2019 Plan.
During the three and nine
months ended March 31, 2024, respectively, the Company granted options to purchase zero 0
shares of Common Stock to employees with a one-year vesting period under the 2023 Plan. During the three and nine months ended March
31, 2023, the Company granted options to purchase zero 0
and 73,200
issued and 0 12,640
forfeited shares of Common Stock to employees with a one-year vesting period, respectively under the 2019 Plan.
During the three and nine months
ended March 31, 2024, the Company granted options to purchase 28,196 and 371,595 shares of Common Stock, to the Board of Directors and
Scientific Advisory Board Members with a one-year vesting period under the 2023 Plan and the 2019 Plan, respectively. During
the three and nine months ended March 31, 2023, the Company granted options to purchase 64,655 and 275,572 shares
of Common Stock, to the Board of Directors and Scientific Advisory Board Members with a one-year vesting period under the 2019 Plan, respectively.
During the three and nine months
ended March 31, 2024, the Company granted options to purchase zero and 26,000 shares, respectively of Common Stock for Scientific Advisory
Board members with immediate vesting under the 2023 Plan. During the three and nine months ended
March 31, 2023, the Company did not grant options to Scientific Advisory Board members to purchase
shares of Common Stock with immediate vesting.
During
the three and nine months ended March 31, 2024, the Company granted options to purchase 10,000 shares of Common Stock to a consultant
with ten months vesting. During the three and nine months ended March 31, 2024, the Company forfeited zero and 7,000 options, respectively,
to purchase shares of Common Stock to a consultant with immediate vesting.
All of the above options
are exercisable at the market price of the Company’s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931 eligible employee
and consultant options from the original issued exercise price to $1.92 per share, the closing price of the Company’s Common Stock
on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $886,849 for the period ended March 31, 2024.
To date the Company has granted
options under the 2014, 2019 and 2023 Plans (“Plan Options”) to purchase 6,306,275 shares of Common Stock. At March 31, 2024,
the Company has 4,875,419 options available to be issued under the 2023 Plan.
A summary of the status of the
Plan Options outstanding at March 31, 2024, is presented below:
Schedule of stock options outstanding | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Options Outstanding | |
Options Exercisable |
| |
Exercise Price Ranges | |
Number Outstanding | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price | |
Number Exercisable | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price |
| | |
$ | 0.45–4.50 | | |
| 4,885,441 | | |
| 7.43 | | |
$ | 1.91 | | |
| 3,410,589 | | |
| 7.10 | | |
$ | 1.98 | |
| | |
$ | 4.51–6.50 | | |
| 167,634 | | |
| 6.73 | | |
$ | 5.33 | | |
| 135,376 | | |
| 6.06 | | |
$ | 5.49 | |
| | |
$ | 6.51–12.00 | | |
| 115,231 | | |
| 4.91 | | |
$ | 7.63 | | |
| 111,585 | | |
| 4.82 | | |
$ | 7.61 | |
Total | | |
| | | |
| 5,168,306 | | |
| 7.35 | | |
$ | 2.15 | | |
| 3,657,550 | | |
| 6.99 | | |
$ | 2.28 | |
A summary of the status of the
Plan Options at March 31, 2024, and changes since July 1, 2023, are presented below:
Schedule of stock option activity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
Weighted Average Exercise Price |
|
Average Remaining Life |
|
Weighted Average Intrinsic Value |
|
|
|
|
|
|
|
|
|
Outstanding at beginning of period |
|
|
|
4,401,211 |
|
|
$ |
4.78 |
|
|
|
7.82 |
|
|
$ |
— |
|
Granted |
|
|
|
4,624,026 |
|
|
$ |
1.97 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Expired/Canceled |
|
|
|
(3,856,931 |
) |
|
$ |
4.94 |
|
|
|
|
|
|
|
|
|
Outstanding at end of period |
|
|
|
5,168,306 |
|
|
$ |
2.15 |
|
|
|
7.35 |
|
|
$ |
— |
|
Exercisable at end of period |
|
|
|
3,657,550 |
|
|
$ |
2.28 |
|
|
|
6.99 |
|
|
$ |
3,839,725 |
|
At March 31, 2024, the Company had Plan Options to purchase 3,657,550 shares
of common stock that were exercisable. The total intrinsic value of options exercisable at March 31, 2024, was $3,839,725. Intrinsic value
is measured using the fair market value at the date of exercise (for shares exercised) and at March 31, 2024 (for outstanding options),
less the applicable exercise price.
Common Stock Purchase Warrants
A summary of the status of the
Common Stock Purchase Warrants outstanding at March 31, 2024, is presented below:
Schedule of common stock purchase warrants outstanding | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Warrants Outstanding | |
Warrants Exercisable |
| |
Exercise Price | |
Number Outstanding | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price | |
Number Exercisable | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price |
| | |
$ | 0.53 | | |
| 471,698 | | |
| 1.41 | | |
| | | |
| 471,698 | | |
| 1.41 | | |
| | |
| | |
$ | 0.65 | | |
| 741,274 | | |
| 3.25 | | |
| | | |
| 741,274 | | |
| 3.25 | | |
| | |
| | |
$ | 1.14 | | |
| 1,189,036 | | |
| 3.98 | | |
| | | |
| 1,189,036 | | |
| 3.98 | | |
| | |
Total | | |
| | | |
| 2,402,008 | | |
| 3.25 | | |
$ | 0.87 | | |
| 2,402,008 | | |
| 3.25 | | |
$ | 0.87 | |
A summary of the warrants outstanding at March 31, 2024, and changes since
July 1, 2023, are presented below:
Schedule of warrants outstanding | |
| | | |
| | | |
| | |
| |
Shares | |
Weighted Average Exercise Price | |
Weighted Average Remaining Life |
| |
| |
| |
|
Outstanding at beginning of period | |
| 3,548,302 | | |
$ | 0.73 | | |
| 4.80 | |
Granted | |
| 2,805,050 | | |
$ | 0.65 | | |
| 3.25 | |
Exercised | |
| (3,951,344 | ) | |
$ | 0.59 | | |
| — | |
Cancelled/Expired | |
| — | | |
$ | — | | |
| — | |
Outstanding and exercisable at end of period | |
| 2,402,008 | | |
$ | 0.87 | | |
| 3.25 | |
At March 31, 2024, the Company had 2,402,008 exercisable Common Stock Purchase
Warrants outstanding. The total intrinsic value of warrants exercisable at March 31, 2024, was $4,277,992. Intrinsic value is measured
using the fair market value at the date of exercise (for shares exercised) and at March 31, 2024 (for outstanding warrants), less the
applicable exercise price.
Restricted Stock Awards (RSA)
The Company recognized stock-based compensation expense related to RSAs of
$535,009 and $1,068,865 for the three and nine months ended March 31, 2024, respectively. The restricted stock awards are related to a
grant of 1,000,000 shares of restricted stock with a 3-year vesting period made to a director as consideration for advisory
services, with a total value of $2,760,000. At March 31, 2024, the Company had $1,691,135 of unrecognized stock-based compensation expense
remaining to be amortized.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
COMMITMENTS AND CONTINGENCIES
|
9 Months Ended |
Mar. 31, 2024 |
Commitments and Contingencies Disclosure [Abstract] |
|
COMMITMENTS AND CONTINGENCIES |
NOTE 10 — COMMITMENTS AND CONTINGENCIES
Commitments
On July 9, 2018, the Company entered
into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company
with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration of HIV in humans,
and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including
but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20
months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of the 20 months, the monthly consulting
fee of $25,000 continued for scientific consulting and knowledge transfer on existing HIV experiments until the services were no longer
being rendered or the G-Tech Agreement is terminated. As of May 25, 2022, the consultant was no longer able to render services; therefore,
no expense was incurred for the three and nine months ended March 31, 2024 and 2023.
On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech, and
G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute
(“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license
(the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV)
infections.
The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24 month period, and provides for an up-front payment of $1.2 million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a 2% royalty to G-Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $1.2 million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.
The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement in the three and nine months ended March 31, 2024, and 2023.
The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies
sub-section below).
On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the “License Development Agreement”), by and among the Company, G-Tech
and SRI (collectively, the “Licensors”), whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development
License”) to research, develop, and commercialize certain formulations which were aimed at preventing and treating pan-coronavirus
or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza
(the “Prevention and Treatment”).
The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides
for an up-front payment of $10,000,000 and a $760,000 payment for expenditures to date prior to the effective date related to research
towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional payments
upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement, in each
case subject to the terms of the Development License Agreement.
The Development License Agreement
provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates
that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license
(see Contingencies sub-section below).
On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”) with Serhat
Gümrükcü and SRI (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $600,000 and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $600,000.
G-Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.
Shares held for
non-consenting shareholders – The 17,414
remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have
been reflected as issued and outstanding in the accompanying financial statements. There were zero shares of Common Stock issued
to such non-consenting stockholders during the three and nine months ended March 31, 2024 (see Note 9.)
Service Agreements –The
Company maintains employment agreements with certain senior staff in the ordinary course of business.
Contingencies
Securities Class Action Litigation.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the “Chow Action” and the latter, the
“Manici Action”) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company’s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company’s relationship
with Serhat Gümrükcü and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice, but the Chow action remains pending. On October
22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead plaintiff filed an amended complaint on December 15, 2023.
The Company has filed a motion to dismiss the amended complaint, but expresses no opinion as to the likelihood of a favorable outcome.
Federal Derivative Litigation.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District
Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action
Litigation. The actions, filed on behalf of the Company, name Serhat Gümrükcü and certain of the Company’s current
and former directors as defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections
14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification,
aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution,
and other costs and expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the
Koenig matter pending resolution of the defendants’ anticipated motion to dismiss in the Securities Class Action Litigation. On
April 6, 2023, the United States District Court for the District of Delaware stayed the Solak matter pending resolution of the defendants’
anticipated motion to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to either complaint. The
Company intends to contest these matters but expresses no opinion as to the likelihood of favorable outcomes.
State Derivative Litigation.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting
similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names
Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The action also names the
Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution and indemnification, aiding and
abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other
costs and expenses. On January 20, 2023, the Court stayed the Midler matter pending resolution of the defendants’ anticipated motion
to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to the complaint. The Company intends to contest
this matter but expresses no opinion as to the likelihood of a favorable outcome.
On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
Gümrükcü, William Anderson Wittekind (“Wittekind”), G Tech Bio LLC (“G Tech”), SG & AW Holdings,
LLC, and Seraph Research Institute (“SRI”) (collectively, the “Defendants”). The Complaint alleges that the Defendants
engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the Defendants’ conduct, the
Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.”
On April 21, 2023, defendants Wittekind, G Tech, SG & AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company’s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.
On December
4, 2023, the Defendants answered the Company’s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, inter
alia, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work & License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently scheduled
to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while pursuing
its claims against the Defendants.
On March 1, 2021, the Company’s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the Court partially granted the Company’s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29,
2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24,
2023, the Court denied the motion for summary judgment. Trial is currently scheduled to begin on July 15, 2024. The Company denies the
allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.
On June
7, 2023, Weird Science LLC (“Weird Science”), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the “Trusts”)
(collectively, “Plaintiffs”) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the “Investor Rights Agreement”). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all “Holders” of “Registrable Securities” at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.
On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (“FAC”). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys’ fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Company denies Plaintiffs’ allegations and intends to vigorously defend against the claims.
On August 24, 2023, counsel on behalf of Weird Science,
Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company’s books and records (the
“Demand”) pursuant to Delaware General Corporation Law, § 220 (“Section 220”). The Demand seeks the
Company’s books and records in connection with various issues identified in the Demand. The Company takes its obligations under
Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those obligations.
On January
23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District
of California against certain officers, directors, and investors of the Company, as well as other defendants. The Verified Stockholder
Derivative Complaint (“Derivative Complaint”) alleges, among other claims, violations of Section 13(d) and 14(a) and Rules
10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary duty, corporate
waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory, exemplary and punitive
damages and certain injunctive relief. Simultaneously with the Derivative Complaint, Weird Science and Wittekind filed an emergency Ex
Parte Application for Temporary Restraining Order (“Application”) asking the Court to enjoin a special meeting of the
Company’s stockholders noticed for January 25, 2024. As the basis for the Application, Weird Science and Wittekind recited many
of the same allegations as in the Derivative Complaint. The Court denied the Application on January 24, 2024. The defendants have not
yet responded to the Derivative Complaint. The Company denies the allegations in the Derivative Complaint and intends to vigorously defend
against the claims asserted therein.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
RELATED PARTY TRANSACTIONS
|
9 Months Ended |
Mar. 31, 2024 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
NOTE 11 — RELATED PARTY TRANSACTIONS
As of March 31, 2024, the
Company has accrued $111,750
of compensation related expenses for the Company’s Chief Executive Officer, Mark Dybul, related to budget constraints.
On March 26, 2024, the Company
issued a Promissory Note to Paseco ApS, a Danish entity and greater than 5% shareholder, in the principal amount of $160,000. The Note
bears an interest rate of 10% per annum and was to mature on May 1, 2024. On May 1, 2024, the Company and Paseco ApS entered into an amendment
to the Promissory Note to extend that maturity to July 1, 2024 (the “Maturity Date”). The Company is required to pay interest
on the maturity date. As of March 31, 2024, the Company accrued $215 of interest expense that is included in accrued expenses on the balance
sheet. The Note balance at March 31, 2024 is $160,000 (see Note 8.)
On February 16, 2024, the Company received an exercise
notice from RS Bio to exercise 471,699 warrants outstanding at an exercise price of $0.53 per share. The holder applied $250,000 of one
of its outstanding note payable balance to the exercise price (see Note 8.)
On February 16, 2024, the Company
received an exercise notice from Paseco ApS to exercise 2,953,700
warrants outstanding with exercise prices ranging from $0.53
to $0.65
per share. The proceeds of $1,750,000
were immediately applied to the outstanding note payable balance (see Note 8.)
On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263.
The Company received $100,000 in gross proceeds after taking into account the 5% original issue discount. The Note bears an interest rate
of 12% per annum and matured on March 1, 2024 (the “Maturity Date”). The obligations under this Note are secured by the Amended
and Restated Security Agreement (discussed below). The Company is required to pay interest on the maturity date. For the three and nine
months ended March 31, 2024, discount amortization of $5,263 was charged to interest expense. As of March 31, 2024, the Company accrued
$3,158 of interest expense that is included in accrued expenses on the balance sheet. The Note balance, net of discount at March 31, 2024
is $105,263 (see Note 8.)
On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315
(the “January 2024 Note”). The Company received a total of $500,000 in gross proceeds after taking into account the 5% original
issue discount. The January 2024 Note bears an interest rate of 12% per annum and shall mature on March 1, 2024 (the “Maturity
Date”). The Company is required to pay interest on the maturity date. For the three and nine months ended March 31, 2024, discount
amortization of $26,315 was charged to interest expense. As of March 31, 2024, the Company accrued $15,789 of interest expense
that is included in accrued expenses on the balance sheet. The January 2024 Note balance, net of discount at March 31, 2024 is $526,315
(see Note 8.) In connection with the entry into the January 2024 Note, the Company and Paseco ApS agreed to amend and restate the Security
Agreement (see Note 8) to add the Company’s obligations under the November 2023 Note and the January 2024 Note to the Secured Obligations
(as defined in the Amended and Restated Security Agreement).
On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000 (the
“November 2023 Note”). The Company received a total of $950,000 in gross proceeds after taking into account the 5% original
issue discount. The discount of $50,000 will be accreted over the life of the Note. The Note bears an interest rate of 12% per annum
and shall mature on January 1, 2024 (the “Maturity Date”). The Company is required to pay interest on the maturity date (see
Note 8.)
On
October 10, 2023, the Board of Directors of the Company (the “Board”) appointed Avram Miller to the Board, effective October
11, 2023, to fill a vacancy. Mr. Miller will serve until the Company’s 2024 Annual Meeting of Stockholders subject to this re-election
or until his successor has been duly elected and qualified. In addition to Mr. Miller’s appointment to the Board, Mr. Miller, the
co-founder of Intel Capital, entered into an advisory agreement with the Company (the “Advisory Agreement”), pursuant
to which Mr. Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation,
business development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will
issue Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will
vest in 2026, subject to Mr. Miller’s continued service through each applicable vesting date.
On August 1, 2023, RS Bio, purchased
in a Private Placement 70,126 of the Company’s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of
$500,000. Mr. Rene Sindlev, the Chairman of the Company’s Board of Directors, holds the sole
voting and disposition power of the shares owned by RS Bio. The Board of Directors (excluding Mr. Sindlev) approved the participation
of certain officers and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement
(see Note 8.)
On August 1, 2023, Paseco ApS,
in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company’s Units at a price
per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company’s Units at a price per
Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS
was deemed to be an affiliate of the Company (see Note 8.)
The Company currently has a consulting
agreement with Paseco ApS for business advisory services since December of 2019. For the three and nine months ended March 31, 2024 the
Company issued zero and 1,000,000 restricted common shares as payment for services rendered thereunder.
The Company currently has a consulting agreement with
Paseco for business advisory services that commenced in December of 2019. For the three and nine months ended March 31, 2024 the Company
issued zero and 1,000,000 restricted common shares, respectively, for services provided.
The information
set forth above in Note 8—Debt—Notes Payable—Promissory Note relating to the Promissory Note issued to Paseco ApS is
incorporated herein by reference.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
ACQUISITION
|
9 Months Ended |
Mar. 31, 2024 |
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] |
|
ACQUISITION |
NOTE
12 — ACQUISITION
On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GEDi Cube Intl Ltd.,
a private company formed under the laws of England and Wales (“GEDi Cube”) to acquire 100% of the equity interests
of GEDi Cube from its equity holders (the “Sellers”). On September 28, 2023, the Board of Directors of the Company,
and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and on January 25, 2024, the shareholders of the Company
approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement. The acquisition adds complementary product candidates and technologies
from GEDi Cube and may accelerate the Company's product development and therapeutic approaches for cancer and other diseases.
On February
13, 2024 (the “Closing Date”), the Company consummated the previously announced acquisition of GEDi Cube and the other transactions
contemplated by the Stock Purchase Agreement (collectively, the “Transaction”). As a result of the Transaction, GEDi Cube
became a wholly-owned subsidiary of the Company.
Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a “GEDi Cube Share” and, collectively, the “GEDi Cube Shares”)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller’s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”), which represents the
67,224,089 shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously
issued to a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director
of the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the “Closing
Consideration”) plus 5,610,100 shares of Common Stock representing the Seller’s Earnout Shares (defined below) resulting
from the automatic conversion of the Company’s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller’s
pro rata percentage of the shares of Common Stock (the “Earnout Shares” and, together with the Closing Consideration, the
“Exchange Consideration”) to be issued to the Sellers upon the exercise or conversion of any of the Company’s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the “Closing Derivative Securities”).
Each Seller’s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.
The
transaction was accounted for in accordance with the provisions of ASC 805-10 - Business Combinations. As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.
The
assets acquired and liabilities assumed are recognized provisionally in the accompanying condensed consolidated balance sheets at
their estimated fair values as of the acquisition date. The initial accounting for the business combination is not complete as the
Company is in the process of obtaining additional information for the valuation of acquired intangible assets and deferred tax
liabilities. The provisional amounts are subject to change to the extent that additional information is obtained about the facts and
circumstances that existed as of the acquisition date. Under U.S. GAAP, the measurement period shall not exceed one year from the
acquisition date and the Company will finalize these amounts no later than February 13, 2025. The estimated fair values as of the
acquisition date are based on information that existed as of the acquisition date. During the measurement period the Company may
adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that the Company has
subsequently obtained regarding facts and circumstances that existed as of the acquisition date.
The
acquisition-date fair value of the consideration transferred totaled approximately $156 156,559,131
million, which consisted of the following:
Schedule
of acquisition date fair value | |
| | |
Common stock | |
$ | 136,001,631 | |
Contingent consideration | |
| 20,557,500 | |
Total consideration transferred | |
$ | 156,559,131 | |
The
fair value of the Company’s common shares issued as consideration was based on the closing price of the Company’s common
stock as of the Acquisition Date. The fair value determination of the contingent consideration is further detailed in Note 4 to
these condensed consolidated financial statements.
The following
table details the provisional fair values of the assets acquired and liabilities assumed at the acquisition date:
Schedule of fair values of the assets acquired and liabilities assumed | |
| | |
Cash | |
$ | 65,851 | |
Prepaid & Other Assets | |
| 151,544 | |
Fixed Assets | |
| 16,243 | |
Operating lease ROU | |
| 624,366 | |
In-process research and development | |
| 10,684,091 | |
Total Assets Acquired: | |
| 11,542,095 | |
| |
| | |
Accounts Payable | |
| 583,577 | |
Accrued Expenses | |
| 722,509 | |
Operating Lease liability | |
| 624,367 | |
Notes Payable | |
| 1,832,460 | |
Deferred tax liabilities | |
| 2,756,495 | |
Total Liabilities Assumed | |
| 6,519,408 | |
Net Assets Acquired | |
| 5,022,687 | |
| |
| | |
Goodwill | |
| 151,536,444 | |
Total Consideration | |
$ | 156,559,131 | |
The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.
The
fair values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach
valuation methodology used for the intangible assets acquired makes use of Level 3 inputs.
The in-process
research and development acquired represents know-how and intellectual property being developed by GEDi Cube pertaining to its diagnostic
platform currently being developed. The fair value of this asset was determined based on a cash flow model with forecasted revenues and
expenses specifically tied to the diagnostic platform. Those cash flows were then discounted at 19.2% over the life of the projections.
The discount rate was determined by the use of a weighted average return on assets analysis.
The
Company recognized approximately $1.2
million of acquisition related costs that were expensed during the period ended March 31, 2024. These costs are included in
“selling, general and administrative expenses” in the accompanying condensed consolidated statements of operations.
The amounts
of revenue and loss of GEDi Cube, included in the Company’s consolidated statements of operations from the Closing Date through
March 31, 2024 are as follows:
Schedule of consolidated
statements of operations |
|
|
|
|
Revenues |
|
$ |
— |
|
Net loss |
|
$ |
(398,597 |
) |
Consolidated unaudited pro forma information:
The following consolidated pro forma information assumes
that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the nine-month period ended March
31, 2024. These amounts have been estimated after applying the Company’s accounting policies:
Schedule of consolidated
proforma information | |
| | |
Revenues | |
$ | — | |
Net loss | |
$ | (33,622,997 | ) |
|
X |
- References
+ Details
Name: |
us-gaap_BusinessCombinationAndAssetAcquisitionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent
+ Details
Name: |
us-gaap_BusinessCombinationDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
SUBSEQUENT EVENTS
|
9 Months Ended |
Mar. 31, 2024 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
NOTE 13 — SUBSEQUENT EVENTS
On April 5, 2024, the Company issued 33,760 shares of common
stock for consulting services valued at $94,190.
On April 9, 2024, the Company
issued a Promissory Note to Paseco ApS in the principal amount of $150,000. The Note bears an interest rate of 10% per annum and shall
mature on June 1, 2024 (the “Maturity Date”). The Company is required to pay interest on the Maturity Date.
From April 15, 2024, to May 7,
2024, the Company issued Promissory Notes to Paseco ApS in the aggregate principal amount of $855,149. The Company received $855,149 in
proceeds. The Notes bear an interest rate of 10% per annum and shall mature on July 1, 2024 (the “Maturity Date”). The Company
is required to pay interest on the Maturity Date.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
|
9 Months Ended |
Mar. 31, 2024 |
Accounting Policies [Abstract] |
|
Business |
Business
– On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(“Renovaro”, and together with its subsidiaries, the “Company”, “we” or “us”). In
August 2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company engages
in the research and development of pharmaceutical and biological products for the treatment of cancer, HIV, and HBV with the intent
to manufacture said products. On February 13, 2024, Renovaro Inc. acquired Renovaro Cube Intl Ltd and its subsidiaries (“Renovaro Cube”), as a wholly
owned subsidiary pursuant to a stock purchase agreement.
|
Basis of Presentation |
Basis of Presentation
– The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange
Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash
flows at March 31, 2024, and 2023 and for the periods then ended have been made. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying
unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto
included in the Company’s June 30, 2023, audited financial statements. The results of operations for the period ended March
31, 2024 are not necessarily indicative of the operating results for the full year.
|
Consolidation |
Consolidation – For
the three and nine months ended March 31, 2024, and 2023, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.
|
Accounting Estimates |
Accounting Estimates –
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses
during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value of assets
acquired in a business acquisition, contingent consideration, and equity instruments issued for goods or services.
|
Functional Currency & Foreign Currency Translation |
Functional
Currency & Foreign Currency Translation – The functional currency of Renovaro Denmark is the Danish Kroner
(“DKK”) and the functional currency of Renovaro Cube is the Euro (“EUR”). The Company’s reporting
currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated
into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average
exchange rates prevailing during the periods ended March 31, 2024, and 2023. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the
statement of operations as incurred.
|
Cash and Cash Equivalents |
Cash and Cash Equivalents –
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.
|
Concentration of Credit Risk |
Concentration of Credit Risk
– Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits
are held. As of March 31, 2024 and June 30, 2023, the Company has not experienced losses on these accounts and management believes the
Company is not exposed to significant risks on such accounts.
|
Property and Equipment |
Property and Equipment –
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5.)
|
Intangible Assets |
Intangible Assets – The
Company has both definite and indefinite life intangible assets.
Definite life intangible assets
include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Definite life intangible
assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent
will not be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized
on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.
Indefinite life intangible assets
include in-process research and development (“IPR&D”) and goodwill. The Company accounts for indefinite life intangible
assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. IPR&D represents the fair value of the technology
on the date acquired and is tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying
value may not be recoverable.
|
Goodwill |
Goodwill – Goodwill
is not amortized but is evaluated for impairment annually as of June 30th of each fiscal year or whenever events or changes
in circumstances indicate the carrying value may not be recoverable.
|
Impairment of Goodwill and Indefinite Life Intangible Assets |
Impairment of Goodwill and Indefinite
Life Intangible Assets – We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. The Company has elected to perform its annual analysis on June 30th.
The annual fair value analysis performed on goodwill supported that goodwill was not impaired as of June 30, 2023. There have been no
events which have caused the Company to conduct an interim evaluation of its goodwill through March 31, 2024 (see Note 6.)
For indefinite life intangible assets, such as IPR&D, on an annual basis
on June 30th we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the
asset over its fair value. For the year ended June 30, 2023, the carrying value of the IPR&D exceeded its fair value. Therefore, the
Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023. During the quarter ended March 31, 2024, the Company
recorded an impairment loss of $42,611,000 related to the termination of the license agreement with Weird Science LLC (see Note 6.).
|
Impairment of Long-Lived Assets |
Impairment of Long-Lived Assets
– Long-lived assets, such as property and equipment, definite and indefinite life intangible assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which
could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes
in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast
of continuing losses associated with the use of the asset; and current expectations that the asset will more likely than not be sold or
disposed of significantly before the end of its estimated useful life.
Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be
generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
|
Leases |
Leases – In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.
Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations.
For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on
a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited
condensed consolidated statements of operations.
The Company has elected the practical
expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance,
insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred
(see Note 7.)
|
Research and Development Expenses |
Research and Development Expenses
– The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Oncology, HIV and HBV therapies and technologies for use in the prevention,
treatment, amelioration of and/or therapy for Oncology, HIV and HBV. Research and development expenses for the three and nine months ended
March 31, 2024, amounted to $1,087,156, and $2,274,321, respectively. Research and development expenses for the three and nine months
ended March 31, 2023, amounted to $239,137, and $3,170,471, respectively.
|
Income Taxes |
Income Taxes – The
Company accounts for income taxes in accordance with FASB ASC Topic 740, “Accounting for Income Taxes”, which requires an
asset and liability approach for accounting for income taxes.
|
Loss Per Share |
Loss Per Share – The
Company calculates earnings/ (loss) per share in accordance with FASB ASC Topic 260, “Earnings Per Share”. Basic earnings
per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings
per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential
shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted
but have not been exercised and shares issuable upon conversion of convertible preferred stock and convertible notes. Because of the net
loss for the three and nine months ended March 31, 2024, and 2023, the dilutive shares for all periods were excluded from the Diluted
EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 9,522,967 and 5,410,460 potential
shares of Common Stock excluded from the Diluted EPS calculation as of March 31, 2024, and March 31, 2023, respectively.
|
Fair Value of Financial Instruments |
Fair Value of Financial Instruments
– The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, “Fair Value Measurements”. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of March 31, 2024 and
2023, respectively. Level 3 liabilities held as of March 31, 2024, consisted of a contingent consideration
liability related to the February 13, 2024, acquisition of Renovaro Cube (see Note 4.)
|
Stock Options and Restricted Share Units |
Stock Options and Restricted
Share Units – The Company has granted stock options, restricted share units (“RSUs”) and warrants. The Company accounts
for stock-based awards in accordance with the provisions of FASB ASC Topic 718, “Compensation - Stock Compensation”.
|
Stock-Based Compensation |
Stock-Based Compensation
– The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation - Stock Compensation”.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for
based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably
measurable. Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized
based on the fair value of the equity instruments issued and are recognized over the required service period, which is generally
the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the three and nine months ended March
31, 2024 were $1,861,601 and $3,844,658, respectively. Stock based compensation costs for the vesting of options and RSUs granted for
the three and nine months ended March 31, 2023 were $1,076,203 and $2,922,166, respectively (See Note 9.)
|
Recently Adopted Accounting Pronouncements |
Recently Adopted Accounting
Pronouncements – Recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material
impact on the Company’s present or future financial statements.
|
X |
- References
+ Details
Name: |
RENB_BusinessPolicyTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_StockOptionsAndRestrictedShareUnitsPolicyTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_CompensationRelatedCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for credit risk.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
+ Details
Name: |
us-gaap_ConcentrationRiskCreditRisk |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1
+ Details
Name: |
us-gaap_ConsolidationPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1
+ Details
Name: |
us-gaap_FairValueOfFinancialInstrumentsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4
+ Details
Name: |
us-gaap_IntangibleAssetsFiniteLivedPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1
+ Details
Name: |
us-gaap_LesseeLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Restatement Of Previously Issued Financial Statements |
|
Schedule of restatement of previously issued financial statements |
Schedule
of restatement of previously issued financial statements | |
| |
| |
|
| |
As Reported | |
Change | |
As Rested |
Indefinite
life intangible assets | |
$ | 44,945,255 | | |
$ | (34,190,000 | ) | |
$ | 10,755,255 | |
| |
| | | |
| | | |
| | |
Total
other assets | |
$ | 210,570,510 | | |
$ | (34,190,000 | ) | |
$ | 176,380,510 | |
Total
assets | |
$ | 212,279,340 | | |
$ | (34,190,000 | ) | |
$ | 178,089,340 | |
Accumulated
deficit | |
$ | (274,757,816 | ) | |
$ | (34,190,000 | ) | |
$ | (308,947,816 | ) |
Total
stockholders’ equity | |
$ | 168,595,556 | | |
$ | (34,190,000 | ) | |
$ | 134,405,556 | |
Total
liabilities and stockholders’ equity | |
$ | 212,279,340 | | |
$ | (34,190,000 | ) | |
$ | 178,089,340 | |
Intangible
asset impairment | |
$ | 8,421,000 | | |
$ | 34,190,000 | | |
$ | 42,611,000 | |
Total
operating expenses for the three months ended March 31, 2024 | |
$ | 17,190,840 | | |
$ | 34,190,000 | | |
$ | 51,380,840 | |
Total
operating expenses for the nine months ended March 31, 2024 | |
$ | 30,345,029 | | |
$ | 34,190,000 | | |
$ | 64,535,029 | |
Loss
from operations three months ended March 31, 2024 | |
$ | (17,190,840 | ) | |
$ | (34,190,000 | ) | |
$ | (51,380,840 | ) |
Loss
from operations nine months ended March 31, 2024 | |
$ | (30,345,029 | ) | |
$ | (34,190,000 | ) | |
$ | (64,535,029 | ) |
Net
loss for the three months ended March 31, 2024 | |
$ | (17,024,414 | ) | |
$ | (34,190,000 | ) | |
$ | (51,214,414 | ) |
Net
loss for the nine months ended March 31, 2024 | |
$ | (30,728,563 | ) | |
$ | (34,190,000 | ) | |
$ | (64,918,563 | ) |
Comprehensive
loss for the three months ended March 31, 2024 | |
$ | (15,963,213 | ) | |
$ | (34,190,000 | ) | |
$ | (50,153,213 | ) |
Comprehensive
loss for the nine months ended March 31, 2024 | |
$ | (29,664,711 | ) | |
$ | (34,190,000 | ) | |
$ | (63,854,711 | ) |
Basic
and diluted net loss per share for the three months ended March 31, 2024 | |
$ | (0.16 | ) | |
$ | (0.32 | ) | |
$ | (0.48 | ) |
Basic
and diluted net loss per share for the nine months ended March 31, 2024 | |
$ | (0.39 | ) | |
$ | (0.43 | ) | |
$ | (0.82 | ) |
|
X |
- References
+ Details
Name: |
RENB_DisclosureRestatementOfPreviouslyIssuedFinancialStatementsAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3
+ Details
Name: |
srt_ScheduleOfCondensedFinancialStatementsTableTextBlock |
Namespace Prefix: |
srt_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
FAIR VALUE MEASUREMENTS (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Fair Value Disclosures [Abstract] |
|
Schedule of fair value contingent consideration |
Schedule of fair value contingent consideration | |
| | |
Stock Price | |
$ | 2.65 | |
Exercise Price | |
| $0.46 - $4.50 | |
Volatility | |
| 109% - 140% | |
Risk Free Rate | |
| 4.11% - 5.26% | |
Expected Dividends | |
| 0 | % |
Discount Rate (Monte-Carlo model only) | |
| 12 | % |
Expected Term (years) | |
| 0.43 – 9.75 | |
At initial recognition of the contingent consideration,
the inputs were:
Stock Price | |
$ | 1.92 | |
Exercise Price | |
| $0.46 - $4.50 | |
Volatility | |
| 107% - 133% | |
Risk Free Rate | |
| 4.22% - 5.14% | |
Expected Dividends | |
| 0 | % |
Discount Rate (Monte-Carlo model only) | |
| 12 | % |
Expected Term (years) | |
| 0.56 – 9.88 | |
|
Schedule of consolidated balance sheet at fair value on a recurring basis |
Schedule of consolidated balance sheet at
fair value on a recurring basis | |
| | | |
| | | |
| | |
| |
Fair Value Measurements at Reporting Date Using |
| |
Quoted Prices in Active Markets for Identical Assets Inputs | |
Significant Other Observable Inputs | |
Significant Other Unobservable Inputs |
| |
(Level 1) | |
(Level 2) | |
(Level 3) |
| |
| |
| |
|
The roll forward of the contingent consideration liability is as follows: | |
| | | |
| | | |
| | |
Balance June 30, 2023 | |
| — | | |
| — | | |
$ | — | |
Contingent consideration in Acquisition | |
| — | | |
| — | | |
| 20,557,500 | |
Fair value adjustment | |
| — | | |
| — | | |
| (486,500 | ) |
Contingent Consideration Liability at March 31, 2024 | |
| — | | |
| — | | |
$ | 20,071,000 | |
|
X |
- DefinitionTabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-22
+ Details
Name: |
us-gaap_FairValueConcentrationOfRiskTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
PROPERTY AND EQUIPMENT (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Property, Plant and Equipment [Abstract] |
|
Schedule of property and equipment |
Schedule of property and equipment | |
| |
| |
|
| |
Useful Life | |
March 31, 2024 | |
June 30, 2023 |
Lab Equipment and Instruments | |
| 4-7 | | |
$ | 617,882 | | |
$ | 576,298 | |
Leasehold Improvements | |
| 10 | | |
| 224,629 | | |
| 224,629 | |
Furniture, Fixtures and Equipment | |
| 4-7 | | |
| 194,398 | | |
| 172,861 | |
Total | |
| | | |
| 1,036,909 | | |
| 973,788 | |
Less Accumulated Depreciation | |
| | | |
| (547,994 | ) | |
| (464,799 | ) |
Net Property and Equipment | |
| | | |
$ | 488,915 | | |
$ | 508,989 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
INTANGIBLE ASSETS AND GOODWILL (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
Schedule of intangible assets |
Schedule of intangible assets | |
| |
| |
| |
| |
| |
| |
|
| |
Useful Life | |
June 30, 2023 | |
Additions | |
Amortization | |
Impairment | |
Translation Adjustment | |
March 31, 2024 |
Definite Life Intangible Assets | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Patents | |
20 Years | |
$ | 290,936 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | (3,856 | ) | |
$ | 287,080 | |
Less Accumulated Amortization | |
| |
| (251,260 | ) | |
| — | | |
| (7,524 | ) | |
| — | | |
| 2,746 | | |
| 256,038 | |
Net Definite-Life Intangible Assets | |
| |
$ | 39,676 | | |
$ | — | | |
$ | (7,524 | ) | |
$ | — | | |
$ | (1,110 | ) | |
$ | 31,042 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Indefinite Life Intangible Assets and Goodwill | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Goodwill | |
| |
| 11,640,000 | | |
| 151,536,444 | | |
| — | | |
| — | | |
| 1,010,408 | | |
| 164,186,852 | |
IPR&D | |
| |
$ | 42,611,000 | | |
| 10,684,091 | | |
| — | | |
| (42,611,000 | ) | |
| 71,164 | | |
| 10,755,255 | |
Total Indefinite Life Intangible Assets and Goodwill | |
| |
$ | 54,251,000 | | |
$ | 162,220,535 | | |
$ | — | | |
$ | (42,611,000 | ) | |
$ | 1,081,572 | | |
$ | 174,942,107 | |
|
Schedule of expected future amortization expense |
Schedule of expected future amortization expense | |
|
Year ending June 30, | |
|
| 2024 | | |
$ | 1,942 | |
| 2025 | | |
| 9,700 | |
| 2026 | | |
| 9,700 | |
| 2027 | | |
| 9,700 | |
| Total | | |
$ | 31,042 | |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
LEASES (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Leases |
|
Schedule of lease commitments |
| Schedule of
lease commitments | | |
| | |
Year Ending June 30th | |
Lease Expense |
| 2024 | | |
| 286,252 | |
| 2025 | | |
| 557,851 | |
| 2026 | | |
| 349,204 | |
| 2027 | | |
| 309,491 | |
| 2028 | | |
| 59,439 | |
| Sub-total | | |
| 1,562,237 | |
| Less imputed interest | | |
| (108,658 | ) |
| Total | | |
$ | 1,453,579 | |
|
Schedule of net operating lease expenses |
Schedule of net operating
lease expenses | |
| | | |
| | | |
| | | |
| | |
| |
For the Three Months Ended | |
For the Nine Months Ended |
| |
March 31, | |
March 31, |
| |
2024 | |
2023 | |
2024 | |
2023 |
| |
| |
| |
| |
|
Operating Lease Expense | |
$ | 106,790 | | |
$ | 99,099 | | |
$ | 236,455 | | |
$ | 239,759 | |
Sub lease Income | |
| — | | |
| (53,310 | ) | |
| — | | |
| (159,930 | ) |
| |
| | | |
| | | |
| | | |
| | |
Total Net Lease Expense | |
$ | 106,790 | | |
$ | 45,789 | | |
$ | 236,455 | | |
$ | 79,829 | |
|
X |
- References
+ Details
Name: |
RENB_DisclosureLeasesAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCostTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
STOCKHOLDERS’ EQUITY (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Equity [Abstract] |
|
Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted |
Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted | |
| | |
| |
Renovaro Inc. |
Expected term (in years) | |
| 5.0 – 6.5 | |
Volatility | |
| 84.33% – 108.79 | % |
Risk free interest rate | |
| 3.12% – 4.83 | % |
Dividend yield | |
| 0 | % |
|
Schedule of stock options outstanding |
Schedule of stock options outstanding | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Options Outstanding | |
Options Exercisable |
| |
Exercise Price Ranges | |
Number Outstanding | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price | |
Number Exercisable | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price |
| | |
$ | 0.45–4.50 | | |
| 4,885,441 | | |
| 7.43 | | |
$ | 1.91 | | |
| 3,410,589 | | |
| 7.10 | | |
$ | 1.98 | |
| | |
$ | 4.51–6.50 | | |
| 167,634 | | |
| 6.73 | | |
$ | 5.33 | | |
| 135,376 | | |
| 6.06 | | |
$ | 5.49 | |
| | |
$ | 6.51–12.00 | | |
| 115,231 | | |
| 4.91 | | |
$ | 7.63 | | |
| 111,585 | | |
| 4.82 | | |
$ | 7.61 | |
Total | | |
| | | |
| 5,168,306 | | |
| 7.35 | | |
$ | 2.15 | | |
| 3,657,550 | | |
| 6.99 | | |
$ | 2.28 | |
|
Schedule of stock option activity |
Schedule of stock option activity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
Weighted Average Exercise Price |
|
Average Remaining Life |
|
Weighted Average Intrinsic Value |
|
|
|
|
|
|
|
|
|
Outstanding at beginning of period |
|
|
|
4,401,211 |
|
|
$ |
4.78 |
|
|
|
7.82 |
|
|
$ |
— |
|
Granted |
|
|
|
4,624,026 |
|
|
$ |
1.97 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Expired/Canceled |
|
|
|
(3,856,931 |
) |
|
$ |
4.94 |
|
|
|
|
|
|
|
|
|
Outstanding at end of period |
|
|
|
5,168,306 |
|
|
$ |
2.15 |
|
|
|
7.35 |
|
|
$ |
— |
|
Exercisable at end of period |
|
|
|
3,657,550 |
|
|
$ |
2.28 |
|
|
|
6.99 |
|
|
$ |
3,839,725 |
|
|
Schedule of common stock purchase warrants outstanding |
Schedule of common stock purchase warrants outstanding | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Warrants Outstanding | |
Warrants Exercisable |
| |
Exercise Price | |
Number Outstanding | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price | |
Number Exercisable | |
Weighted Average Remaining Contractual Life (years) | |
Weighted Average Exercise Price |
| | |
$ | 0.53 | | |
| 471,698 | | |
| 1.41 | | |
| | | |
| 471,698 | | |
| 1.41 | | |
| | |
| | |
$ | 0.65 | | |
| 741,274 | | |
| 3.25 | | |
| | | |
| 741,274 | | |
| 3.25 | | |
| | |
| | |
$ | 1.14 | | |
| 1,189,036 | | |
| 3.98 | | |
| | | |
| 1,189,036 | | |
| 3.98 | | |
| | |
Total | | |
| | | |
| 2,402,008 | | |
| 3.25 | | |
$ | 0.87 | | |
| 2,402,008 | | |
| 3.25 | | |
$ | 0.87 | |
|
Schedule of warrants outstanding |
Schedule of warrants outstanding | |
| | | |
| | | |
| | |
| |
Shares | |
Weighted Average Exercise Price | |
Weighted Average Remaining Life |
| |
| |
| |
|
Outstanding at beginning of period | |
| 3,548,302 | | |
$ | 0.73 | | |
| 4.80 | |
Granted | |
| 2,805,050 | | |
$ | 0.65 | | |
| 3.25 | |
Exercised | |
| (3,951,344 | ) | |
$ | 0.59 | | |
| — | |
Cancelled/Expired | |
| — | | |
$ | — | | |
| — | |
Outstanding and exercisable at end of period | |
| 2,402,008 | | |
$ | 0.87 | | |
| 3.25 | |
|
X |
- References
+ Details
Name: |
RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ScheduleOfWarrantsOutstandingTableTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
ACQUISITION (Tables)
|
9 Months Ended |
Mar. 31, 2024 |
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] |
|
Schedule of acquisition date fair value |
Schedule
of acquisition date fair value | |
| | |
Common stock | |
$ | 136,001,631 | |
Contingent consideration | |
| 20,557,500 | |
Total consideration transferred | |
$ | 156,559,131 | |
|
Schedule of fair values of the assets acquired and liabilities assumed |
Schedule of fair values of the assets acquired and liabilities assumed | |
| | |
Cash | |
$ | 65,851 | |
Prepaid & Other Assets | |
| 151,544 | |
Fixed Assets | |
| 16,243 | |
Operating lease ROU | |
| 624,366 | |
In-process research and development | |
| 10,684,091 | |
Total Assets Acquired: | |
| 11,542,095 | |
| |
| | |
Accounts Payable | |
| 583,577 | |
Accrued Expenses | |
| 722,509 | |
Operating Lease liability | |
| 624,367 | |
Notes Payable | |
| 1,832,460 | |
Deferred tax liabilities | |
| 2,756,495 | |
Total Liabilities Assumed | |
| 6,519,408 | |
Net Assets Acquired | |
| 5,022,687 | |
| |
| | |
Goodwill | |
| 151,536,444 | |
Total Consideration | |
$ | 156,559,131 | |
|
Schedule of consolidated statements of operations |
Schedule of consolidated
statements of operations |
|
|
|
|
Revenues |
|
$ |
— |
|
Net loss |
|
$ |
(398,597 |
) |
|
Schedule of consolidated proforma information |
Schedule of consolidated
proforma information | |
| | |
Revenues | |
$ | — | |
Net loss | |
$ | (33,622,997 | ) |
|
X |
- References
+ Details
Name: |
RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionProFormaInformationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_BusinessCombinationAndAssetAcquisitionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Accounting Policies [Abstract] |
|
|
|
|
Research and development expense |
$ 1,087,156
|
$ 239,137
|
$ 2,274,321
|
$ 3,170,471
|
Stock based compensation costs for vesting of options and RSUs granted |
$ 1,861,601
|
$ 1,076,203
|
$ 3,844,658
|
$ 2,922,166
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionValue, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1
+ Details
Name: |
us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.24.2.u1
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
|
Mar. 31, 2024 |
Dec. 31, 2023 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Sep. 30, 2022 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Indefinite lived intangible assets |
$ 10,755,255
|
|
|
|
|
|
$ 10,755,255
|
|
$ 42,611,000
|
|
Total assets |
178,089,340
|
|
|
|
|
|
178,089,340
|
|
58,300,796
|
|
Accumulated deficit |
(308,947,816)
|
|
|
|
|
|
(308,947,816)
|
|
(244,029,253)
|
|
Total stockholders' equity |
134,405,556
|
$ 43,595,536
|
$ 46,746,312
|
$ 66,128,153
|
$ 66,899,356
|
$ 70,324,842
|
134,405,556
|
$ 66,128,153
|
46,502,111
|
$ 72,618,848
|
Total liabilities and stockholders' equity |
178,089,340
|
|
|
|
|
|
178,089,340
|
|
$ 58,300,796
|
|
Total operating expenses |
51,380,840
|
|
|
4,063,436
|
|
|
64,535,029
|
15,621,918
|
|
|
Loss from operations |
(51,380,840)
|
|
|
(4,063,436)
|
|
|
(64,535,029)
|
(15,621,918)
|
|
|
Net loss |
(51,214,414)
|
$ (4,529,121)
|
$ (9,175,028)
|
(4,328,296)
|
$ (4,457,748)
|
$ (7,699,760)
|
(64,918,563)
|
(16,485,804)
|
|
|
Comprehensive loss |
$ (50,153,213)
|
|
|
$ (4,330,406)
|
|
|
$ (63,854,711)
|
$ (16,487,753)
|
|
|
Net loss per share |
$ (0.48)
|
|
|
$ (0.08)
|
|
|
$ (0.82)
|
$ (0.30)
|
|
|
Diluted net loss per share |
$ (0.48)
|
|
|
$ (0.08)
|
|
|
$ (0.82)
|
$ (0.30)
|
|
|
Previously Reported [Member] |
|
|
|
|
|
|
|
|
|
|
Indefinite lived intangible assets |
$ 44,945,255
|
|
|
|
|
|
$ 44,945,255
|
|
|
|
Total other assets |
210,570,510
|
|
|
|
|
|
210,570,510
|
|
|
|
Total assets |
212,279,340
|
|
|
|
|
|
212,279,340
|
|
|
|
Accumulated deficit |
(274,757,816)
|
|
|
|
|
|
(274,757,816)
|
|
|
|
Total stockholders' equity |
168,595,556
|
|
|
|
|
|
168,595,556
|
|
|
|
Total liabilities and stockholders' equity |
212,279,340
|
|
|
|
|
|
212,279,340
|
|
|
|
Intangible asset impairment |
|
|
|
|
|
|
8,421,000
|
|
|
|
Total operating expenses |
17,190,840
|
|
|
|
|
|
30,345,029
|
|
|
|
Loss from operations |
(17,190,840)
|
|
|
|
|
|
(30,345,029)
|
|
|
|
Net loss |
(17,024,414)
|
|
|
|
|
|
(30,728,563)
|
|
|
|
Comprehensive loss |
$ (15,963,213)
|
|
|
|
|
|
$ (29,664,711)
|
|
|
|
Net loss per share |
$ (0.16)
|
|
|
|
|
|
$ (0.39)
|
|
|
|
Diluted net loss per share |
$ (0.16)
|
|
|
|
|
|
$ (0.39)
|
|
|
|
Revision of Prior Period, Adjustment [Member] |
|
|
|
|
|
|
|
|
|
|
Indefinite lived intangible assets |
$ (34,190,000)
|
|
|
|
|
|
$ (34,190,000)
|
|
|
|
Total other assets |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Total assets |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Accumulated deficit |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Total stockholders' equity |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Total liabilities and stockholders' equity |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Intangible asset impairment |
|
|
|
|
|
|
34,190,000
|
|
|
|
Total operating expenses |
34,190,000
|
|
|
|
|
|
34,190,000
|
|
|
|
Loss from operations |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Net loss |
(34,190,000)
|
|
|
|
|
|
(34,190,000)
|
|
|
|
Comprehensive loss |
$ (34,190,000)
|
|
|
|
|
|
$ (34,190,000)
|
|
|
|
Net loss per share |
$ (0.32)
|
|
|
|
|
|
$ (0.43)
|
|
|
|
Diluted net loss per share |
$ (0.32)
|
|
|
|
|
|
$ (0.43)
|
|
|
|
Restated [Member] |
|
|
|
|
|
|
|
|
|
|
Indefinite lived intangible assets |
$ 10,755,255
|
|
|
|
|
|
$ 10,755,255
|
|
|
|
Total other assets |
176,380,510
|
|
|
|
|
|
176,380,510
|
|
|
|
Total assets |
178,089,340
|
|
|
|
|
|
178,089,340
|
|
|
|
Accumulated deficit |
(308,947,816)
|
|
|
|
|
|
(308,947,816)
|
|
|
|
Total stockholders' equity |
134,405,556
|
|
|
|
|
|
134,405,556
|
|
|
|
Total liabilities and stockholders' equity |
178,089,340
|
|
|
|
|
|
178,089,340
|
|
|
|
Intangible asset impairment |
|
|
|
|
|
|
42,611,000
|
|
|
|
Total operating expenses |
51,380,840
|
|
|
|
|
|
64,535,029
|
|
|
|
Loss from operations |
(51,380,840)
|
|
|
|
|
|
(64,535,029)
|
|
|
|
Net loss |
(51,214,414)
|
|
|
|
|
|
(64,918,563)
|
|
|
|
Comprehensive loss |
$ (50,153,213)
|
|
|
|
|
|
$ (63,854,711)
|
|
|
|
Net loss per share |
$ (0.48)
|
|
|
|
|
|
$ (0.82)
|
|
|
|
Diluted net loss per share |
$ (0.48)
|
|
|
|
|
|
$ (0.82)
|
|
|
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetImpairment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RestatementAxis=srt_RestatementAdjustmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RestatementAxis=RENB_RestatedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
GOING CONCERN (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
Mar. 31, 2024 |
Dec. 31, 2023 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Sep. 30, 2022 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Jun. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
|
|
|
|
|
|
|
Net loss |
$ 51,214,414
|
$ 4,529,121
|
$ 9,175,028
|
$ 4,328,296
|
$ 4,457,748
|
$ 7,699,760
|
$ 64,918,563
|
$ 16,485,804
|
|
Cash and cash equivalents |
312,697
|
|
|
|
|
|
312,697
|
|
$ 1,874,480
|
Accumulated deficit |
308,947,816
|
|
|
|
|
|
308,947,816
|
|
$ 244,029,253
|
Working capital deficit |
$ 19,654,098
|
|
|
|
|
|
$ 19,654,098
|
|
|
X |
- References
+ Details
Name: |
RENB_WorkingCapitalDeficit |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.2.u1
X |
- References
+ Details
Name: |
RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
FAIR VALUE MEASUREMENTS (Details 1)
|
9 Months Ended |
Mar. 31, 2024
USD ($)
|
Fair Value, Inputs, Level 1 [Member] |
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
Balance June 30, 2023 |
$ 0
|
Contingent consideration in Acquisition |
0
|
Fair value adjustment |
0
|
Contingent Consideration Liability at March 31, 2024 |
0
|
Fair Value, Inputs, Level 2 [Member] |
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
Balance June 30, 2023 |
0
|
Contingent consideration in Acquisition |
0
|
Fair value adjustment |
0
|
Contingent Consideration Liability at March 31, 2024 |
0
|
Fair Value, Inputs, Level 3 [Member] |
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
Balance June 30, 2023 |
0
|
Contingent consideration in Acquisition |
20,557,500
|
Fair value adjustment |
(486,500)
|
Contingent Consideration Liability at March 31, 2024 |
$ 20,071,000
|
X |
- References
+ Details
Name: |
RENB_ContingentConsideration |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of liability recognized arising from contingent consideration in a business combination.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6
+ Details
Name: |
us-gaap_BusinessCombinationContingentConsiderationLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.
+ References
+ Details
Name: |
us-gaap_LiabilitiesFairValueAdjustment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.24.2.u1
X |
- References
+ Details
Name: |
RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShare |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_ShareAcquisitionContingentConsideration |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of liability recognized from contingent consideration in asset acquisition.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3
+ Details
Name: |
us-gaap_AssetAcquisitionContingentConsiderationLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
PROPERTY AND EQUIPMENT (Details) - USD ($)
|
Mar. 31, 2024 |
Jun. 30, 2023 |
Property, Plant and Equipment [Line Items] |
|
|
Total |
$ 1,036,909
|
$ 973,788
|
Less Accumulated Depreciation |
(547,994)
|
(464,799)
|
Net Property and Equipment |
488,915
|
508,989
|
Lab Equipment And Instruments [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total |
$ 617,882
|
576,298
|
Leasehold Improvements [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Useful Life |
10 years
|
|
Total |
$ 224,629
|
224,629
|
Furniture and Fixtures [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total |
$ 194,398
|
$ 172,861
|
Minimum [Member] | Lab Equipment And Instruments [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Useful Life |
4 years
|
|
Minimum [Member] | Furniture and Fixtures [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Useful Life |
4 years
|
|
Maximum [Member] | Lab Equipment And Instruments [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Useful Life |
7 years
|
|
Maximum [Member] | Furniture and Fixtures [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Useful Life |
7 years
|
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
INTANGIBLE ASSETS AND GOODWILL (Details)
|
9 Months Ended |
Mar. 31, 2024
USD ($)
|
Finite-Lived Intangible Assets [Line Items] |
|
Net definite-life intangible assets at beginning |
$ 39,676
|
Net definite-life intangible assets, Additions |
0
|
Net definite-life intangible assets, Amortization |
(7,524)
|
Net definite-life intangible assets, Impairment |
0
|
Net definite-life intangible assets, Translation adjustment |
(1,110)
|
Net definite-life intangible assets at ending |
31,042
|
Indefinite life intangible assets and goodwill at beginning |
54,251,000
|
Indefinite life intangible assets and goodwill, Additions |
162,220,535
|
Indefinite life intangible assets and goodwill, Amortization |
0
|
Indefinite life intangible assets and goodwill, Impairment |
(42,611,000)
|
Indefinite life intangible assets and goodwill, Translation adjustment |
1,081,572
|
Indefinite life intangible assets and goodwill at ending |
$ 174,942,107
|
Patents [Member] |
|
Finite-Lived Intangible Assets [Line Items] |
|
Useful life |
20 years
|
Net definite-life intangible assets at beginning |
$ 290,936
|
Net definite-life intangible assets, Additions |
0
|
Net definite-life intangible assets, Amortization |
0
|
Net definite-life intangible assets, Impairment |
0
|
Net definite-life intangible assets, Translation adjustment |
(3,856)
|
Net definite-life intangible assets at ending |
287,080
|
Accumulated Amortization [Member] |
|
Finite-Lived Intangible Assets [Line Items] |
|
Net definite-life intangible assets at beginning |
(251,260)
|
Net definite-life intangible assets, Additions |
0
|
Net definite-life intangible assets, Amortization |
(7,524)
|
Net definite-life intangible assets, Impairment |
0
|
Net definite-life intangible assets, Translation adjustment |
2,746
|
Net definite-life intangible assets at ending |
256,038
|
Goodwill [Member] |
|
Finite-Lived Intangible Assets [Line Items] |
|
Indefinite life intangible assets and goodwill at beginning |
11,640,000
|
Indefinite life intangible assets and goodwill, Additions |
151,536,444
|
Indefinite life intangible assets and goodwill, Amortization |
0
|
Indefinite life intangible assets and goodwill, Impairment |
0
|
Indefinite life intangible assets and goodwill, Translation adjustment |
1,010,408
|
Indefinite life intangible assets and goodwill at ending |
164,186,852
|
IPR&D [Member] |
|
Finite-Lived Intangible Assets [Line Items] |
|
Indefinite life intangible assets and goodwill at beginning |
42,611,000
|
Indefinite life intangible assets and goodwill, Additions |
10,684,091
|
Indefinite life intangible assets and goodwill, Amortization |
0
|
Indefinite life intangible assets and goodwill, Impairment |
(42,611,000)
|
Indefinite life intangible assets and goodwill, Translation adjustment |
71,164
|
Indefinite life intangible assets and goodwill at ending |
$ 10,755,255
|
X |
- References
+ Details
Name: |
RENB_FiniteLivedIntangibleAssetNet |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_NetDefinitelifeIntangibleAssetsAmortization |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_NetDefinitelifeIntangibleAssetsImpairment |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_TotalIndefiniteLifeIntangibleAssetsAndGoodwillAdditions |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_TotalIndefiniteLifeIntangibleAssetsAndGoodwillAmortization |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_TotalIndefiniteLifeIntangibleAssetsAndGoodwillImpairment |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_TotalIndefiniteLifeIntangibleAssetsAndGoodwillTranslationAdjustment |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherIndefiniteLivedIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_AccumulatedAmortizationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_IPRAndDMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Jun. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
|
|
|
|
Definite-life intangible assets |
$ 31,042
|
|
$ 31,042
|
|
$ 39,676
|
Amortization expense |
$ 779
|
$ 1,580
|
$ 7,524
|
$ 4,572
|
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
LEASES (Details)
|
Mar. 31, 2024
USD ($)
|
Leases |
|
2024 |
$ 286,252
|
2025 |
557,851
|
2026 |
349,204
|
2027 |
309,491
|
2028 |
59,439
|
Sub-total |
1,562,237
|
Less imputed interest |
(108,658)
|
Total |
$ 1,453,579
|
X |
- References
+ Details
Name: |
RENB_DisclosureLeasesAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_LesseeOperatingLeaseLiabilitySubTotalAmount |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.2.u1
LEASES (Details 1) - USD ($)
|
3 Months Ended |
9 Months Ended |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Leases |
|
|
|
|
Operating Lease Expense |
$ 106,790
|
$ 99,099
|
$ 236,455
|
$ 239,759
|
Sub lease Income |
0
|
(53,310)
|
0
|
(159,930)
|
Total Net Lease Expense |
$ 106,790
|
$ 45,789
|
$ 236,455
|
$ 79,829
|
X |
- References
+ Details
Name: |
RENB_DisclosureLeasesAbstract |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_OperatingLeasesRentExpensesNet |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating lease expense. Excludes sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4
+ Details
Name: |
us-gaap_OperatingLeaseExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of sublease income excluding finance and operating lease expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_SubleaseIncome |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.24.2.u1
LEASES (Details Narrative) - USD ($)
|
|
|
|
|
3 Months Ended |
9 Months Ended |
Apr. 18, 2023 |
Jun. 20, 2022 |
Jun. 19, 2018 |
Nov. 13, 2017 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Lease premises, description |
|
|
On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.
|
On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.
|
|
|
|
|
Weighted-average remaining term |
|
|
|
|
2 years 9 months 7 days
|
|
2 years 9 months 7 days
|
|
Weighted-average discount rate |
|
|
|
|
5.16%
|
|
5.16%
|
|
Sublease agreement description |
|
On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.
|
|
|
|
|
|
|
Lease payment |
$ 139,460
|
|
|
|
|
|
|
|
Security deposit |
35,540
|
|
|
|
|
|
|
|
Termination fee |
$ 175,000
|
|
|
|
|
|
|
|
Operating lease payments |
|
|
|
|
$ 108,441
|
$ 98,950
|
$ 232,237
|
$ 339,993
|
Operating lease expense |
|
|
|
|
|
|
|
79,829
|
Cash payments |
|
|
|
|
|
339,993
|
|
339,993
|
Accrual payments related to the termination of lease |
|
|
|
|
|
|
|
77,242
|
General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
Lease expense |
|
|
|
|
$ 106,790
|
$ 45,789
|
$ 236,455
|
$ 79,829
|
X |
- References
+ Details
Name: |
RENB_CashPaidForTheTerminationOfLease |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_OperatingLeaseExpenses |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of lease cost recognized by lessee for lease contract.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDescription of terms and conditions of residual value guarantee provided by sublessee on finance sublease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of lessee's operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of early contract termination fees included in liabilities subject to compromise.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.
+ References
+ Details
Name: |
us-gaap_PaymentsForLeasingCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_SecurityDeposit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
DEBT (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
|
|
|
Mar. 14, 2024 |
Feb. 15, 2024 |
Feb. 05, 2024 |
Jan. 31, 2024 |
Jan. 11, 2024 |
Jan. 02, 2024 |
Nov. 30, 2023 |
Nov. 23, 2023 |
Nov. 03, 2023 |
Jun. 26, 2023 |
Dec. 30, 2022 |
May 17, 2022 |
Mar. 30, 2020 |
Feb. 06, 2020 |
Oct. 05, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Feb. 20, 2024 |
Jan. 12, 2024 |
Feb. 11, 2021 |
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,645,000
|
$ 0
|
|
|
|
Proceeds from private placement |
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000,000
|
2,483,000
|
|
|
|
Down payment amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
646,128
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 303,802
|
$ 122,289
|
758,057
|
310,766
|
|
|
|
Finance Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Monthly instalments amount |
|
|
|
|
|
|
$ 77,127
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Down payment amount |
|
|
|
|
|
|
$ 235,000
|
|
|
|
|
|
|
|
|
223,945
|
374,367
|
|
840,992
|
|
|
|
Total interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,436
|
|
12,692
|
|
|
|
|
Other Current Liabilities [Member] | Finance Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rate of interest |
|
|
|
|
|
|
7.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
$ 906,834
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest Expense [Member] | Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72,500
|
$ 74,621
|
357,536
|
$ 223,863
|
|
|
|
Warrant [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant purchase price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.53
|
|
|
Warrant [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant purchase price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.65
|
|
|
Convertible Notes Payables [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 600,000
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
Secured Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
|
|
|
Feb. 28, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of shares |
|
|
|
|
|
|
|
|
|
|
198,439
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
|
29,419
|
|
|
|
|
|
|
|
|
|
|
|
Prepayment shares |
|
|
|
|
|
|
|
|
|
|
169,020
|
|
|
|
|
|
|
|
|
|
|
|
Share price |
|
|
|
|
|
|
|
|
|
|
$ 1.03
|
|
|
|
|
|
|
|
|
|
|
|
Obligation value |
|
|
|
|
|
|
|
|
|
|
$ 1,200,000
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued, value |
|
|
|
|
|
|
|
|
|
|
204,392
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid interest |
|
|
|
|
|
|
|
|
|
|
174,090
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest amount |
|
|
|
|
|
|
|
|
|
|
$ 30,302
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued for debt conversion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,200,000
|
|
|
|
|
Secured Notes [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued for debt conversion, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,132,075
|
|
|
|
|
RS Bio ApS [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 105,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
Mar. 01, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds original issue discount rate |
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RS Bio ApS [Member] | Bridge Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
105,263
|
|
$ 105,263
|
|
|
|
|
RS Bio ApS [Member] | Interest Expense [Member] | Bridge Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,263
|
|
|
|
|
RS Bio ApS [Member] | Accrued Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,158
|
|
|
|
|
January 2024 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
$ 526,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
Mar. 01, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds original issue discount rate |
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 2024 Note [Member] | Bridge Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
526,315
|
|
526,315
|
|
|
|
|
January 2024 Note [Member] | Interest Expense [Member] | Bridge Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,315
|
|
26,315
|
|
|
|
|
January 2024 Note [Member] | Accrued Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,789
|
|
|
|
|
Loan Agreement [Member] | Bridge Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639,544
|
|
639,544
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loan Agreement [Member] | Accrued Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,545
|
|
|
|
|
November 2023 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
Mar. 01, 2024
|
|
|
Jan. 01, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
|
|
|
$ 950,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
750,000
|
|
750,000
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount accreted |
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds original issue discount rate |
|
|
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes Payable |
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants exercised |
|
|
|
|
|
|
|
|
471,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price per share |
|
|
|
|
|
|
|
|
$ 0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise warrants amount |
|
|
|
|
|
|
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November 2023 Note [Member] | Interest Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
50,000
|
|
|
|
|
November 2023 Note [Member] | Accrued Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46,583
|
|
|
|
|
Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
|
|
|
|
Nov. 30, 2023
|
Nov. 30, 2021
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
|
Stock issued for debt conversion |
|
|
|
|
|
|
|
|
|
|
|
|
$ 501,370
|
|
|
|
|
|
|
|
|
|
Stock issued for debt conversion, shares |
|
|
|
|
|
|
|
|
|
|
|
|
188,485
|
|
|
|
|
|
|
|
|
|
Issuance of common stock |
|
|
|
|
|
|
|
|
|
|
|
$ 299,178
|
$ 493,192
|
|
|
|
|
|
|
|
|
|
Rate of interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.00%
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
47,115
|
|
|
|
|
|
|
|
|
|
74,054
|
Market price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 298,178
|
Promissory Note balance, net of discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,237,500
|
|
$ 1,237,500
|
|
|
|
|
Promissory Note [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rate of interest |
|
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
|
|
Promissory Note [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rate of interest |
|
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
$ 20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share price |
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
567,588
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants purchased |
|
|
|
|
|
|
|
|
|
283,794
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant purchase price |
|
|
|
|
|
|
|
|
|
$ 0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from private placement |
|
|
|
|
|
|
|
|
|
$ 300,822
|
|
|
|
|
|
|
|
|
|
|
|
|
March Note 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bear interest percentage |
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
Mar. 15, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January Note 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
$ 460,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 125,000
|
|
Bear interest percentage |
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
Jan. 11, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 29, 2024
|
|
|
|
|
Conversion price |
|
|
|
|
$ 3.38
|
|
|
|
|
|
|
|
|
|
|
$ 3.38
|
|
$ 3.38
|
|
|
|
|
Bear interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
12.00%
|
|
|
|
|
Principal outstanding balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 585,000
|
|
$ 585,000
|
|
|
|
|
December Note 2023 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 560,000
|
|
$ 560,000
|
|
|
|
|
Conversion price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3.38
|
|
$ 3.38
|
|
|
|
|
Bear interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
12.00%
|
|
|
|
|
Principal outstanding balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 560,000
|
|
$ 560,000
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,463
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,645,000
|
|
1,645,000
|
|
|
|
|
December Note 2023 [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
560,000
|
|
|
|
|
Note 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,463
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,645,000
|
|
1,645,000
|
|
|
|
|
Note 2023 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,105,263
|
|
|
|
|
|
|
|
Bear interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sep. 05, 2024
|
|
|
|
|
|
|
|
Conversion price |
|
|
|
|
$ 3.38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
134,719
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,055,694
|
|
2,055,694
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
Original issue discount percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
Discount accreted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 105,263
|
|
|
|
|
|
|
|
Common Stock and receives gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
Offering price per share percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00%
|
|
|
|
|
|
|
|
Floor of per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.50
|
|
|
|
|
|
|
|
Amortization of debt discount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 26,316
|
|
$ 55,694
|
|
|
|
|
X |
- References
+ Details
Name: |
RENB_CommonStockAndReceivesGrossProceeds |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_DebtInstrumentOriginalIssueDiscount |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_DebtInstrumentsFloorOfPerShare |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_ExerciseWarrants |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_ExerciseWarrantsAmount |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_GrossProceedsDiscountPercentage |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_MarketPrice |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_MonthlyInstallments |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_OfferingPricePerSharePercentage |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_OriginalIssueDiscountPromissoryNotePercentage |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_PrepaymentShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_PromissoryNoteBalanceNetOfDiscount |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_RepaymentOnFinanceAgreement |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_WarrantsOutstandingPerShare |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_WarrantsPurchased |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3
+ Details
Name: |
us-gaap_ContractualObligation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of annual principal payment for debt instrument.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentAnnualPrincipalPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncremental percentage increase (decrease) in the stated rate on a debt instrument.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount (premium).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFixed interest rate related to the interest rate derivative.
+ References
+ Details
Name: |
us-gaap_DerivativeFixedInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionInterest and debt related expenses associated with nonoperating financing activities of the entity.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_InterestAndDebtExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest expense classified as other.
+ References
+ Details
Name: |
us-gaap_InterestExpenseOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermDebtPercentageBearingFixedInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5
+ Details
Name: |
us-gaap_PrepaidInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_SharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=RENB_PromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNotesPayablesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_SecuredNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_RSBioApSMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=RENB_AccruedExpensesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_January2024NoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_LoanAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_November2023NoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_MarchNote2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_DecemberNote2023Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_Note2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_Note2023Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
dei_LegalEntityAxis=RENB_RenovaroMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
STOCKHOLDERS' EQUITY (Details 1) - Share-Based Payment Arrangement, Option [Member]
|
9 Months Ended |
Mar. 31, 2024
$ / shares
shares
|
Option Indexed to Issuer's Equity [Line Items] |
|
Number share option outstanding | shares |
5,168,306
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
7 years 4 months 6 days
|
Options Outstanding, Weighted Average Exercise Price |
$ 2.15
|
Options Exercisable | shares |
3,657,550
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
6 years 11 months 26 days
|
Options Exercisable, Weighted Average Exercise Price |
$ 2.28
|
Exercise Price Range 1 [Member] |
|
Option Indexed to Issuer's Equity [Line Items] |
|
Exercise Prices, Lower |
0.45
|
Exercise Prices, Upper |
$ 4.50
|
Number share option outstanding | shares |
4,885,441
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
7 years 5 months 4 days
|
Options Outstanding, Weighted Average Exercise Price |
$ 1.91
|
Options Exercisable | shares |
3,410,589
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
7 years 1 month 6 days
|
Options Exercisable, Weighted Average Exercise Price |
$ 1.98
|
Exercise Price Range 2 [Member] |
|
Option Indexed to Issuer's Equity [Line Items] |
|
Exercise Prices, Lower |
4.51
|
Exercise Prices, Upper |
$ 6.50
|
Number share option outstanding | shares |
167,634
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
6 years 8 months 23 days
|
Options Outstanding, Weighted Average Exercise Price |
$ 5.33
|
Options Exercisable | shares |
135,376
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
6 years 21 days
|
Options Exercisable, Weighted Average Exercise Price |
$ 5.49
|
Exercise Price Range 3 [Member] |
|
Option Indexed to Issuer's Equity [Line Items] |
|
Exercise Prices, Lower |
6.51
|
Exercise Prices, Upper |
$ 12.00
|
Number share option outstanding | shares |
115,231
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
4 years 10 months 28 days
|
Options Outstanding, Weighted Average Exercise Price |
$ 7.63
|
Options Exercisable | shares |
111,585
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
4 years 9 months 25 days
|
Options Exercisable, Weighted Average Exercise Price |
$ 7.61
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_OptionIndexedToIssuersEquityLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
STOCKHOLDERS' EQUITY (Details 2) - Employee Stock Options [Member] - USD ($)
|
9 Months Ended |
12 Months Ended |
Mar. 31, 2024 |
Jun. 30, 2023 |
Option Indexed to Issuer's Equity [Line Items] |
|
|
Options Outstanding at beginning of period |
4,401,211
|
|
Weighted Average Exercise Price, Outstanding at beginning of period |
$ 4.78
|
|
Weighted Average remaining life |
7 years 4 months 6 days
|
7 years 9 months 25 days
|
Weighted Average Intrinsic Value, Outstanding at beginning of period |
$ 0
|
|
Granted |
4,624,026
|
|
Weighted average exercise price, Granted |
$ 1.97
|
|
Exercised |
0
|
|
Weighted average exercise price, Exercised |
$ 0
|
|
Forfeited |
0
|
|
Weighted Average Exercise Price, Forfeited |
$ 0
|
|
Cancelled/Expired |
(3,856,931)
|
|
Weighted Average Exercise Price, Expired |
$ 4.94
|
|
Options Outstanding at end of period |
5,168,306
|
4,401,211
|
Weighted Average Exercise Price, Outstanding at ending of period |
$ 2.15
|
$ 4.78
|
Weighted Average Intrinsic Value, Outstanding at end of period |
$ 0
|
$ 0
|
Options Exercisable |
3,657,550
|
|
Weighted Average Exercise Price, Exercisable at ending of period |
$ 2.28
|
|
Weighted Average Remaining Life, Exercisable |
6 years 11 months 26 days
|
|
Weighted Average Intrinsic Value, Exercisable end of period |
$ 3,839,725
|
|
X |
- References
+ Details
Name: |
RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_OptionIndexedToIssuersEquityLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price of options that were either forfeited or expired.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_EmployeeStockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member]
|
9 Months Ended |
Mar. 31, 2024
$ / shares
shares
|
Option Indexed to Issuer's Equity [Line Items] |
|
Number share option outstanding |
2,402,008
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
3 years 3 months
|
Options Exercisable |
2,402,008
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
3 years 3 months
|
Options Outstanding, Weighted Average Exercise Price | $ / shares |
$ 0.87
|
Options Exercisable, Weighted Average Exercise Price | $ / shares |
0.87
|
Exercise Price Range 1 [Member] |
|
Option Indexed to Issuer's Equity [Line Items] |
|
Exercise Prices | $ / shares |
$ 0.53
|
Number share option outstanding |
471,698
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
1 year 4 months 28 days
|
Options Exercisable |
471,698
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
1 year 4 months 28 days
|
Exercise Price Range 2 [Member] |
|
Option Indexed to Issuer's Equity [Line Items] |
|
Exercise Prices | $ / shares |
$ 0.65
|
Number share option outstanding |
741,274
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
3 years 3 months
|
Options Exercisable |
741,274
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
3 years 3 months
|
Exercise Price Range 3 [Member] |
|
Option Indexed to Issuer's Equity [Line Items] |
|
Exercise Prices | $ / shares |
$ 1.14
|
Number share option outstanding |
1,189,036
|
Options Outstanding, Weighted Average Remaining Contractual Life (years) |
3 years 11 months 23 days
|
Options Exercisable |
1,189,036
|
Options Exercisable, Weighted Average Remaining Contractual Life (years) |
3 years 11 months 23 days
|
X |
- References
+ Details
Name: |
RENB_ExercisePrices |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_OptionIndexedToIssuersEquityLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
STOCKHOLDERS' EQUITY (Details 4) - Common Stock Purchase Warrant [Member] - $ / shares
|
9 Months Ended |
12 Months Ended |
Mar. 31, 2024 |
Jun. 30, 2023 |
Option Indexed to Issuer's Equity [Line Items] |
|
|
Outstanding at beginning of period |
3,548,302
|
|
Weighted average exercise price, Outstanding at beginning of period |
$ 0.73
|
|
Weighted Average remaining life, Outstanding |
3 years 3 months
|
4 years 9 months 18 days
|
Granted |
2,805,050
|
|
Weighted average exercise price, Granted |
$ 0.65
|
|
Weighted Average remaining life, Granted |
3 years 3 months
|
|
Exercised |
(3,951,344)
|
|
Weighted average exercise price, Exercised |
$ 0.59
|
|
Cancelled/Expired |
0
|
|
Weighted average exercise price, Expired |
$ 0
|
|
Outstanding at end of period |
2,402,008
|
3,548,302
|
Weighted average exercise price, Outstanding at ending of period |
$ 0.87
|
|
X |
- References
+ Details
Name: |
RENB_CommonStockPurchaseWarrant |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_CommonStockPurchaseWarrantsWeightedAverageEndingExercisePrice |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_OptionIndexedToIssuersEquityLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
|
|
|
|
|
|
|
2 Months Ended |
3 Months Ended |
9 Months Ended |
|
|
|
|
Feb. 20, 2024 |
Feb. 15, 2024 |
Feb. 13, 2024 |
Dec. 04, 2023 |
Oct. 23, 2023 |
Aug. 01, 2023 |
Sep. 28, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Jun. 30, 2023 |
Jun. 20, 2023 |
Jun. 20, 2022 |
Feb. 06, 2014 |
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock shares authorized |
|
|
|
|
|
|
|
10,000,000
|
|
10,000,000
|
|
10,000,000
|
|
|
|
Preferred stock, par value |
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
0
|
|
0
|
|
0
|
|
|
|
Preferred stock, shares outstanding |
|
|
|
|
|
|
|
0
|
|
0
|
|
0
|
|
|
|
Common stock, shares authorized |
|
|
|
|
|
|
|
350,000,000
|
|
350,000,000
|
|
350,000,000
|
|
|
|
Common stock, par value |
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
Common stock, shares issued |
|
|
|
|
|
|
|
147,488,598
|
|
147,488,598
|
|
63,698,144
|
|
|
|
Common stock, shares outstanding |
|
|
|
|
|
|
|
147,488,598
|
|
147,488,598
|
|
63,698,144
|
|
|
|
Obligation to purchase |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20,000,000
|
|
Issuance of common stock shares |
|
50,000
|
|
525,945
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock shares, value |
|
|
|
$ 341,865
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock under private placement |
|
$ 344,827
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
Common stock par value under private placement |
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of private placement |
|
$ 1,000,000
|
|
|
|
|
|
|
|
$ 3,000,000
|
$ 2,483,000
|
|
|
|
|
Common stock reserved for issuance |
|
|
|
|
|
|
|
17,414
|
|
17,414
|
|
17,414
|
|
|
|
Common stock issued |
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
$ 886,849
|
|
|
|
|
|
Unrecognized compensation cost related to non-vested options |
|
|
|
|
|
|
|
$ 579,305
|
|
579,305
|
|
|
|
|
|
stock-based compensation expense |
|
|
|
|
|
|
|
1,861,601
|
$ 1,076,203
|
3,844,658
|
$ 2,922,166
|
|
|
|
|
Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
stock-based compensation expense |
|
|
|
|
|
|
|
$ 535,009
|
|
$ 1,068,865
|
|
|
|
|
|
Restricted stock awards |
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
Restricted stock vesting period |
|
|
|
|
|
|
|
|
|
3 years
|
|
|
|
|
|
Unrecognized stock-based compensation expense |
|
|
|
|
|
|
|
|
|
$ 1,691,135
|
|
|
|
|
|
Common Stock Purchase Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock purchase warrants exercisable outstanding |
|
|
|
|
|
|
|
2,402,008
|
|
2,402,008
|
|
|
|
|
|
Total intrinsic value of options exercisable |
|
|
|
|
|
|
|
$ 4,277,992
|
|
$ 4,277,992
|
|
|
|
|
|
Share-Based Payment Arrangement, Tranche One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option granted |
|
|
|
|
|
|
|
0
|
0
|
0
|
184,800
|
|
|
|
|
Shares forfeited |
|
|
|
|
|
|
|
|
0
|
|
18,960
|
|
|
|
|
Share-Based Payment Arrangement, Tranche Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option granted |
|
|
|
|
|
|
|
0
|
0
|
0
|
73,200
|
|
|
|
|
Shares forfeited |
|
|
|
|
|
|
|
|
0
|
|
12,640
|
|
|
|
|
Equity Incentive Plan 2014 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock reserved for issuance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,206,000
|
Plan Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option granted |
|
|
|
|
|
|
|
|
|
6,306,275
|
|
|
|
|
|
Options available to be issued |
|
|
|
|
|
|
|
|
|
4,875,419
|
|
|
|
|
|
Equity Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
$ 1,326,592
|
$ 1,076,203
|
$ 2,775,793
|
$ 2,922,166
|
|
|
|
|
Dan Drit Denmark [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, shares outstanding |
|
|
|
|
|
|
|
167,639
|
|
167,639
|
|
|
|
|
|
Employees [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option granted |
|
|
|
|
|
|
|
0
|
15,000
|
366,500
|
193,000
|
|
|
|
|
Board Of Directors And Scientific Advisory Board [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option granted |
|
|
|
|
|
|
|
28,196
|
64,655
|
371,595
|
275,572
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock purchase warrants exercisable outstanding |
2,953,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants aggregate amount |
1,750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised |
$ 0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised |
$ 0.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Purchase Agreement Of Renovaro Cube [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock shares |
|
|
70,834,183
|
|
|
|
|
|
|
|
|
|
|
|
|
Single Range [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock purchase warrants exercisable outstanding |
471,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised |
$ 0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants aggregate amount |
250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Renovaro Cube [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock converted shares |
|
|
561,010
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate preferred stock converted into common stock |
|
|
5,610,100
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
696,021
|
|
|
Series A Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock shares authorized |
|
|
|
|
|
|
|
10,000,000
|
|
10,000,000
|
|
10,000,000
|
|
|
|
Preferred stock, par value |
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
Preferred stock designated shares |
|
|
|
|
|
|
|
1,000,000
|
|
1,000,000
|
|
1,000,000
|
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
0
|
|
0
|
|
0
|
|
|
|
Preferred stock, shares outstanding |
|
|
|
|
|
|
|
0
|
|
0
|
|
0
|
|
|
|
Preferred Stock Issuances [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, par value |
|
|
|
|
|
$ 7.13
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
280,505
|
|
|
|
|
|
|
|
|
|
Closed private placement units |
|
|
|
|
|
280,505
|
|
|
|
|
|
|
|
|
|
aggregate proceeds |
|
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
Conversion of promissory note |
|
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
Aggregate preferred stock shares |
|
|
|
|
|
|
|
|
|
561,010
|
|
|
|
|
|
Aggregate common stock shares |
|
|
|
|
|
|
|
|
|
5,610,100
|
|
|
|
|
|
Warrants sold |
|
|
|
|
|
|
|
2,805,050
|
|
2,805,050
|
|
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
$ 0.65
|
|
|
|
|
|
Common Stock Issuances [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock shares |
|
|
|
|
|
|
2,000,000
|
|
|
|
|
|
|
|
|
Advisory Services [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock shares |
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
X |
- References
+ Details
Name: |
RENB_AggregateCommonStockShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_AggregatePreferredStockShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_CommonStockParValuePrivatePlacement |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_CommonStocksSharesAuthorized |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_ConversionOfPromissoryNote |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_PreferredStockDesignatedShares |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_WarrantsSold |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of expense or revenue offset related to the warrants or rights.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of common shares issuable upon conversion of preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockConvertibleSharesIssuable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.
+ References
+ Details
Name: |
us-gaap_ProceedsFromRepaymentsOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.
+ References
+ Details
Name: |
us-gaap_PurchaseObligation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_SharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionValue, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1
+ Details
Name: |
us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the period in the number of shares issued.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPer share increase in exercise price of warrant. Excludes change due to standard antidilution provision.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_WarrantExercisePriceIncrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=RENB_PlanOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=RENB_SingleRangeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=RENB_PreferredStockIssuancesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=RENB_AdvisoryServicesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
|
Sep. 10, 2021 |
Aug. 25, 2021 |
Feb. 06, 2020 |
Jan. 31, 2020 |
Nov. 15, 2019 |
Jul. 09, 2018 |
Mar. 31, 2024 |
Jun. 30, 2023 |
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
|
|
|
|
|
Up-front payment |
|
|
|
|
$ 10,000,000
|
|
|
|
Payment for expenditures |
|
|
|
|
$ 760,000
|
|
|
|
Initial payment |
$ 600,000
|
$ 600,000
|
|
|
|
|
|
|
Remaining shares |
|
|
|
|
|
|
17,414
|
17,414
|
G Tech [Member] | Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
|
|
|
|
|
Maximum consulting expenses per month |
|
|
|
|
|
$ 130,000
|
|
|
Monthly consulting fee |
|
|
|
|
|
$ 25,000
|
|
|
G Tech [Member] | License Agreement [Member] |
|
|
|
|
|
|
|
|
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
|
|
|
|
|
Payment for license |
|
|
$ 1,200,000
|
$ 1,200,000
|
|
|
|
|
Royalty percentage |
|
|
|
2.00%
|
|
|
|
|
X |
- References
+ Details
Name: |
RENB_ConsultingExpenses |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_InitialPayment |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_MonthlyConsultingFee |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_PaymentForExpenditures |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_RoyaltyPercentage |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_UpfrontPayment |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DefinedBenefitPlanDisclosureLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for fees classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=RENB_ConsultingAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
|
|
|
May 02, 2024 |
Mar. 26, 2024 |
Feb. 16, 2024 |
Feb. 05, 2024 |
Jan. 11, 2024 |
Jan. 02, 2024 |
Nov. 03, 2023 |
May 17, 2022 |
Mar. 30, 2020 |
Mar. 31, 2024 |
Sep. 30, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
May 07, 2024 |
Apr. 09, 2024 |
Jan. 12, 2024 |
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payables |
|
|
|
|
|
|
|
|
|
|
|
$ 1,710,000
|
$ 0
|
|
|
|
Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
$ 3,645,000
|
$ 0
|
|
|
|
January Note 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
$ 460,000
|
|
|
|
|
|
|
|
|
|
|
$ 125,000
|
Debt maturity period |
|
|
|
|
Jan. 11, 2025
|
|
|
|
|
|
|
Dec. 29, 2024
|
|
|
|
|
Interest rate |
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
Debt maturity period |
|
|
|
|
|
|
|
Nov. 30, 2023
|
Nov. 30, 2021
|
|
|
|
|
|
|
|
Mark Dybul [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued balance |
|
|
|
|
|
|
|
|
|
|
|
$ 111,750
|
|
|
|
|
Paseco Aps [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price |
|
|
2,953,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payables |
|
|
$ 1,750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paseco Aps [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price per share |
|
|
$ 0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paseco Aps [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price per share |
|
|
$ 0.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paseco Aps [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
10.00%
|
|
Paseco Aps [Member] | Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
$ 160,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity period |
|
May 01, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net of debt discount |
|
|
|
|
|
|
|
|
|
$ 160,000
|
|
160,000
|
|
|
|
|
Paseco Aps [Member] | Promissory Note [Member] | Accrued Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest expense |
|
|
|
|
|
|
|
|
|
|
|
215
|
|
|
|
|
Paseco Aps [Member] | Promissory Note [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity period |
Jul. 01, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RS Bio [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
$ 105,263
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity period |
|
|
|
Mar. 01, 2024
|
|
|
Jan. 01, 2024
|
|
|
|
|
|
|
|
|
|
Warrant exercise price |
|
|
471,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price per share |
|
|
$ 0.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payables |
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization discount |
|
|
|
|
|
|
|
|
|
|
$ 5,263
|
5,263
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
3,158
|
|
|
|
|
Note balance |
|
|
|
|
|
|
|
|
|
105,263
|
|
105,263
|
|
|
|
|
RS Bio [Member] | January Note 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
$ 526,315
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
|
Debt maturity period |
|
|
|
|
|
Mar. 01, 2024
|
|
|
|
|
|
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
Amortization discount |
|
|
|
|
|
|
|
|
|
26,315
|
|
26,315
|
|
|
|
|
Note balance |
|
|
|
|
|
|
|
|
|
$ 526,315
|
|
526,315
|
|
|
|
|
Gross proceeds original issue discount rate |
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
$ 15,789
|
|
|
|
|
RS Bio [Member] | November 2023 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
Original issue discount promissory note percentage |
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
Gross proceeds |
|
|
|
|
|
|
$ 950,000
|
|
|
|
|
|
|
|
|
|
Gross proceeds original issue discount rate |
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
Discount accreted |
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
|
|
X |
- References
+ Details
Name: |
RENB_GrossProceedsOriginalIssueDiscountRate |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_InterestExpenses |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_OriginalIssueDiscountPromissoryNotePercentage |
Namespace Prefix: |
RENB_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe average effective interest rate during the reporting period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateDuringPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIncremental percentage increase (decrease) in the stated rate on a debt instrument.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of unamortized debt discount (premium) and debt issuance costs.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount (premium).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionInterest and debt related expenses associated with nonoperating financing activities of the entity.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_InterestAndDebtExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=RENB_AccruedExpensesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=RENB_November2023NoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- References
+ Details
Name: |
RENB_BusinessCombinationContingentConsiderationCommonStock |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7
+ Details
Name: |
us-gaap_BusinessCombinationConsiderationTransferred1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of asset recognized arising from contingent consideration in a business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-7
+ Details
Name: |
us-gaap_BusinessCombinationContingentConsiderationAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
ACQUISITION (Details - 1) - USD ($)
|
Mar. 31, 2024 |
Feb. 13, 2024 |
Jun. 30, 2023 |
Business Acquisition [Line Items] |
|
|
|
Goodwill |
$ 164,186,852
|
|
$ 11,640,000
|
G E Di Cube [Member] |
|
|
|
Business Acquisition [Line Items] |
|
|
|
Cash |
|
$ 65,851
|
|
Prepaid & Other Assets |
|
151,544
|
|
Fixed Assets |
|
16,243
|
|
Operating lease ROU |
|
624,366
|
|
In-process research and development |
|
10,684,091
|
|
Total Assets Acquired: |
|
11,542,095
|
|
Accounts Payable |
|
583,577
|
|
Accrued Expenses |
|
722,509
|
|
Operating Lease liability |
|
624,367
|
|
Notes Payable |
|
1,832,460
|
|
Deferred tax liabilities |
|
2,756,495
|
|
Total Liabilities Assumed |
|
6,519,408
|
|
Net Assets Acquired |
|
5,022,687
|
|
Goodwill |
|
151,536,444
|
|
Total Consideration |
|
$ 156,559,131
|
|
X |
- References
+ Details
Name: |
RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedExpenses |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsFixedAssets |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsInProcessResearchAndDevelopment |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentNotesPayable |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentOperatingLeaseLiability |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- References
+ Details
Name: |
RENB_BusinessAcquisitionsNetIncomeLoss |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
RENB_BusinessAcquisitionsRevenue |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- References
+ Details
Name: |
us-gaap_BusinessCombinationAndAssetAcquisitionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.2.u1
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7
+ Details
Name: |
us-gaap_BusinessCombinationConsiderationTransferred1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.2.u1
X |
- References
+ Details
Name: |
RENB_ProceedFromIssuanceOfDebt |
Namespace Prefix: |
RENB_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term notes payable classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_OtherNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=RENB_ConsultingServicesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Aug 2023 to Aug 2024